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Abstract 
Ubiquitin (76 amino acids) has been used as a model for protein folding studies with 
the synthesis of analogues including both single and double substitutions. Chemical 
synthesis has allowed for the facile incorporation of both unnatural amino acids and a 
novel synthetic fluorinated amino acid. Purification of synthetic ubiquitin by a variety 
of protocols has identified important steps in the folding pathway. We have 
investigated the placement of fluorine within the hydrophobic core of ubiquitin 
through the synthesis of three double substitutions at positions 43&67, 50&67, 
56&67 and one single substitution at position 67 using (2S,4S)-5-fluoroleucine to 
replace leucine. Methyl transfer across the hydrophobic core has been considered 
using the double substitution analogue [3-norleucine,43-norvaline]ubiquitin involving 
a modification in the distribution of alkyl groups. The importance of the chirality of 
the single histidine on the final strand of n-sheet has been examined in the synthesis of 
the analogue [68-Dhistidine]ubiquitin. 
The contribution of secondary structural features in protein folding has been 
investigated by studying peptide fragments corresponding to the N and C-terminal 
halves of ubiquitin and three overlapping peptides on the final strand of 3-sheet. The 
complementation of the N and C-terminal halves to regenerate the native fold has also 
been studied. 
"Knowledge is wonderful but imagination is even better." 
Einstein. 
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Introduction 
Chapter 1. Introduction 
Section 1.1. Folding Studies on Ubiquitin. 
1.1.1. How does a protein fold? 
It is now over 90 years since Emil Fischer and Franz Hofmeister independently 
concluded that proteins are composed of ct-amino acids covalently linked together' 
However, although nature has encoded for these twenty simple building blocks it 
gives no clues as to how they assemble efficiently to give the unique three dimensional 
structure which is the defining feature of proteins. 
The process of folding involves attainment of the native state from the primary 
sequence of amino acids through hydrophobic interactions and formation of specific 
secondary and tertiary structures. This is generally assumed to be under 
thermodynamic control as stated by Anfinsen (1973)2  and reiterated by Kim & 
Baldwin (1990) stating "the evidence is good that the final three dimensional structure 
of a protein is under thermodynamic, not kinetic control." 3 
However, a simple calculation reveals that random search among all possible 
configurations is a highly ineffective search strategy for formation of the native fold. 
For example, consideration of a 100 amino acid protein and allowing three 
configurations for each amide bond with a sampling rate of 10' 3 s1 results in a search 
time of 1027  years! Nevertheless, proteins do fold on a millisecond to second 
timescale and hence the famous Levinthal Paradox. 4 
It has been suggested that the problem of matching speed with stability of folding can 
be resolved by considering the shape rather than the size of conformational space 
available. This will be determined by effective search strategies and is succinctly 
stated by Dill : "searching for a needle in a haystack by random sampling would take 
forever, but with a big magnet it would be quick."' Similarly, it has been suggested 
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that nature has selected for sequences that have both the ability to fold rapidly and 
arrive at the thermodynamically stable structures. 
Ultimately, the goal of the protein chemist would be the development of a folding 
code, analogous to the genetic code allowing for accurate prediction of 3D structure 
from the linear sequence of amino acids. Increased challenges in this area for 
"cracking the second half of the genetic code" result from the expected completion of 
the human genome project in 2005 . 6  However, this task is ably assisted by advances 
in the chemical synthesis of proteins which allow for the specific modification of a 
sequence far beyond the twenty proteinogenic a-amino acids. 
We have approached the study of protein folding through the chemical synthesis of 
both protein analogues and fragments of the protein ubiquitin. In particular we are 
interested in the modification of the primary sequence with unnatural and novel amino 
acids and the subsequent changes in the secondary and tertiary structure. 
1.1.2. Ubiquitin. 
Ubiquitin (Ub) is a small globular protein (76 amino acids, 8565 Da) found in all 
eukaryotic cells7  and also recently reported in prokaryotes.' It is involved in a myriad 
of biological functions as reflected in a recent paper titled "Cell Cycle-Ubiquitin with 
Everything." 9  The functions of ubiquitin derives from its ability to mediate the 
responses of other proteins by marking or tagging them with either single or multiple 
ubiquitin molecules. This is most clearly demonstrated in the nonlysosomal 
intracellular degradation of proteins which involves the formation of multi-ubiquitin 
chains through isopeptide bonds between an 6 amino group of lysine in the target 
protein and the C-terminal glycine in ubiquitin. Substrates which have been identified 
include cyclin which is involved in cell regulation," the tumour repressor p53, 11 and 
the transcription factors myc and fos.'2 
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However, ubiquitin conjugation does not always result in proteolysis suggesting other 
roles for ubiquitin ligation in influencing protein function. These relatively stable 
ubiquitin conjugates include ubiquitinated forms of the nuclear histones (H2A & H2B) 
which may be involved in regulating transcription, some cell surface receptors 
(lymphocyte homing & platelet derived growth factor receptors) are found as 
ubiquitin conjugates and a family of neurodegenerative diseases (Alzheimer's and 
Parkinson's) are linked by the presence of insoluble ubiquitin-protein conjugates.' 3 
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Figure 1.1. Simplified annotation of protein ubiquitination and degradation. 
Basal levels of ubiquitin are provided by ubiquitin carboxyl extension proteins 
(UbCEP's) while the polyubiquitin genes are only switched on during cellular 
stress and are a component of the heat shock response. Multi-ubiquitin chains 
that form on proteolytic substrates are dynamic structures with ubiquitinating 
(El, E2 and E3) and deubiquitinating (Ubps) enzymes rapidly modifying these 
adducts. IJbiquitinated substrates are degraded by a large protease called the 
26S protease complex. 
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The primary sequence (figure 1.2.) containing no cysteine or tryptophan exhibits 
unparalleled conservation between species being identical in human, bovine, chicken, 







39 	 76 
Human DQQRLI FAGKQLEDGRTLSDYNIQKE S TLHLVLRLRGG 
Yeast 
Oat------------------ A------------------- 
Figure 1.2. Primary sequence of human, yeast and oat ubiquitin. 
This remarkable level of conservation may be important for the many diverse 
functions of ubiquitin whereby a substitution that is harmless for one function may be 
detrimental in others. Alternatively the conservation pressure may be associated with 
some physical property, such as the ability to undergo conformational changes. At 
present three states of ubiquitin are known to exist at 298K native (N), unfolded (U) 
which is formed in 6M guanidinium chloride (GdmCl) or in 8M urea and the A-state 
which is formed in 60% aqueous methanol at pH 2. These all reflect the concept of a 
flexible molecule which interacts with a multitude of other proteins and co-factors. 
1.1.3. Ubiquitin-a model for folding studies. 
Ubiquitin is an excellent model for protein folding studies having a well defined 
secondary and tertiary structure characterised by both x-ray crystallography" and 
solution NIMR.' 6"7 These are in agreement and reveal an extremely compact globular 
structure which is stabilised by a pronounced hydrophobic core and a high degree of 
hydrogen bonding. Only the last 4 amino acids at the C-terminus protrude from the 
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core giving so called 'stinger or tail' which is critical for the 'tagging' properties of 
ubiquitin. 
Figure 1.3. Ribbon diagram of ubiquitin with the hydrophobic residues forming 
the core shaded: produced using Insight II program. 
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The principle features of the structure include three and half turns of cc-helix (residues 
23-34), a short piece of 3 10 helix (residues 56-59) and a five strand mixed 13-sheet. 
Two of the inner strands of the 13-sheet are parallel (residues 1-7 and 64-72) while the 
remaining three strands are antiparallel (residues 10-17, 40-45, and 48-50). 
Association of the a-helix and 13-sheet give the prominent hydrophobic core which is 
formed by three residues from the cc-helix (11e23, Va126, & 11e30) and eleven of the 
thirteen hydrophobic residues from the 13-sheet (Ile3, Val5, 11e13, LeulS, Va117, 
11e36, Leu43, Leu50, Leu56, 11e61, & Leu67), only 1le44 and Va170 are somewhat 
exposed. 
In comparison to the C-terminus the N-terminus is largely inaccessible due to the 
hydrogen bonding of the methionine sulphur to the backbone amide of Lys63. The S-
N distance of 3-6A' is identical to that reported for a similar hydrogen bond in a-
chymotrypsin. 18  Other important structural features include the stabilisation of the 
loop formed by residues 5 1-59 by a total of five hydrogen bond interactions (figure 
1.4.). The first three are typical hydrogen bonds involving the N - 0 bond of the 
reverse turn 51-54 and the two N 0 bonds of the 3 helix. The remaining two are 
more unusual examples and involve the hydrogen bonds between the side-chains of 
Asp58 and Tyr59 with the backbone amides of Thr55 and GluS 1 respectively. 
The tightly packed hydrophobic core and extensive array of hydrogen bonding confers 
a high degree of stability to ubiquitin being stable in the temperature range 23-80°C 
and pH range 1-18-8-43 .19,20   The compact state of ubiquitin is also reflected in its 
resistance to proteolysis with complete digestion by trypsin only observed when the 
protein is unfolded in 65M urea. 2122 
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Figure 1.4. Loop containing residues 50-59: produced using Sybil molecular 
modelling program. 
1.1.4. The ubiquitin Wo roll-a protein superfold. 
The ubiquitin structure has been classified as one of the nine currently determined 
protein superfolds called the ubiquitin a/f3 roll. Other proteins sharing this fold 
include the BI domain (56 residues including the NH2-terminal methionine) of 
streptococcal protein G 24 ' 25 and the Ras binding domain (81 residues) of the 
serine/threonine kinase c-Rafl known as Raf 26 ' 27 These are unrelated by sequence 
(<25% similarity) but all share a similar topology (figure 1.5.). This structure 
similarity in the absence of sequence similarity strongly suggests that the high 
conservation pressure exerted on the ubiquitin sequence is not simply a result to 






BI domain of streptococcal protein G 
Figure 1.5. Diagram of the overall topologies of A) Raf, B) ubiquitin and C) Bi 
domain of streptococcal protein G. 13-Strands are represented by arrows and a-
helices by cylinders. The connecting loops are not drawn to scale. 
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1.1.5. Ubiquitin-like proteins. 
In contrast to ubiquitin whose sequence of amino acids is highly conserved, there is a 
family of ubiquitin-like proteins that deviate from each other but have sufficient 
identity to ubiquitin to establish their relationship (figure 1.6.). The interesting 
question is whether these ubiquitin-like proteins retain some limited properties of 
ubiquitin that are important for their biological functions. 
Protein 1 	 38 
1 M--QIFVKTLTGKTITLEVEPS--DTIENVKAKIQDKEGIPP 
2 MGWDLTVKMLAGNE F- -QVSLSS SMS VSELKQI TQKIGVHA 
3 	LS ILVRNNKGRSSTYEVRLT--QTVAHLKQQVSGLEGVQD 
4 M--QLTWCLQRGECSLQVPED--ELVS TLKQLVSEKLNVPV 
5 L--EVLVKTLDSQTRTFIVGAQ--MNVKEFKHIBASVS IPS 
6 M- -ELFIETLTGTCFELRVSPY--ETVTSVKSKIQRLEGIPV 
7 M- -ELFIETLTGTC FELRVSPY- -ETVTSVKSKIQRLEGIPV 
8 M--QIFIKTLTGKTITAETEPA--ETVADLKQKIADKEGVPV 
9 	 QDKEGIPP 
10 M--QIFVKTLTGKTITLEVEPS--DTIENVKAKIQDKEGIPP 
11 M--QIFVKTLTGKTITLEVEPS---DTIENVKAKIQDKEGIPP 
Protein 39 	 76 
1 DQQRL-- I FAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
2 FQQRLAVHPSGVALQDRVPLS QGLGPGSTVLLVVDKCDEP 
3 DL FWL- - TFEGKPLEDQLPLGEYGLKPLSTVFMNLRLRGG 
4 RQQRL--LFKGKLADGKRLSDy5 IGPNSNLVVKPLEK 
5 EKQRL--IYQGRVLQDDKKLQEYNVGGKV- IHLVERP.PPQ 
6 AQQHL-- IRNNMELEDECSLSGYNISEGCTLK1V1VLInRGG 
7 AQQHL-- IWNNMELEDECSLSDYNISEGCTLKMVLJIRGG 
8 DQQRL-- IFAGKQLEDSKTMADYNIQKESTLHMVLRLRGG 
9 DQQRL-- IFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
10 DQQRL--IFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
11 DQQRL--IFAGKQLEDGRSLSDYNIQKESTLHLVLRLRGS 
Figure 1.6. An alignment of the amino acid sequence from 1. Ub (human) and 
the ubiquitin-like domains of: 2. UCRP-A (Human), 3. UCRP-B (Human), 4. 
Gdx (human), 5. BAT3 (human), 6. Anla (Xenopus laevis), 7. Anib (Xenopus 
laevis), 8. v-Ubi an Autographica californica baculovirus encoded protein 
(AcMNPV), 9. BVDV CP1 (1), 10. BVDV CP1 (II) and 11. BVDV Osloss. 
Residues of ubiquitin-like proteins which are identical to ubiquitin (human) are 
shown in bold. 
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The first of these is an interferon induced protein known as ubiquitin cross reactive 
protein (UCRP) 28 which comprises two ubiquitin-like domains (76 and 80 residues) 
linked head to tail. The C-terminal domain of UCRP contains the -LRLRGG motif 
and is a functional ubiquitin analogue retaining the ability to conjugate with 
intracellular proteins . 29 The Gdx gene on the Human X chromosome encodes for a 
157 amino acid protein 30  with the N-terminal 76 residues sharing 43% identity with 
ubiquitin while the C-terminal portion shows no homology. BAT3, 31 a gene from the 
human major histocompatibility complex class III encodes a single ubiquitin-like 
domain with 35% identity to ubiquitin. Two Ani mRNA isoforms from Xenopus 
laevis designated Anla (693 amino acids) and Anib (701 amino acids) have N-
terminal ubiquitin-like domains (residues 28-104) with 50% sequence homology to 
ubiquitin. 32 
There are also several examples of ubiquitin-like proteins encoded by viral genes e.g. 
baculovirus and bovine viral diarrhoea viruses (BVDV). The baculovirus 
Autographica calfornica nuclear polyhedrosis virus (AcMINPV) encodes a 77 amino 
acid protein, v-ubi with an extra tyrosine at the C-terminus and shares 76% identity to 
ubiquitin. 33 Two types of BVDV are observed, CP1 which comprises one truncated 
and one full size ubiquitin moiety and Osloss which encodes a single ubiquitin domain 
with 97% similarity to human ubiquitin. 34 
There are important questions concerning the structural and functional aspects of 
these ubiquitin-like proteins. For example, recombinant expression of UCRP gave a 
large proportion of insoluble precipitate which is typical for a misfolded protein and 
would suggest that it lacks the structural stability of ubiquitin. 29 
1.1.6. Characterisation of the ubiquitin folding pathway. 
The highly co-operative nature and rapidity of protein folding provides challenges for 
studying folding through characterisation of folding intermediates between the 
unfolded and native states. One of the main difficulties is the highly transient 
10 
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existence of folding intermediates which often exist for only a few milliseconds and 
therefore cannot be isolated for study. Nevertheless, experiments have been devised 
to gain structural information on kinetic intermediates using stopped flow hydrogen-
deuterium exchange labelling, 35 ' 36, circular dichroism (CD), 37 fluorescence studies, 38 
and the binding of the fluorescent probe, 1-anilino-napthalene-8-sulphonate. 39 
Detailed information on the folding of ubiquitin has been obtained using stopped flow 
techniques including both hydrogen exchange labelling in combination with 2D NMR 
and fluorescence studies. A schematic representation of the pulsed hydrogen 
exchange method is shown in figure 1.7. 
3 	A"ho 	:q 
Unfolded protein 	Refolding 	D-H exchange 	Refolded 
in D20 	 begins labelling 	 protein 
data 
refolding time 	 pulse tirne 
oillect 
Si denatured 	IS21 refolding 	 S3 pulse buffer 	IS41 quench buffer 
protein in D 20 	buffer 1 	(1-120, high pH) 	(1-120, low pH) 
Figure 1.7. Schematic illustration of pulsed hydrogen exchange method. Two 
representative amide probes are shown in the protein, the first amide proton 
becomes protected against exchange and remains deuterated, while the second 
amide still exposed at this time becomes protonated with D to H exchange by an 
EX2 mechanism occurring during the labelling pulse. A diagram of the NMR 
quenched flow apparatus with three mixing stages (MI/M2/M3) and two 
variable time delays is shown. Syringes Si and S2 are activated at timeO to 
initiate refolding by dilution of the denaturant in Ml. After a refolding time, 
the protein is mixed in M2 with 1120 buffer at high pH 9-10 to start the D to H 
exchange. After a pulse time, exchange is quenched by lowering the pH in M3 
under conditions that favour rapid refolding. Adapted from reference. 40 
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Using various refolding times, the folding intermediates sandwiched between the 
unfolded and native states can be mapped from the H/D protection pattern obtained. 
It is generally assumed that protection from exchange occurs only when native-like 
structure is formed. The main limitations are that only those peptide amide protons 
that are stable to exchange in the native protein can be used as probes because only 
these protons appear in the 2D NMR spectrum in D 20 and for H bonded amide 
protons the method does not give the location of the acceptor. 
1.7. Hydrogen exchange in native ubiquitin. 
Briggs & Roder used pulsed hydrogen-deuterium exchange labelling in conjunction 
with 2D NIvIR analysis to explore the kinetics of ubiquitin folding. 4 ' The protection 
pattern for 26 backbone amide protons that form stable H-bonds upon refolding and 
exchange only slowly under native conditions were measured using various refolding 
times from 34ms to 20s. A major co-operative folding event was observed with 80% 
of the amide probes including all of those in the a-helix and most of those in the - 
sheet becoming protected within 8ms, followed by two minor phases with time 
constants (and amplitudes) of lOOms (12%) and lOs (8%). This simultaneous 
protection of amides from diverse structural elements suggests that both the 
secondary structure and the hydrophobic core of the protein is formed in a single 
folding event. Two to threefold slower protection rates were observed for the amide 
probes Tyr59 and Leu6 1 which are part of the surface loop and also Leu69 which is 
on the final strand of 13-sheet indicating that these regions are stabilised in a 
subsequent step after formation of the hydrophobic core. The amide protons of 
Gln4 1 and Arg42 also exhibit more pronounced slower protection phases which can 
be attributed to non-native cis peptide bonds proceeding Pro37 & Pro38. Since the 
slow folding of residues 37 to 42 does not propagate to other parts of the molecule it 
is suggested that this region is structurally decoupled from the remainder of the 
protein. The folding of ubiquitin is extremely rapid compared to cytochrome C, 42 
barnase43 and hen lysozyme44 also studied by pulsed hydrogen-deuterium exchange. 
12 
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For example, in cytochrome c, rapid protection is observed for the amide probes in 
the N and C-terminal helices with 40% protection obtained in 30ms, however it is not 
until 200ms that 50% protection is obtained for all the amide probes and complete 
protection requires 10 seconds. 
1.1.8. Hydrogen exchange in the ubiquitin mutant [Trp 45]Ub. 
Further kinetic studies by Roder et al on the ubiquitin mutant [Trp45]Ub incorporated 
tryptophan to replace phenylalanine as a sensitive chromophoric probe to monitor 
changes occurring specifically within the hydrophobic core . 4' The 2D 'H NMR of 
[Trp45]Ub is very similar to wild-type (WT) with only limited chemical shift changes 
observed for residues in the vicinity of Trp45 and, in addition, the biological activity 
of the mutant is indistinguishable from that of WT. Furthermore, NMR and circular 
dichroism measurements of the reversible GdmCl induced unfolding transition show 
that the mutation lowers the stability by less than 04kcalmol' (zG=7 1 compared 
with 75kcalmol'). This similarity means that structural information gained using the 
mutant can be directly related to WT ubiquitin. Trp45 is sandwiched between the a-
helix/0-sheet at the edge of the hydrophobic core and is therefore strategically placed 
to provide information on unfolding. It is largely buried (97%) and exhibits a four 
fold increase in fluorescence upon unfolding with 6M GdmCl with the maximum 
shifted from 336 to 353nm which is expected of a solvent exposed free tryptophan. 
This compares to the chromophoric Tyr59 already present in WT which is part of the 
surface loop (residues 50-59) and is largely solvent exposed and consequently exhibits 
only small changes in fluorescence upon unfolding. 46 
The kinetics of unfolding and folding for [Trp 45]Ub were measured at two 
temperatures 8 & 25 °C, over a wide range of GdmCl concentrations (05-6M) at pH 5 
using fluorescence-detected stopped flow measurements. At both temperatures 
studied and at concentrations greater than 2M GdmCl the kinetic behaviour follows 
the expected two state model of unfolding 47 ' 48 without significant population of 
intermediates between the unfolded and folded conformations, with a major 
13 
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exponential phase accounting for 90% of the amplitude and a minor slow phase 
observed. This slow phase can be attributed to non-native proline isomers previously 
observed in hydrogen exchange with native ubiquitin 
At lower concentrations <2M GdmCl contrasting results were obtained at the two 
temperatures studied. The results at 8°C and at low concentrations of GdmCl again 
follow the expected two-state model i.e. at 1M GdmCl a major exponential phase 
with amplitude (and time constant) 75% (57ms) and two minor slow phases with 18% 
(05s) and 7% (lOOs) are observed. However, at 25°C and at low denaturant 
concentrations <2M GdmCl the folding kinetics are inconsistent with a simple two 
state model i.e. at 1M GdmCl a major burst phase with 50% amplitude occurs in the 
2ms deadtime of the stopped flow measurement with three slower kinetic phases with 
amplitudes (and time constants), 36% (5ms), 11% (75ms) and 3% (20s) observed. 
This burst-phase is destabilised with increasing GdmCl concentrations and is no 
longer populated in the unfolding transition (midpoint=365M). This burst 
intermediate can be assigned to an early folding intermediate with a partially 
developed hydrophobic core involving Trp45. The destabilisation of the burst phase 
intermediate at low temperature suggests that the collapsed state is primarily stabilised 
by hydrophobic interactions which are known to be weakened at lower 
temperatures. 49 
1.1.9. A-state of ubiquitin. 
The conformational flexibility of ubiquitin was first observed by Wilkinson & Mayer 
who detected a non-native structure with 50% helicity as monitored by circular 
dichroism in alcohol/water mixtures." Harding et al further studied a partially 
structured form of ubiquitin termed the A-state which is formed in 60% aqueous 
methanol, pH 2 at 298K. 5 ' The A-state can be regarded as a putative molten globule 
(MG) and characterisation of this intermediate is fundamental for analysing the folding 
pathway of ubiquitin since the MG or a similar form may conceivably be on the 
folding pathway. Formation of the A-state is not observed using pH or temperatures 
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separately but requires both low pH and 60% aqueous methanol. In lower 
concentrations of methanol (30-60%) and at 298K equilibrium mixtures of the N and 
A-states of ubiquitin are observed. The effects of the conditions used to attain the A-
state are twofold, the low pH will alter charge-charge interactions in particular salt 
bridges e.g. the interactions between Lysi 1/G1u34 and Lys27/Glu48 will be broken 
while aqueous methanol will diminish the driving force for excluding nonpolar 
residues compared to water. 52  Heating the A-state in the temperature range 300-
335K suggests the protein is approaching a random coil with increased temperature 
but some ordered structure still persists at 335K. This compares to native ubiquitin at 
pH 58 which retains the native structure in the temperature range 298-335K but 
precipitates at higher temperatures. Complete assignment of the 'H NtvlIR spectrum 
of the A-state was not possible due to limited chemical shift dispersion in certain 
regions. However, some NOE's were able to be assigned in the 3-sheet region as 
shown below (figure 1.8.). 
H 	H H 	H HJ 12 H H 
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Figure 1.8. NOE data in the f3-sheet structure of the A-State. 
Additional information on the A-state was obtained from a hydrogen-deuterium 
exchange refolding experiment which allows identification of amide protons that are 
protected from exchange and hence postulated to be involved in 2 ° & 3° structure. 
This involved dissolving the protein in 60%CD 30D/40%D20 pH 2 for 30 minutes 
which is sufficient time to allow all amide protons not protected from the solvent to 
exchange with deuterons, and the methanol was then removed by centrifugation and 
the pH adjusted to 47. This resulted in the identification of 14 slowly exchanging 
amides comprising 11 amides from the first three strands of n-sheet (13, F4, V5, K6, 
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T7,113, L15, V17, L67, L69 & V70) and three amides from the cc-helix (V26, A28 & 
E34). The conclusions drawn from these results are that the first three strands of 13-
sheet (1-7, 11-17 and 65-70) and a more flexible cc-helix (22-34) are present in the A-
state while the remaining residues 37-62 assume an essentially random coil. 
Complete assignment for more than 90% of the residues in the A-state was achieved 
using 3D heteronuclear NIvIR analysis of uniformly ' 5N enriched ubiquitin. 53 This 
confirmed the presence of the first two strands of 13-sheet and also the a-helix. These 
elements can be regarded as associating to give a single folded domain which is stable 
in the absence of the C-terminal half of the molecule. No evidence was found for the 
presence of the third strand of 13-sheet (65-70). 
1.1.10. Hydrogen exchange in the native and A-states of ubiquitin. 
Pan & Briggs studied hydrogen exchange rates in the putative MG of ubiquitin, the A-
state which is formed at low pH in 40-60% aqueous methanol. 54 Protection factors 
for 41 slowly exchanging amides in the native state were compared to 30 observable 
amides in the A-state. The ii protons not seen in the A-state include five amides 
(Q2, T12, E16, T22 and Q49) which are not hydrogen bonded in the crystal structure 
but which exchange slowly enough albeit with low protection factors to be detected in 
the native state. The other six amides which exchange too quickly to be observed in 
the A-state are mostly located on the periphery : T7 and Li 5 which are at the end and 
outer edge respectively of the N-terminal 13-sheet, D32 at the C-terminal end of the a-
helix, D58 and N60 in the 3 10 helix and 1468 in the central 13-strand. The protection 
factors observed are shown in figure 1.9. 
It is apparent that the same pattern of protection occurs in both the native and A-
states differing only in their magnitude of protection. The protection factors are much 
lower in the A-state ranging from 26 to 42 compared to the native state which range 
from 22 to 10 5 . The similar pattern of protection and increase in exchange rates for 
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the A-state suggests that it retains the major secondary structural elements present in 
the native state but that these are significantly destabilised. 
Figure 1.9. Protection factors in the native and A-states of ubiquitin. 
Protection factors (P) are defined as the ratio of k to k, where k is the 
intrinsic exchange rate of a given amide in a random coil peptide and k is the 
experimentally determined value. High protection factors are obtained for 
folded or partially folded structures and low values for unfolded structures. 
The most strongly protected amides in both cases are those located in the interior of 
the hydrophobic core. This methanol induced state is similar to the previously 
discussed kinetic intermediate containing non-native cis peptide bonds proceeding P37 
and P38 in that most of the native secondary structure is present and the association 
of the cc-helix and 3-sheet has occurred. The main difference between the two is for 
the region P37 to R42 which has non-native structure in the kinetic intermediate but 
native structure in the A-state. This can be explained in terms of the denaturing 
environment used in the kinetic folding experiment giving an unfolded state which 
allows cis-trans equilibration of proline residues, while in the A-state the structure is 
not sufficiently "loosened" to allow trans to cis isomerisation of peptidyl-prolyl bonds. 
Another difference for the A-state is seen at that the ends of the cc-helix and 3-sheet 
which are destabilised in the methanol induced state reflecting a more dynamic flexible 
structure expected of a MG. 
The result obtained by Pan & Briggs differs from that of Harding et a!5 ' who observed 
many fewer exchanging amides; only 14 (2 of which are not observed by Pan & 
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Briggs) compared to the 30 reported by Pan & Briggs. 54  This discrepancy can be 
attributed to the different experimental conditions whereby Pan & Briggs used a series 
of exchange times ranging from 30s to 2 hours followed by 10 fold dilution with 
NMR buffer & subsequent ultrafiltration to concentrate the sample while Harding et 
al used only one 30 minute exchange period, following which the methanol was 
removed by vacuum centrifugation & then diluted with NIvIR buffer. This latter 
method effectively results in a much longer exchange period and may also have 
resulted in structural perturbation. 
1.1.11. Protein dissection of the A-state. 
The complexity of protein folding can be reduced by studying smaller segments or 
folded domains of a protein's sequence. Harding et al have done this for the A-state 
of ubiquitin by studying the synthetic peptides Ub(1-21), Ub(1-35) and Ub(62-72) in 
isolation from the remainder of the molecule to gauge their intrinsic stability's. 55 CD 
analysis (figure 1.10.) of the peptides Ub(1-21) and Ub(1-35) in 60% aqueous 
methanol pH 2 indicate maintenance of the 13-sheet structure in the absence of wider 
interactions with the C-terminal half of ubiquitin. In contrast the A-state exhibits a 
large increase in helicity in 60% aqueous methanol pH 2 which can be attributed to 
promotion of random helicity in the C-terminal portion. 








Ub(native) 	Ub(A-state) 	Ub(1 -35) 	Ub(1 -21) 
Peptide 
Figure 1.10. Deconvolutions of CD spectra into apparent secondary structure 
contributions expressed as the number of residues adopting each of the 
following structures: heavily shaded bars, cc-helix; clear bars, 13-sheet and 
patterned bars, remainder. 
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Comparison of the 'H NMR spectra of Ub(1-21) and Ub(1-35) in 60% aqueous 
methanol pH 2 with the A-state show that corresponding resonance's have closely 
related chemical shifts confirming the existence of the N-terminal 0-hairpin 
independently of wider interactions with the C-terminal portion of ubiquitin. Earlier 
work by Harding et a!5 ' also suggested the existence in the A-state of the 13—strand 
comprising residues 62-72, however monitoring by 'H NIVI1R of 1:1 mixture Ub(1-35) 
and Ub(62-72) found no evidence to support any significant interaction between these 
peptides. 
This strong tendency of the N-terminal region of ubiquitin to form the correct 
secondary structure suggests that folding might also occur from the N-terminus in the 
same way as the synthesis of the protein occurs on the ribosome. However, the 
kinetics of folding found no evidence to support this with only one major co-operative 
folding event observed. Folding from the N-terminus has been observed in several 
multi-domain proteins with folding occurring after completion of each domain while 
the remainder of the protein is synthesised. 16  The biological activity of ubiquitin is 
predominantly through conjugation to other proteins via the C-terminus so these 
results raise interesting questions regarding the structure of these C-terminal 
conjugates. 
1.1.12. Molecular modelling of the A-state-reconciliation of theory and 
experiment. 
Characterisation of the A-state by 2D & 3D NMR supports the idea that the N-
terminal half of the molecule contains disrupted but native-like structure while the C-
terminal half is largely unstructured and/or contains non-native structure. This is in 
conflict with the hydrogen exchange data for the A-state which concluded that the 
similar hydrogen exchange protection pattern combined with lower protection factors 
reflected a more dynamic and flexible native structure in the A-state. Molecular 
modelling simulations were used in an attempt to reconcile the interpretation of these 
different experimental findings. 17  The simulation protocols used all proceed from the 
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metastable folded protein 
[Unfolding Simulation] 
Ubiquitin MD @ 498K 	 lvii) @ 498K 	 lvii) @ 498K 
Crystal 	 'early 	 10 	'late 	 b. D 498K 
Structure 60 ris in H20 	\, 39 ps in FO j 	311 ps in I-O 	fully 
I early, IO 	I early, methanol 
partially unfolded partially unfolded 
Figure 1.11. Simulation protocols and description of simulations done. 
Abbreviations used : MD, molecular dynamic simulations : N, native : I, 
intermediate : D, denatured. Simulation protocols for I(early) i) MD @ 335K, 
500 Ps in 1120, ii) MD @ 335K, 500 Ps in 60% aqueous methanol and for I(late) 
iii) MD @ 335K, 500 ps in 1120 and iv) MD @ 335K, 500 Ps in 60% aqueous 
methanol. Adapted from reference. 57 
To allow greater conformational freedom during unfolding native ubiquitin was 
denatured at high temperature (498K) and in H 20, rather than methanol where 
reduced protein mobility is known to occur. 58 Two "snapshots" were taken during 
unfolding giving two intermediates I(early) and I(late) occurring at 60 and 198 Ps 
respectively. These were further simulated in H 20 and 60% aqueous methanol at the 
lower and more meaningful temperature of 335K where the A-state is known to be 
stable. Control simulations with native ubiquitin were also performed at 298K and 
335K. The tertiary structures obtained for the simulations are shown in figure 1.12. 
unfolded 
I late, IiO 	I late, methanol 
partially unfolded partially unfolded 
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e,MeOH 	 N 	 e,H20 
Crystai' 298 
I, MeOH 	 D 49 	 1, H2O 
Figure 1.12. Representative structures for each of the 500. ps simulations. 
Abbreviations used : N, native: I, intermediate: D, denatured : e, early: I, late. 
The simulations for N(33 5K) and the early intermediates, I(early H 20) and I(early 
methanol) show only limited changes from the native fold being slightly less compact 
than N(298K). In contrast the later intermediates I(late H 20) and I(late methanol) and 
D(498K) are considerably more disrupted with expanded structures. However, I(late 
methanol) does retain the 3-hairpin comprising the first two strands of t3-sheet and the 
a-helix. 
Partial unfolding in these simulations is reflected in both an increase in the radius of 
gyration of the a-carbons and a concomitant increase in solvent accessible area (figure 
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1.13.). This is increased at higher temperatures and in organic solvents e.g. 60% 
aqueous methanol. The increase in solvent accessible area is accompanied with a 
corresponding exposure of hydrophobic residues from the core which are stabilised by 
favourable interactions with methanol. 59 









23 4 5 6 7  
Intermediate 
Figure 1.13. Series 1, % increase in the radius of gyration of the a-carbons and 
series 2, °h increase in the solvent accessible surface area compared to the 
crystal structure. Intermediate 1, N(298K) : 2, N(335K) : 3, I(early H 20) : 4, 
I(early methanol) : 5, I(Iate H20): 6, I(late methanol): 7, D(498K). 
The conformational flexibility of I(early methanol) and I(late methanol) were accessed 
from two snapshots taken at 210 and 500 ps which shows that the N-terminal portion 
remains relatively constant in both while the C-terminal portion is very mobile in I(late 
methanol) but remains fixed in I(early methanol). Furthermore, comparison of the 
calculated NOE's in the 13-strands 1, 2 and 5 shows that I(late methanol) is more 
similar to the A-state having the expected NOE's between the first two strands of 
sheet whereas  I(early methanol) is more structured. 
The hydrogen exchange pattern of N(298K), I(early methanol) and I(late methanol) 
were calculated and compared to the experimental results obtained by Pan & Briggs 54 
and Harding et al" for the both the native and A-state of ubiquitin. For the 
simulations a 10% cut off was arbitrarily chosen as the maximum percentage of time 
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that an amide hydrogen can participate in hydrogen bonds with water and still remain 
protected. The overall results are summarised in table 1.1. 
Table 1.1. Protection factors, P denotes protected to exchange with deuterium 
in : I) native Ub as reported by Pan & Briggs, II) as calculated in molecular 
simulation of native Ub N(298K), 1111) A-state of Ub as reported by Pan & 
Briggs, 54  IV) A-state as reported by Harding et a!, 5 ' V) as shown in molecular 
simulation of the A-state I(early, MeOB) and VI) as shown in molecular 
simulation of the A-state I(late MeOH). 
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Good correlation is seen for the native state, N(298K) with the experimental results of 
Pan and Briggs with a slight overestimation of protection in the N(298K) simulation 
suggesting that the arbitrarily assigned % cut-off of 10% is too high. The results for I 
(late methanol) compare favourably with the experimentally obtained values of Pan & 
Briggs for the A-state while for I(early methanol) an overestimation of protection is 
seen. 
Overall from the data acquired (tertiary structure, NOE data, hydrogen exchange 
data), I(late methanol) is more similar to the A-state than I(early methanol). The 
simulation of I(late methanol) and the 2D and 3D 'H NIV1R of the A-state clearly 
illustrate the non-native and unstructured C-terminal half of ubiquitin which gives the 
experimentally observed native-like protection. This has important implications for 
the interpretation of hydrogen exchange data where it is generally assumed that 
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protection from exchange signifies native like structure. The paradox can be resolved 
by consideration of the additional factors that contribute to protection from exchange 
which include steric shielding of amide hydrogen's in small hydrophobic clusters, 
preferential interactions with methanol and the formation of intraprotein hydrogen 
bonds with side or main chain groups. This anomaly has recently been demonstrated 
in monellin where the 13-sheet adopts a non-native a-helical structure in alcohol as 
determined by 2D NMR but gives native-like protection patterns. 60 
1.1.13. Summary. 
The folding of ubiquitin has been shown to be extremely rapid with a partial collapsed 
intermediate stabilised primarily by hydrophobic interactions formed within 2ms of 
initiation of folding. This partial condensed state brings residues in close proximity to 
each other resulting in the formation of secondary and tertiary structure on the 8ms 
timescale as demonstrated in hydrogen exchange studies on native ubiquitin. 
The initial collapsed intermediate will significantly reduce the conformational space 
available to the protein and thus help in overcoming the Levinthal Paradox. These 
results strongly suggest a nonhierarchical folding model for ubiquitin in which the 
main driving force is the hydrophobicity of the amino acid sequence which results in 
the internal organisation of the protein. 
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Section 1.2. Chemical Synthesis of Proteins. 
1.2.1. General. 
The chemical synthesis of proteins requires the unambiguous formation of an amide 
bond between two a-amino acids to efficiently replicate the translational machinery of 
the ribosomes (figure 1.14.). This requires protection of the N  amino group of one 
and the carboxyl group of the other amino acid to prevent unwanted coupling 
reactions. Furthermore, the unprotected carboxyl group requires to be activated with 
an electron withdrawing group to ensure nucleophilic attack by the unprotected N' 
amino group. Additionally, protection is required for functional side-chains present in 
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Figure 1.14. Unambiguous formation of a dipeptide from two a-amino acids. 
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1.2.2. Solid Phase Peptide Synthesis (SPPS). 
The development of SPPS began over three decades ago when the method was first 
proposed by Merrifield 6 ' and for which he was later awarded the Nobel Prize. 62 The 
general principle involves the stepwise assembly of peptides from the C to the N-
terminus while attached to an insoluble support. The final step involves the 
simultaneous cleavage of the peptide from the resin and the removal of amino acid 
side-chain protecting groups. 
SPPS offers several advantages over solution synthesis of peptides and these include; 
• no need to isolate and purify intermediates 
• unreacted reagents and side products are removed by filtration & washing 
• large excess of activated amino acid ensures high % couplings 
• SPPS can be fully automated 
There are two main strategies in SPPS, the first of which is associated with Merrifield 
and involves N tertiary-butyloxycarbonyl (Boc) protected amino acids in combination 
with benzyl based protecting groups (PG's) for functional amino acid side-chains. 
The Boc group is cleaved by trifluoracetic acid while the more acid stable PG's 
require cleavage by stronger acids such as hydrogen fluoride or 
trifluoromethanesulphonic acid. Disadvantages of Boc SPPS include the requirement 
of specialised apparatus for safe usage of strong acids and the repeated acidolysis to 
remove the Na Boc group can result in acid catalysed side reactions involving 
cleavage of acid sensitive bonds and/or cleavage of the peptide resin linkage. 
These concerns resulted in the development of a second approach to SPPS using a 
truly orthogonal strategy and involves Na 9-fluorenylmethoxycarbonyl (Fmoc) 
protected amino acids 63 ' 64 cleaved with the mild base, piperidine and tertiary-butyl 
based PG's cleaved with trifluoroacetic acid. 
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BzI OBzI Z 
Boc T Ser—Asp—L~s-CO— —Resin 
CF3COOH 	 HF 
But aBut Boc 
Fmoc T Ser—Asp—Ly's-CO— —Resin 
CT 	CF3COOH 
Figure 1.15. Protecting group strategies in Boc and Fmoc SPPS. Z group, 
benzyloxycarbonyl; Bzl, benzyl; But,  tertiary-butyl; Boc, tertiary-
butyloxycarbonyl and Fmoc, 9-fluorenylmethoxycarbonyl. 
1.2.3. The solid support. 
In FMOC SPPS a more acid labile peptide resin linkage can be used such as the 4-
alkoxybenzylalcohol resin (Wang) 65 (1) compared to the phenylacetoamidomethyl 
resin (PAM)66 (2) in Boc SPPS. 
I-1ocH2__-Q__ocH2__0__.[poIYstYrene] 
HOCH2__ ..Q__CFNFcH2__-Q.__[PdYstYrene] 
The above resins give the C-terminal carboxylic acid on cleavage, however other 
functionality's can be obtained by modifying the linker. For example C-terminal 
amides are obtained from using the methylaminocarbomethoxy-5-
(9'Fmoc)aminodibenocycloheptadiene resin in Fmoc SPPS (3)67  or 4-methyl 
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(v) 
0 	 0  
NH2CHRn—' , l , uIu.NH_CHR2__NH_Cf1R1__èL0H 
Figure 1.16. General scheme of N  Fmoc SPPS; (i) attachment of first amino 
acid to the resin, (ii) capping with acetic anhydride, (iii) deprotection of N 
Fmoc with piperidine, (iv) coupling of the next amino acid and (v) simultaneous 
cleavage of PG's and peptide-resin linkage with aqueous trifluoroacetic acid. 
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1.2.4. Activation procedure and coupling methods. 
For efficient coupling in SPPS, the protected carboxylic acid requires to be activated 
with a suitable electron-withdrawing substituent (X) to enhance the electrophilicity of 
the carbonyl carbon and thus facilitate nucleophilic attack by the amino group of a 
second a-amino acid. 
0 	 0 
H Activation 	II 
R—C—OH 	 R—C—X 
The activating group needs to ensure high coupling efficiencies in the absence of 
unwanted side reactions. 
One highly effective activation procedure currently employed in SPPS is symmetrical 
anhydrides. These are formed by the reaction of two equivalents of protected 
carboxylic acid with one equivalent of carbodiimide. In practice, di-
isopropylcarbodiimide (DIC) is routinely used as the coupling agent, since the 
diisopropylurea by-product is fully soluble in the solvents used in SPPS in comparison 
to the insoluble dicyclohexylurea by-product of dicyclohexylcarbodiimide (DCC). 
0 HN—R' 





RC' 	 0 




Figure 1.17. Formation of symmetrical anhydride by the action of carbodiimide. 
Symmetrical anhydride activation is wasteful with only 50% of the carboxylic product 
incorporated into the peptide. Other disadvantages, also include the dehydration of 
Asn & Gin to the nitrile and high levels of racemisation with His. However, these 




The active esters are prepared from reaction of one equivalent of carboxylic acid with 
one equivalent of the appropriate alcohol in DIC. A commonly used and extremely 
effective coupling agent is l-hyroxybenzotriazole (HOBt) (5) whose catalytic activity 










Analogues developed as a consequence of the highly efficient coupling of HOBt esters 
include, 1 -hydroxy--7-azabenzotriazole (6) 0 and ethyl-i -hydroxy- 1H- 1,2,3 -triazole-4- 
carboxylate (HOCt) (7)•71 
1.2.5. Fmoc SPPS - side-chain protection. 
As mentioned previously side-chain protection in Fmoc SPPS is based on tertiary- 
butyl based PG's, the notable exceptions to this are Arg, Cys and His. 
Amino acid Protecting group 
Arg Mtr/Pmc 
Asn/Gln Mbh / Trt 
Asp/Glu But esters 
Cys Acm / Trt / SBut 
His it-Bum / t-Trt 
Lys Boc 
Ser/Thr/Tyr But ethers 
Trp Boc 
Table 1.2. Side-chain protection in Fmoc SPPS. 
Protection for the strong nucleophilic guanidino side chain group of Arg have been 
developed on ring substituted atylsuphonyl derivatives such as the 4-methoxy-2,3,6- 
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trimethylbenzenesulphonyl (Mtr) (8).72  However, the Mtr is somewhat resistant to 
TFA cleavage requiring extended cleavage times especially in multiple Arg 
sequences73  and hence the more acid labile 2,2,5,7,8-pentamethylchroman-6-sulphonyl 
(Pmc) (9) is now preferred. 74,75 
OCH3 
cH :H3 
(8) Mtr 	 (9) Pmc 
His presents problems in that both the free and t protected derivatives are prone to 
racemisation when activated due to intramolecular base catalysis by the it nitrogen of 
the imidazole ring. Trityl protection of the t nitrogen significantly reduces the basicity 
of the it nitrogen and therefore suppresses proton abstraction from the cc-carbon. 
However, racemisation is not completely eliminated but can be further reduced by 





Figure 1.18. Histidine racemisation. 
Blocking of the it nitrogen has been shown to virtually eliminate His racemisation 76 
and it nitrogen protected with tertiary-butoxymethyl (Bum) 77 is available, however it 








Differential protection is available for Cys on the basis of TFA lability and can be 
chosen on the criteria to have free or protected cysteines during the initial purification. 
Cys protected with trityl is TFA labile and is therefore cleaved to generate the free 
thiol during the standard cleavage. Alternatively, Cys protection can be retained if 
protected by the acetamidomethyl (Acm) or B utthio  (SBu) groups, both of which are 
stable to TFA. The Acm group is cleaved with silver trifluoromethane sulphonate 78 or 
mercury II ion 79  and SBut  is cleaved by reduction with 3-mercaptoethanol 8° or 
tributylphosphine. 81 
1.2.6. Fmoc SPPS-monitoring. 
Coupling efficiencies cannot be assumed to go to completion and can often drop 
dramatically due to sequence effects such as steric hindrance e.g. the coupling of 
Cys(Trt) to His(Trt). Deprotection of Fmoc with base (20% piperidine/DMF) by a 
elimination mechanism results in a dibenzofulvene adduct which is quenched with 
excess piperidine giving an fulvene-piperidine adduct. This has a strong UV 
absorbance at 302nm and thus monitoring of the deprotection solution provides a 
quantitative estimation of the % efficiency at each cycle. 
Figure 1.19. Deprotection of an Fmoc-protected peptide. 
Although this technique provides a reliable estimation of coupling efficiencies at each 
cycle it does not importantly allow intervention to repeat the coupling or use extended 
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times if a particularly inefficient coupling has occurred. Towards this goal, 
monitoring of the activated amino acid by continuous circulation has been examined 
although this can be complicated by UV absorbance of the activating group. This 
therefore necessitates the development of a non UV active activating group which at 
the same time maintains high coupling efficiencies. 
1.2.7. Fmoc SPPS -acidolytic cleavage. 
The simultaneous cleavage of the peptide-resin linkage and removal of side-chain 
PG's can be achieved in most cases with 95% aqueous TFA by an SNJ  mechanism. 
This generates tertiary-butyl cations and tertiary-butyl trifluoroacetate which are 
quenched with scavengers (1 ,2-ethanedithiollethylmethylsulphide/phenol/thioanisole) 
to prevent tertiary-butylation of Met, Trp and Tyr. The scavengers are also important 
in shifting the cleavage mechanism from an SN1 to SN2 for certain less acid labile PG's 








Figure 1.20. Acid catalysed cleavage of the peptide from the Wang resin. 
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1.2.8. Chemical ligation. 
Advances in SPPS allow for the synthesis of moderately sized peptides of ca 100 
amino acids in length before the accumulation of deletion products becomes 
prohibitively large. 12  To extend beyond this range, the chemical ligation of 
unprotected fragments to form larger proteins has been developed. This requires 
chemo selectivity in the unprotected peptides so that only the intended sites can react 
with each other in the presence of many side-chain functionality's. 
Chemical ligation involving a native peptide bond between the two fragments has been 
developed by Kent83 and is shown in figure 1.21. Ligation proceeds via nucleophilic 
attack by the thiol side chain of the N-terminus cysteine of peptide-2 with the 
thioester at the C-terminus of peptide-1. The ligation product then undergoes rapid 
intramolecular reaction via a favourable five membered ring and rearrangement to 
give the product with a native peptide bond at the ligation site. This methodology has 
been successfully used in the synthesis of the 72 amino acid human interleukin 8 which 
contains a total of four cysteines. 
0 	 0 
Peptide-1 F_-Ji___SR 	NH3—CH—t!___l Peptide-2 
I Chemoselective 
+ reaction 
P 10 NH 	_____11 
Peptide-1 	 Peptide-2 
Spontaneous 
rearrangement 
Peptide-1 F_ —NH-CH— _H Peptide-2 
HS 
Figure 1.21. Chemical ligation between the C-terminal thioester of peptide-1 
and the N-terminal cysteine of peptide-2. 
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However, ligation is not restricted to the native peptide bond with other ligation 
chemistries developed to include thioester-forming ligation 14,11,86  thioether 
formation," thiazolidine ring formation" and oxime forming ligations. 89 
In a recent outstanding paper by Canne, three ligation reactions involving two 
thioester and one oxime forming ligations were performed to give the biologically 
active 20 kilodalton cMyc-Max heterodimer and the covalent Max homodimer which 
are important proteins for regulating gene expression through their DNA binding 
specificity's. 9° 
1.2.9. Summary. 
Therefore, continued advances in SPPS methodology allow for the synthesis of larger 
proteins, which in some instances may be difficult to obtain by recombinant DNA 
technology. Additionally, SPPS and chemical ligation allow for subtle changes in 
amino acid side-chains with unnatural or synthetic amino acids or indeed the peptide 
backbone through the use of non-native ligation procedures. Thus, an increasing 
array of tools are available to the protein chemist which provide new and exciting 
opportunities for the study of protein structure and function. 
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Chapter 2. Discussion 
Section 2.1. Project statement. 
The protein ubiquitin has been used as a model for folding studies with the synthesis 
of ubiquitin analogues including both single and double substitutions. Chemical 
synthesis has allowed for the facile incorporation of both unnatural amino acids and a 
novel synthetic fluorinated amino acid. 
Purification of synthetic ubiquitin by a variety of protocols has identified important 
steps in the folding pathway of ubiquitin. These results have been used in the 
modification of subsequent purification's. 
We have investigated the placement of fluorine within the hydrophobic core of 
ubiquitin through the synthesis of three double substitutions at positions 43&67, 
50&67, 56&67 and one single substitution at position 67 using (2S,4S)-5-
fluoroleucine to replace leucine at specific positions in the sequence. Methyl transfer 
across the hydrophobic core has been considered in the double substitution analogue 
[3-norleucine,43-norvaline]ubiquitin involving a modification in the distribution of 
alkyl groups. The importance of the chirality of the single histidine on the final strand 
of f3-sheet has been examined in the synthesis of [68-Dhistidine]ubiquitin. 
The contribution of secondary structural features in protein folding has been 
investigated by studying peptide fragments corresponding to the N and C-terminal 
halves of ubiquitin and three overlapping peptides on the final strand of 3-sheet. The 
complementation of the N and C-terminal halves to regenerate the native fold has also 
been considered. 
Structural information has been obtained using far UV circular dichroism, 
fluorescence studies, 1D & 2D 'H NMR and where applicable ' 9F NMR. The 
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biological activity has also been determined in order to correlate structure activity 
relationships. 
Section 2.2. Synthetic ubiquitin. 
During the purification of ubiquitin protein analogues it became apparent that some 
steps were crucial for the attainment of the native fold. In order to identify the best 
purification procedure synthetic ubiquitin was purified using several techniques. In 
particular it was found that high purity samples had a non-native fold and we were 
interested in purification/folding procedures which would allow access to the native 
fold. 
The synthesis of ubiquitin gave an overall final yield of 66% for the N-terminal 
methiomne on the resin as determined by quantitative Fmoc deprotection, which 






0 	 19 	 38 	 57 	 76 
Progress of Synthesis 
Figure 2.1. Progress of Ub(syn) synthesis as monitored by UV at 302nm of the 
deprotection solution containing the piperidine-fulvene adduct. 
The observed % yields during chain assembly were observed to be greater than 100% 
which can be attributed to the swelling properties of the polystyrene resin that vary 
according to both the type of solvents used and the peptide sequence being 
synthesised. It is thought that increased resin swelling could result in the absorption 
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of more solvent which would increase the concentration of the piperidine-fulvene 
adduct in solution and hence result in observed % yields greater than 100%.' 
The different purification protocols used in the purification of synthetic ubiquitin are 
summarised in figure 2.2. 
Tbfmoc Purification Protocol 
Gel Filtration G50 Sephadex 
Synthetic Ub I 
Refolding from 6M GdmCl buffer 
Synthetic Ub II 
/\ 
Cation Exchange 	FPLC Superdex 75 
Synthetic Ub III Synthetic Ub IV 
Non-Tbfmoc Purification Protocol 
Gel Filtration G50 Sephadex 
Refolding from 6M GdmCI buffer 
/\ 
Cation Exchange 	FPLC Superdex 7 
and RP HPLC 	Synthetic Ub VI 
Synthetic Ub V 
Figure 2.2. Purification protocols used in the study of synthetic ubiquitin. 
2.2.1. Tbfmoc Purification Protocol. 
During solid phase peptide synthesis acetylated truncates accumulate on the resin due 
to incomplete coupling steps and need to be separated from the desired peptide 
sequence. This can be achieved by derivatising the N-terminus with the base labile 
1 7-tetrabenzo[a, c,g, i]fiuorenylmethoxycarbonyl (Tbthioc) group and exploiting its 
hydrophobicity to enable separation of the Tbfinoc-peptide from the truncates. Two 
methods of purification have been developed using either affinity purification on 
porous graphitised carbon (PGC) through the non covalent binding of the Tbfmoc-
peptide or alternatively reverse phase HPLC which enables separation through the 
increased retention time of the Thfhoc-peptide. 92' 93 ' 94' 95 For the purification of 
ubiquitin protein analogues the TbfmocfPGC purification (figure 2.3.) was chosen in 
preference to reverse phase HPLC since initial studies had shown limited recovery of 












TFA I Scavengers 
-•- -E 
-Sr-- - --- -Tbfmoc 







Key: Amino acids are coded for by 	
• 	
etc, 
c: 	and 	represents acetate group and POC respectively 
Figure 2.3. Schematic diagram of PGCffbfmoc purification. 
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The solvent chosen for the procedure was a 1:1 mixture of an aqueous 6M 
guanidinium chloride & isopropanol. The reasons for this were twofold, the 
guanidinium chloride was used to ensure the solubility of the Tbfhioc-protein which 
tended to be rather insoluble and the isopropanol because it had previously been 
shown that 50% aqueous isopropanol was a good solvent to ensure complete 
recovery of the peptide from the PGC after cleavage of the Tbfmoc moiety with 
base. 96 
Initial purification of synthetic ubiquitin used the TbfmocfPGC protocol followed by 
desalting by gel filtration giving Ub(syn) I. The AAA and MALDI MS for Ub(syn) I 
were as required, however the analytical RP HPLC of this was much broader 
compared to Ub(bovine) (figure 2.6). 
A portion of Ub(syn) I was refolded from 6M guanidinium chloride to give Ub(syn) II 
and the 1D NMR spectra were recorded at 600 MHz on both Ub(syn) I (figure 2.4.) 
and Ub(syn) II to assess the degree of folding. Comparison of the 1D 'H NIMR's of 
Ub(syn) I & II indicated they were similar to Ub(bovine) but with broader NMIR 
signals and lack of chemical shift dispersion indicating a non-native fold with perhaps 
mc 
ppm 	
iv.0 	8.0 	6.0 	4.0 	2.0 	0.0 	-2.1) 
Figure 2.4. 1D 'II NMR of Ub(syn) I at 600 MHz, pH 48 and 25 °C. 
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The secondary structure content of Ub(syn) I was investigated using far UV circular 
dichroism (figure 2.5.). 





Ub(syn) I 	Ub(bovine) 	Ub(syn) I 	Ub(bovine) 
pH 7 pH 7 50% TFE 50% TFE 
Figure 2.5. Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures : heavily shaded bars, cc-helix and clear bars, 
n-sheet 
The CD analysis at pH 7 indicate both reduced a-helicity from 19% in Ub(bovine) to 
14% in Ub(syn) I, and similarly reduced f3-sheet to 47% in Ub(syn) from 56% in 
TJb(bovine). Addition of 50% TFE increases the cc-helicity and decreases the 13-sheet 
by approximately the same proportion in both, indicating similar structural 
preferences. These results indicate a similar secondary structure in Ub(syn) I and 
Ub(bovine), however CD analysis does not allow for identification of the actual 
residues involved in secondary structure. 
A portion of Ub(syn) II was further purified by cation exchange chromatography on 
CM-Sepharose CL613. The separation is based on the reversible adsorption of 
positively charged protein molecules to a negatively charged matrix. The protein 
sample initially binds to the matrix and selective separation and elution of protein is 
achieved by application of a pH gradient followed by a salt gradient. This resulted in 
the isolation of five protein fractions, of which the analytical RP HPLC profile of 




Figure 2.6. Analytical PP HPLC's of (a) Ub(syn) I, (b) Ub(syn)ffl F4 and 
(c)Ub(bovine). 
Furthermore, the 1D 'H NMR spectrum of Ub(syn) III F4 (figure 2.7.)was 
indistinguishable from that of Ub(bovine). This clearly shows that cation exchange is 
crucial for the folding of ubiquitin and in this instance should be viewed as a folding 
ppm 	10.0 	8.0 	6.0 	4.0 	2.0 	0.0 
Figure 2.7. 1D 'H NMR of Ub(syn) ifi F4 at 600 MHz, pH 48 and 25 °C. 
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In order to quantify the importance of cation exchange chromatography a second 
portion of Ub(syn) II was further purified using FPLC Superdex 75 with the 
separation based on size differences. Two fractions were isolated, Ub(syn) IV Fl and 
F2, with the second fraction co-eluting with Ub(bovine). The analytical RP HPLC's 
of these were sharper than Ub(syn) I & II but less sharp than synthetic Ub(syn) III F4. 
The 1D 1H NIFvIR of Ub(syn) IV F2 was less well defined with reduced chemical shift 
dispersion compared to Ub(syn) III F4 indicating a non-native fold. 
From these results we can conclude that the Tbfiuioc group is perturbing the folding of 
the protein at a very early stage. The Tbfmoc group is highly hydrophobic and could 
be postulated to act as a template for the clustering of hydrophobic amino acids 
around it. 
Another plausible explanation is that the N-terminus of ubiquitin plays an important 
role in directing the folding to the native state. Attachment of the Tbfmoc group to 
the N-terminus significantly distorts the folding to a non-native fold. The process of 
cation exchange chromatography does allow formation of the native fold and is 
obviously an important step in the folding of ubiquitin. Further work is required on 
the structure of Tbfinoc-ubiquitin, although difficulties would be encountered in 
working with it due to limited solubility. 
	
Tbfmoc-Ub-Resin 	 H-Ub-Resin 
Jr 	 I 
Tbfmoc-Ub-OH 	 H-Ub-ON 
I I 
Folding from C-Terminus 	 Folding fron N-Terminus 
Non-native Folding 	 Native Folding 
Figure 2.8. Ubiquitin folding pathways (secondary structure shown for non-




The non-native folding is postulated to occur predominantly from the C-terminus 
prior to release of the purified protein from the PGC (figure 2.8.). 
The conditions used in the Tbfmoc/PGC purification were investigated to see if they 
caused any structural changes. In particular, we studied the deprotection of the 
Tbfhioc group which used high pH to evaluate any structural perturbation. Therefore, 
Ub(bovine) was treated with 10% piperidine in 1:1 mixture of guanidinium 
chloride/isopropanol and subsequently desalted by semipreparative RP HPLC & 
lyophilised. The 1D 'H NMR of this material was identical to non-treated Ub(bovine) 
confirming that the actual experimental conditions caused no structural changes but 
rather the Tbflnoc group resulted in non-native folding. 
Several other proteins have been purified using the Tbfhioc purification protocol with 
no perturbation of structure observed. One example is the helix substitution analogue 
[26-a-aminobutyric,30-norvaline]ubiquitjn which was purified using the TbfmocfRP 
HPLC protocol and showed no overall change in architecture apart from the slight 
rotation of Nva30 as determined by x-ray crystallography. 97  Although, interestingly 
the 'H NMR of this analogue showed less dispersion of chemical shift suggesting that 
perhaps the physical process of crystallisation favoured formation of the native 
structure. 98 
2.2.2. Non-Tbfmoc Purification Protocol. 
The earlier work of Muir et a199 was repeated in order to confirm the folding of 
ubiquitin using a non-Tbthioc purification protocol. Three step purification by gel 
filtration, cation exchange chromatography and RP HPLC gave Ub(syn) V. The AAA 
and MALDI MS were as required and the analytical RP HPLC was very sharp. 
Furthermore, the 1D 'H NMR of Ub(syn) V was indistinguishable from Ub(bovine) 
with good chemical dispersion in the range up to 9ppm and two lower frequency 
signals at ca -05ppm (figure 2.9.). 
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Figure 2.9. 1D 'H NMR of Ub(syn) V at 600 MHz, pH 48 and 25°C.. 
Additional purification of a second portion by a non-Tfmoc protocol used FPLC 
Superdex 75 column instead of cation exchange chromatography, giving synthetic 
Ub(syn) VI. The AAA and MALDI MS were as required but the analytical RP HPLC 
of this was less sharp. The 1D 'H NMR of Ub(syn) VI showed a similar dispersion of 
chemical shifts to that of Ub(syn) V, but with reduced definition of signal indicating a 
less well formed tertiary structure. 
Conclusion for Synthetic Ubiquitin. 
It has been shown that TbfmocfPGC purification results in a non-native structure for 
ubiquitin. The native fold can be accessed via the use of cation exchange 
chromatography which has important implications for selection of purification 
techniques. This serendipitous result has shown the importance of the N-terminus in 
determining the native fold at a very early stage of protein folding. 
Section 2.3. U biquitin-( 1-35), (36-76)-Peptides. 
The Thfmoc purification protocol has shown that the N-terminus is crucial for the 
attainment of the native fold in ubiquitin. To this end we have studied the intrinsic 
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structural properties of the N and C-terminal halves of ubiquitin. This dissection of 
proteins into fragments allows interpretation of the individual structural preferences of 
the excised fragment and identification of any intrinsic folding domains. A previous 
study by Harding et a!55 on the peptides Ub(1-21) & Ub(1-35) showed that the native 
structure was maintained in the absence of the C-terminal half in 60% aqueous 
methanol pH 2. However, although it is known that native-like structure is found in 
the N-terminal half under these conditions, no information is available for the C-
terminal portion. The peptide Ub(1-35) comprises the 13-hairpin (1-7 & 10-17) and 
the a-helix (23-34) while Ub(36-76) contains the remaining three strands of 13-sheet 
(40-45, 48-50 & 64-72) and the short piece of 3 10 helix (56-59). 
2.3.1. Synthesis and Purification of Ub(1-35) and Ub(36-76). 
Synthesis and purification of both peptides were straightforward giving final yields for 
the N-terminal amino acid on the resin of 70% for Ub(1-35) and a somewhat lower 
yield on the resin of 42% for Ub(36-76). The purification of TJb(1-35) used 
successive semi-preparative RP HPLC purifications. In contrast, due to the reduced 
% yield for Ub(36-76), a three step purification was employed using Tbfhoc/PGC, 
desalting by gel filtration and semi-preparative RP HPLC. The purity of the products 
were confirmed by AAA and MALDI MS (figure 2.10.). 
5000 
0 
Figure 2.10. MALDI MS for Ub(1-35), M+1 requires 39065 Da. 
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2.3.2. Circular Dichroism Analysis on Ub(1-35) and Ub(36-76). 
The far UV circular dichroism spectra of both peptides were measured in both 
methanol/water pH 2 and TFE/water pH 46 mixtures. For in vitro folding studies the 
solvent is very important in determining the secondary structure of the peptide and 
might be compared to the microsolvent environment created by nonlocal amino acids 
during formation of the tertiary structure. Alcohols such as methanol and TFE are 
known to promote the formation of cc-helices in peptides although the precise 
mechanism of structure enhancement is unknown. 100 The helix promoting ability 
(HPA) of these solvent mixtures have been measured for the alanine tripeptide (Ac-
(Ala)3-NIHMe) and the HPA order was calculated to be TFE/water = methanol 
(HPA=12) > methanol/water (HPA=45) > water (HPA=1) > TFE (HPA=03). 
The far UV circular dichroism results for Ub(1-35) are shown in figure 2.11. 
CD Analysis Ub(1-35) 
80 
2 60 
' 40 n 
8 20-JjJJ 
	
1-120 	25% 	50% 	H20 	30% 	60% 
p1-14.6 WE WE pH2 MeOH WOH 
Figure 2.11. Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures : heavily shaded bars, cc-helix and clear bars, 
13-sheet 
The calculated secondary structure for Ub(1-35) as present in the native state is a-
helix (34%), 13-sheet (46%) with remainder (20%). In water pH 4-6 the % of a-helix 
is negligible with the estimated structure divided almost equally between 13-sheet and 
random structure. Addition of 1'FE greatly increases the cc-helix content accompanied 
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by only a slight increase in 13-sheet in both 25 & 50% TFE/water mixtures. In water 
pH 2, the results mirror those of water alone with a slight decrease in 13-sheet 
observed with a corresponding increase in random structure. Addition of methanol 
increases the % of a-helix with 30% methanol giving only a modest increase to 8% 
helicity and 60% methanol increasing the helicity to 25% which is comparable to that 
observed in 50% TFE/water pH 46. The reduced helicity observed in 60% methanol 
pH 2 may result from increased flexibility in this portion of the molecule. In all of the 
solutions studied the % of 13-sheet remains roughly constant thus supporting the 
strong intrinsic conformational preference of the 13-hairpin in Ub(1-35). 
The far UV circular dichroism results for Ub(36-76) are shown in figure 2.12. 
80 
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H20 25% 	50% 	H20 	30% 	60% 
pH 4.6 WE WE pH2 WOH NbOH 
Figure 2.12. Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures: heavily shaded bars, a-helix and clear bars, 
13-sheet. 
The calculated secondary structure for Ub(36-76) as present in the native state is a-
helix (0%), f3-sheet (49%) with remainder (52%). In water pH 46 the % of a-helix is 
low (5%) but higher than for Ub(1-35), and as expected increases sharply with the 
addition of 25 & 50% TFE to 56 & 65% respectively. Surprisingly this increase in a-
helicity is not accompanied by a corresponding decrease in 13-sheet which remains 
reasonably constant. Addition of methanol again increases the ct-helicity, with 30% 
methanol resulting in only a small increase to 12% a-helicity while 60% methanol 
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increases the a-helicity to 55%. Again the t3-sheet structure is maintained with the 
increase in a-helicity correlating with a decrease in the % random coil structure. 
From the actual CD spectra for Ub(36-76) we observe the expected correlation 
between the mean residue ellipticity at 222nm [22]  to the proportion of helical 
content. The large difference between the CD spectra in water and alcohol/water 











Figure 2.13. Far UV circular dichroism spectra for Ub(36-76) in (1) H 20 pH 
4•6, (2) +25% TFE and (3) +50% TFE as indicated. 
The results for Ub(1-35) and Ub(36-76) show that TFE or methanol mixtures 
promote the formation of a-helicity in both peptides studied. In Ub(1-35) the a-helix 
may be regarded as native-like but with increased flexibility while maintenance of f3-
sheet is also native as indicated by the earlier work of Harding et al. 5 ' The increase in 
a-helicity for Ub(36-76) can be regarded as non-native and results entirely from the 
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specific helix promoting abilities of the aqueous alcohol solvents. Further work is 
required to determine whether the j3-sheet structure maintained is native or non-
native. 
2.3.3. Complementation of Ub(1-35) and Ub(36-76). 
The analysis of peptide fragments is important as it is postulated they could form 
structures which are important early events in protein folding. 101  There are several 
examples of fragments of proteins associating together to regenerate the native-like 
fold as shown for the Trp repressor, 102  barnase' °3 and chymotrypsin inhibitor-2.' °4 
Therefore, we were interested to study the interaction between the two peptides 
Ub(1-35) and Ub(36-76). 
The 1D 'H NM1R's ofUb(1-35) and Ub(36-76) were recorded at the lower pH of 3-1 
since it was found that Ub(1-35) formed an insoluble gel at higher pH's. The results 
for both are indicative of a random coil structure with no dispersion of chemical shift 
observed at either below 06ppm or above 85ppm. 
In order to evaluate the association of the two peptides, an equimolar amount of 
Ub(36-76) was mixed with Ub(1-35) and left at 25°C. After 24 hours the 1D 'H 
NIMIR was recorded and showed increased chemical shift dispersion at both the lower 
and higher frequencies, which was further enhanced after 96 hours (figure 2.14.). 
These results indicate that some association has occurred between the two peptides, 
resulting in the increased chemical shift dispersion. However, further 2D N1v1R 
experiments are required to discern the exact details of association 
This experiment between the two peptides was performed in aqueous conditions and 
it would be interesting to investigate the influence of other solvents such as aqueous 
alcohols on directing the association between the two peptides. 
A recent publication has shown that complementary assembly to give the native fold 
occurs in the ubiquitin a113 roll structure of the streptococcal protein G BI domain, 
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between the two fragments (1-40) and (41-56)." 0' Importantly no association was 
seen for other pairs of fragments studied which included (1-10) & (11-56), (1-20) & 
(21-56) and (1-30) & (31-56). 
ppm 
Figure 2.14. 1D 'B NMR for equimolar mix of Ub(1-35) & Ub(36-76) after 96 




Section 2.4. Ubiquitin-(68-76), (66-76), (64-76)-Peptides. 




Three overlapping peptides were synthesised corresponding to the final strand of 3-
sheet (64-72) and purified by semi-preparative RP HPLC. Following purification, the 
purity of the peptides were confirmed by AAA and FAB MS. To access the structural 
preferences of each peptide circular dichroism analysis were recorded in both 
TFE/water pH 46 and methanol/water pH 2 mixtures (figure 2.15.). 
The results for Ub(68-76) indicate that the 13-sheet remains approximately constant in 
all the solutions studied. Addition of TFE or methanol increases the cx-helicity only 
slightly accompanied by a corresponding decrease in 13-sheet. 
For Ub(66-76) the 13-sheet content remains reasonably constant in all but the 30% 
methanol solution where random structure prevails. Addition of 25% or 50% TFE 
increases the cc-helicity to a greater extent than in Ub(68-76) and importantly with no 
decrease in 3-sheet observed. 60% Methanol results in only a minor increase in a-
helicity with a corresponding decrease in 13-sheet seen. 
For Ub(64-76) the f3-sheet structure shows more variation than in the other solutions 
studied. Addition of TFE or methanol increase the a-helicity to the same extent as in 
Ub(66-76) but this time with decreased 13-sheet structure suggesting more flexibility in 
the structure. 
Therefore, overall there is limited helix forming tendencies in these small peptides 
studies but increased a-helicity is observed with increased chain length. The 13-sheet 
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shows limited variation indicating a strong preference for the 13-sheet structure which 
has formed. 









pH 4.6 TEE  
50% 	H20 	30% 	60% 
TEE pH MeOH MeOH 







pH 4.6 TEE 
rim  
50% 	H20 	30% 	60% 
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H20 	25% 	50% 	H20 	30% 	60% 
pH 4.6 TEE TFE pH 2 MeOH MeOH 
Figure 2.15. Deconvolutions of CD spectra for a) Ub(68-76), b) Ub(66-76) and c) 
Ub(64-76) into % secondary structure expressed as one of the following 
structures : heavily shaded bars, a-helix; clear bars, 13-sheet. 
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Section 2.5. Ubiquitiñ Fluorinated Analogues. 
Several fluorine containing ubiquitin analogues have been made in order to investigate 
the structural and biological consequences of fluorine substitution within the primary 
sequence. Chemical synthesis offers the advantage of specific incorporation of the 
fluorine containing amino acid at any predetermined position. This compares to 
biosynthetic means in which all positions in the sequence occupied by a given amino 
acid become fluorine labelled to some degree. Computer graphics indicate that 
incorporation of fluorine into a peptide or protein results in only minor structural 
variation and often no effect on biochemical properties is observed unless a critical 
amino acid has been substituted. 106  The NMR properties of fluorine are particularly 
useful having a spin of '/2, present in 100% natural abundance and a similar sensitivity 
to that of hydrogen. Furthermore, the fluorine nucleus is very sensitive to its 
environment as reflected in the large chemical shift range for fluorine containing 
compounds exceeding 900ppm. 107 Hence, fluorine chemical shifts vary between the 
unfolded and native states of a protein and therefore conformational changes can be 
monitored by ' 9F NMR studies as shown for the native and unfolded forms of the 
intestinal fatty acid-binding protein. 108 A further advantage of 19i  NMR is that we can 
monitor specifically the change in environment for the individual amino acid side-
chain substituted compared to the complexity of 'H NMR relating to all amino acids 
present. 
In order to gain information on the hydrophobic core of ubiquitin we have 
constructed both double and single substitutions using (2S,4S)-5-fluoroleucine (FLeu) 
(figure 2.16.) to replace leucine at specific positions in the sequence. 
II 	 11 STEPS 
H 	 10 
ONCO2H 	 ON 




Figure 2.16. Synthesis of (2S,4S)-5-fluoroleucine by Professor D.W. Young and 
B.A. Starkmann, University of Sussex, UK. 
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These are isosteric replacements and hence should result in negligible steric effects. 
The major change in replacing hydrogen with fluorine is the difference in 
electronegativities between the two and how the highly electronegative fluorine will 
be accommodated within the core. 
Ubiquitin contains a total of nine leucine residues in the primary sequence (figure 
2.17.), five of which are in reasonable proximity to each other and of interest for 
substitution. 
1 	 38 
MQI FVKTLTGKTITLEVEPSDTIENVKLkKIQDKEGI PP 
39 	 76 
DQQRLI FAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
Figure 2.17. Primary sequence of human ubiquitin with leucine residues 
highlighted at positions 8, 15, 43, 50, 56, 67, 69, 71 and 73. 
The relative distance between the five residues 15, 43, 50, 56 & 67 which form part of 
the hydrophobic core are shown in table 2.1. 
Table 2.1. Relative distance (A°) between öl carbon of Len residues in ubiquitin 
based on the 3D structure. 15 
- Leul5 Len 43 Len 50 Len 56 Len 67 
Leul5 - 
Len 43 9.067 - 
Len 50 12.154 4.825 - 
Len 56 9.447 8.419 7.571 - 
Len 67 8.488 4.485 4.182 6.281 
The following double substitution analogues, [FLeu 43 ,FLeu67]Ub, [FLeu50,FLeu67]Ub, 
[FLeu56,FLeu67]ub using position 67 as the banker residue and the mono-substitution 
[FLeu67]ub'°9 were chosen for synthesis. Residues 43, 50 & 67 are on the third, 
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fourth and fifth strands of J3-sheet respectively while residue 56 is part of the surface 
loop comprising residues 51-59. Their related spatial positions are shown in figure 
2.18. 	 ............. 	 . 
Figure 2.18. Diagram of FLeu side-chains at positions 43, 50, 56 and 67 with 6 - 
CH2 F indicated by #: produced using Insight II program. 
All analogues were synthesised using standard solid phase synthesis procedure except 
for the coupling of(2S,4S)-5-fiuoroleucine which utilised sonication to maximise the 
reaction. The synthesis of [FLeu 43 ,FLeu67]Ub and [FLeu 50,FLeu67]IJb gave excellent 
overall yields with 72% and 83% respectively for the N-terminal methionine on the 
resin. The synthesis of [FLeu 56,FLeu67]Ub was less good due to the inefficient 
coupling of the FLeu residues giving an overall yield of 32% for the N-terminal 
methionine on the resin (figure 2.19.). 
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Figure 2.19. Progress of ubiquitin fluorinated analogues syntheses as monitored 
by UV at 302nm of the deprotection solution containing the piperidine-fulvene 
adduct. The inefficient coupling of FLeu67 & FLeu56 in the synthesis of 
[FLeu 56,FLeu 67JUb are indicated by arrows. 
Each ubiquitin fluorinated analogue will be discussed separately apart from an overall 
discussion of the fluorine NItvlR data from all the protein analogues at the end of the 
section. 
Section 2.5.1. [1 O,35,47&53-15N-Glycine, 56&67-(2S,4S)-5-fluoroleucine] 
ubiquitin 
Purification of this analogue by standard chromatographic techniques would have 
proved extremely difficult due to the low overall yield resulting in a high quantity of 
truncates as shown in figure 2.20. 
However, the high capability of the Thflnoc group selectively separates the required 
peptide from the truncates, thus simplifying the purification. Two step purification by 
Thfmoc/PGC and desalting by RP HPLC gave synthetic [FLeu 56,FLeu67]Ub I in 
reasonable quantities. Characterisation by AAA and MALDI MS confirmed the 
authenticity of the purified product. Prior to starting structural analysis, 
[FLeu 56,FLeu67]Ub I was dissolved in 8M urea buffer and sequentially dialysed against 







Figure 2.20. Analytical RP HPLC's of crude Tbfmoc-[FLeu,FLeu 671Ub 
(upper) and purified [FLeu,FLeu 671Ub I (lower). 
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The far UV circular dichroism results for [FLeu 56,FLeu67]Ub I are shown in figure 
2.21. 







[FLeu56&67]t 	Ub(bovine) 	[FLeu56&67]Lb 	Ub(bovine) 
pH 7 pH 7 50% TFE 50% TFE 
Figure 2.21. Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures : heavily shaded bars, cc-helix and clear bars, 
p3-sheet. 
The calculated secondary structure for [FLeu 56 ,FLeu67]TJb I indicates a decrease in the 
ct-helicity from 19% as measured in Ub(bovine) to only 11% in the analogue. This 
compares with the f3-.sheet structure which is approximately equal in both with 52% 
observed in the analogue compared to 56% in Ub(bovine). Addition of 50% TFE 
increases the cx—helicity as expected, but the increase is far greater in the analogue, 
80% compared to only 50% in Ub(bovine). This large increase in cc—helicity is 
accompanied by a corresponding decrease in 13-sheet which suggests the overall 
sheet structure t is less rigid in the analogue being easily promoted to ct-helicity. 
The environment of the single tyrosine at position 59 was investigated using 
fluorescence studies. In Ub(bovine) the fluorescence is partially quenched by the 
surrounding amide bonds in the folded state but increases upon unfolding in 
denaturing conditions. The disadvantages of using Tyr59 to monitor structural 
changes is its lack of sensitivity compared to Trp and also its position on the periphery 
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of the structure which means information gained is really only applicable to the loop 
comprising residues 5 1-59. 
Fluorescence -monitored denaturation of 
[FLeu,FLeu67]Ub & Ub(bovine) 
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Figure 2.22. Plot of relative fluorescence for IFLeu 56,FLeu67lUb I and 
Ub(bovine) versus IGdmCll. 
From figure 2.22. we can clearly observe the expected unfolding curve for TJb(bovine) 
with increasing concentration of denaturant. No unfolding curve is seen for 
[FLeu56 ,FLeu67]Ub I suggesting that Tyr59 is already exposed to the solvent in non-
denaturing conditions. The data set for the guanidinium chloride unfolding curve of 
Ub(bovine) can be fitted with the non-linear regression analysis equation 3, which is 
derived from equations 1 & 2 and assumes a two state model of unfolding. 48 
Equilibrium constant for unfolding: 
Ku = (FN-F) / (F-F e) = exp(-Gu / RT) 	 (1) 
Free energy of unfolding: 




F = FN - (FN - Fu) x exp (m[GdmCl} - AGino/ RT) 
1 + (exp (m[GdmCl] - EG 0 / RT) 	(3) 
where Ku is the equilibrium constant for unfolding, AGu is the free energy of 
unfolding at a particular concentration of denaturant, AG 0 is the free energy of 
unfolding in water, F is the observed fluorescence and FN and F u are the values of 




The free energy of stabilisation for Ub(bovine) was calculated by Grafit, Microsoft 
using nonlinear regression analysis to be which compares 
favourably with the expected value of ca 7kcalmor'. 411  
The 1D 'H NIMR of [FLeu56,FLeu67]Ub I was recorded and shows both less 
dispersion and definition of chemical shifts, although the overall shape of the 
Ub(bovine) is clearly visible (figure 2.23.). 
-- 
I 	 I 	 I 
ppm 10.0 	 8.0 6.0 4.0 	 2.0 	 0.0 
Figure 2.23. 1D 1JJ NMR of [FLeu,FLeu 67JUb I at 600 MHz, pH 51 and 15°C. 
Section 2.5.2. 
[50&67-(2S,4S)-5-Fluoroleucine]ubiqujtjn 
Initially half of the resin bound product was purified using the TbfmocfPGC protocol 
and desalted by gel filtration to give [FLeu 50,FLeu67]Ub I. The MALDI MS and AAA 
were as required indicating a pure sample but the analytical RP HPLC was much 
broader compared to Ub(bovine) (figure 2.24.). Furthermore the 1D 'H NMR of 
[FLeu50,FLeu67]Ub I had a narrower dispersion of chemical shifts in the region ca> 
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8ppm region compared with Ub(bovine), although one lower frequency signal at - 
05ppm is seen (figure 2.24.). The overall shape of the NIvIIR spectra is the same in 
both the analogue and Ub(bovine), but with reduced definition in the analogue 
suggesting slow tumbling between more than one conformation. No improvement in 
the 'H NMIR occurred after denaturation and refolding from 8M urea or from 




b.V 	 1q. 0 	2.0 	0.0 
Figure 2.24. 1D 'H NMR of [FLeu 50,FLeu67]Ub I at 600 MHz, pH 54 and 15°C 
with inset of analytical RP HPLC. 
Further purification of [FLeu 50,FLeu67]IJb I by FPLC Superdex 75 gave synthetic 
[FLeu 50,FLeu67]ub II Fl & F2. During FPLC purification it was noted that that two 
closely spaced protein peaks were observed in the later eluting fraction perhaps 
63 
Discussion 
indicating two slowly interconverting conformations. Again, the analytical RP 
HPLC's of[FLeu 50,FLeu67]Ub II Fl & F2 were broad and in this instance the MALDI 
MS was much more difficult to obtain. In general, we have noticed that it is far easier 
to obtain MALDI MS data for ubiquitin protein analogues that have a well defined 
tertiary structure as indicated by 1H NMIR. 110 
The far UV circular dichroism results for [FLeu 50,FLeu67]Ub II F2 are shown in figure 
2.25. 
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[FLeu5O&67]Lb Ub(bovine) 	[FLeu5O&67]U 	Ub(bovine) 
pH7 	 pH7 50% WE 50% WE 
Figure 2.25 Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures: heavily shaded bars, a-helix and clear bars, 
13-sheet. 
The CD results indicate the ct-helicity is much reduced from 19% in Ub(bovine) to 
only 5% a-helicity in [FLeu 50,FLeu67]Ub II F2, while the 13-sheet content is virtually 
identical in both. Addition of 50% TFE results in a small increase in a-helicity to 
15% in [FLeu50,FLeu67]Ub II F2 compared to 50% in Ub(bovine), at the same time 
the 13-sheet content decreases to ca 37% in both. 
Previous work on Ub(syn) had shown that the native fold could be attained by cation 
exchange, however application of [FLeu 50,FLeu67]Ub H Fl/F2 to the cation exchange 
column resulted in only poor recovery of [FLeu 50,FLeu67]Ub III F1/F2/F3/F4 and no 
further work was done on these fractions. 
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The second half of resin bound product was purified by a two step protocol using gel 
filtration and cation exchange chromatography giving [FLeu 50,FLeu67]Ub IV. Good 
correlation was seen for the AAA, much improved compared to those samples 
purified using the TbfhiocfPGC protocol. We believe this reflects the different 
'folded' structures present in the samples rather than the overall purity. For example, 
previous attempts to optimise the hydrolysis time for [FLeu 50,FLeu67]Ub I with a 
timed hydrolysis at 24, 40, 60 & 70 hours gave no overall improvement in the AAA 
results. 
The analytical RP HPLC of [FLeu 50,FLeu67]Ub IV was as sharp as Ub(bovine) 
although it eluted earlier with a R=174 minutes compared to a R=176 minutes for 
Ub(bovine) (figure 2.27.). The MALDI MS was 171Da higher than expected, and 
furthermore [FLeu 50,FLeu67]Ub IV co-eluted with [MetS-oxide 1 ]Ub(bovine) 
confirming that the methionine had oxidised to the sulphoxide during the purification 
protocol. 
The 1D 'H NIMIR of [FLeu 50,FLeu67]Ub IV was much sharper than those obtained 
previously and indeed with good dispersion of chemical shifts seen albeit with reduced 
definition in the region 8-9ppm indicating formation of a looser native fold (figure 
2.27.). This is expected and was noted by Breslow et al during their study on [MetS-
oxide']Ub because the two possible sulphoxide isomers weaken the stability of the 























(less stable suiphoxide) 
Figure. 2.26. Schematic representation of the hydrogen bond between Metl and 
the two MetS-oxidel isomers with the backbone amide of Lys63. 
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Figure 2.27. Analytical RP LLPLC of [FLeu 50,FLeu67]Ub IV co-injection with 
Ub(bovine) (upper) and 1D 'H NMR of [FLeu 50,FLeu67JUb IV at 600 MHz, pH 
48 and 25°C (lower). 
The methionine suiphoxide was reduced to methionine by treatment with N-
methylmercaptoacetamide in 10% aqueous acetic acid over 48 hours at 37 °C. 
Initially, the reduction reaction was attempted using 50mM NH 4OAc pH 45 instead 
of 10% aqueous acetic acid but the reduction reaction was observed to be only 
negligible after 24 hours and therefore 10% aqueous acetic acid was used. Other 
reagents reported for the reduction of methionine suiphoxide include 0-
mercaptoethanol and dithiothreitol but these were not considered. 112  Cation exchange 
of the reduction reaction to maintain the folded state and lyophilisation gave 
[FLeu50,FLeu67]Ub V. The analytical RP HPLC of this co-eluted with Ub(bovine) 









PMo Calibration: C:'OATAUNTSTO.U3R 	 C.d.: 7O( 4I PM 
0 
Insulin M+2 
Expect 5734.5 Da 
FFLOUSO,FLOU67JUb 
Expect 8601.8 Da 	Insulin M+1 
Expect 11468.0 Da 
1726 	mlz 	 6962 	 16706 	 27959 
Figure 2.28. MALDI MS of reduced product [FLeu 50,FLeu67JUb V. 
Furthermore, the 1D 111 NMR of [FLeu 50,FLeu67]lIJb V was virtually indistinguishable 
from that of TJb(bovine) with both excellent definition of chemical shifts throughout, 
but importantly in the region 8-9ppm indicating formation of the native fold (figure 
2.29.). 
 
ppm IO.0 	8.0 	6.0 	q. 0 	2.0 	0.0 
Figure 2.29. 1D 'H NMR of [FLeu 50,FLeu 67]Ub V at 600 MHz, pH 48 and 25 °C. 
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The far UV circular dichroism results for [FLeu 50,FLeu67]Ub V are shown in figure 
2.30. 






OR 	0 .1 
[FLeu50&67]Ub Ub(bovine) 	[FLeu5O&67]Ub 	Ub(bovine) 
pH7 	 pH7 50%TFE 50%TFE 
Figure 2.30. Deconvolutions of CD spectra into % secondary structure expressed 
as one of the following structures : heavily shaded bars, a-helix and clear bars, 
13-sheet. 
At pH 7, good correlation is seen for the a-helicity content at ca 20% for both 
[FLeu50,FLeu67]Ub V and Ub(bovine). However, the 13-sheet content is much 
reduced from 56% in Ub(bovine) to only 30% in [FLeu 50,FLeu67]Ub V. Addition of 
50% TFE results in a large promotion of a-helicity in [FLeu 50,FLeu67]Ub V with 
complete disappearance of 13-sheet structure indicative of weaker tertiary interactions 
present in the 13-sheet. 
Section 2.5.3. [43&67-(2S,4S)-5-Fluoroleucine]ubiquitin. 
The results for this analogue closely mirror those obtained for the [FLeu 50,FLeu67]Ub 
analogue previously discussed. Initial purification of half the resin bound product by 
the Tbfmoc/PGC protocol gave [FLeu 43 ,FLeu67]Ub I. From the analytical RP HPLC 
of the starting Tbfmoc protein solution several peaks elute between 68-78% aqueous 
CH3 CN indicating that even at this early stage more than one conformation is present 
(figure 2.31.). The MALDI MS and AAA were as required but again the analytical 






- 	 lb 	 I iune (min) 	 32 
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16 	 Time (min) 	 32 
Figure 2.31. Analytical RP IIPLC's of Tbfmoc-[FLeu,FLeu 67]Ub (upper) and 
after purification on PGC and desalting to give IFLeu 43,FLeu671Ub I (lower). 
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The 1D 'H NMIR of [FLeu43 ,FLeu67]Ub I was essentially identical to that obtained for 
[FLeu 50,FLeu67]Ub I with both a reduced dispersion and definition of chemical shifts 
obtained indicating a non-native fold (figure 2.32.). 
ppm w.'' 	U. V 	 t.0 	'LO 	2.0 	0.0 
Figure 2.32. 1D 'H NMR of [FLeu 43,FLeu67JUb I at 600 MHz, pH 51 and 15°C. 
Further purification of [FLeu 43,FLeu67]IJb I by FPLC Superdex 75 gave 
[FLeu43,FLeu67]Ub II Fl & F2. The analytical RP HPLC's of these were broad, the 
AAA were as expected and again the MALDI MS were difficult to obtain. 
The far UV circular dichroism results for [FLeu 43 ,FLeu67]Ub II F2 are shown in figure 
2.33. 
At pH 7, the a—helicity is much reduced to only 6% in [FLeu 43,FLeu67]Ub II F2 from 
19% in Ub(bovine), while the t3-sheet content is similar at 48% for [FLeu 43,FLeu67]Ub 
II F2 compared to 56% in Ub(bovine). Addition of 50% TFE to [FLeu43,FLeu67]Ub 
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II F2 results in only a modest increase in the ct-helicity to 19% with a corresponding 
decrease in the 13-sheet to 35%. 





[FLeu43&67]Lb 	Ub(bovine) 	[FLeu43&67]Lb 	Ub(bovine) 
pH 7 	 pH 7 50% TFE 50% WE 
Figure 2.33. Deconvolutions of CD spectra into % secondary structure expressed 
as each of the following structures : heavily shaded bars, cc-helix; clear bars, 
sheet. 
Attempted tte pted refolding of [FLeu 43 ,FLeu67]Ub II Fl/F2 by cation exchange 
chromatography gave increased recovery compared to [1FLeu 50,FLeu67]Ub. Analytical 
RP HPLC of the third fraction, [FLeu 43,FLeu67]Ub III P3 from the cation exchange 
column was very sharp with two closely eluting peaks. Previous results would 
indicate that these correspond to the methionine and methionine sulphoxide of 
[FLeu43 ,FLeu67]Ub. The MALDI MS gave 86076 and 8832413a corresponding to 
the methionine protein and matrix adduct. The 1D 'H NMR of this material was 
essentially identical to that obtained for [FLeu 50,FLeu67]Ub IV purified by the non-
TbfmocfPGC protocol, therefore cation exchange has successfully folded the material. 
Again, the 1D 'H NIvIIR was much sharper with a good dispersion of chemical shifts 
seen albeit with reduced definition in the region 8-9ppm indicating formation of a 
looser native fold. 
The second half of the resin bound product was purified by a two step protocol using 
gel filtration and cation exchange chromatography giving [FLeu 43,FLeu67]Ub IV. 
This was confirmed as the methionine sulphoxide by both co-elution with [MetS- 
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oxide']Ub(bovine) on analytical RP HPLC and the higher (+171Da) MALDI MS. 
The JD 'H NIIYvIR of this material was sharp with good dispersion albeit with reduced 
definition in the 8-9ppm region (figure 2.34.). 
ppm 	9.0 	6.0 	3.0 	0.0 
Figure 2.34. 1D 'H NMR of [FLeu 43,FLeu67JUb IV at 600 MHz, pH 48 and 25°C 
with inset of analytical RP HPLC. 
Reduction of the methionine sulphoxide with N-methylmercaptoacetamide and cation 
exchange chromatography gave [FLeu 43,FLeu67]Ub V. However,, the MALDI MS of 
this was higher (+20.4) than expected and has been assigned as sodium adduct and 
not the methionine sulphoxide since the product co-eluted with Ub(bovine). The ED 
'H NMR indicates that the sample is weak but a reasonable dispersion of chemical 
shifts is seen. 
The far UV circular dichroism results for [FLeu 43,FLeu67]Ub V are shown in figure 
2.35. The results at pH 7 indicate an increased ct-helicity to 29% for 
[FLeu43,FLeu67]ub V compared to 19% in Ub(bovine). In comparison the n-sheet 
content is much reduced from 56% in Ub(bovine) to 32% in [FLeu 43,FLeu67]TJb V. 
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Addition of 50% TFE results in 100% ct-helicity indicative of a strong helix forming 
tendency perhaps reflecting a less rigid 3-sheet. 









[FLeu43&67]Ub 	Ub(bovine) 	[FLeu43&67]Ub 	Ub(bovine) 
pH7 	 pH7 50% WE 50%TFE 
Figure 2.35. Deconvolutions of CD spectra into % secondary structure 
expressed as one of the following structures : heavily shaded bars, a-helix and 
clear bars, 3-sheet. 
Section 2.2.5. [67-(2S,4S)-5-Fluoroleucine]ubiquitin. 
Structural analysis on this analogue used material purified by Dr A.R.Brown in a 
similar manner to that used in the non-Tbfmoc purification of [FLeu 50,FLeu67]Ub and 
[FLeu43,FLeu67]Ub. The analytical RP HPLC of [FLeu67]Ub co-eluted with 
Ub(bovine) although it was much broader than Ub(bovine) (figure 2.36.). The 
MALDI MS was more difficult to obtain giving MH= 8605 7Da which is 271)a 
higher than expected and has been assigned as the sodium adduct. The integrity of 
the methionine was confirmed by a trial N-methylmercaptoacetamide reduction in 
which no change in the analytical RP HPLC profile was seen after 48hrs incubation 
confirming no methionine sulphoxide was present. 
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ppm 	9.0 	6.0 	3.0 	0.0 
Figure 2.36. 1D 'H NMIR of [FLeu 67]Ub at 600 MHz, pH 48 and 25°C with inset 
of analytical RP HPLC. 
The 1D 'H NMR is very similar to that obtained for the Thfinoc purified analogues 
i.e. a reduced definition of signal but the same overall shape (figure 2.36.). The 
chemical shift dispersion is slightly increased to 9ppm compared to 8ppm seen in the 
Tbfmoc purified analogues indicative of some tertiary structure formation. 
The far UV circular dichroism analysis are shown in figure 2.37. Excellent correlation 
is seen for the 13-sheet content in [FLeu 67]Ub and Ub(bovine) at both pH 7 and 50% 
TFE. In contrast the ct—helicity is much reduced to only 8% at pH 7 compared to 









[FLeu67]Ub 	Ub(bovine) 	[FLeu67]Ub 	Ub(bovine) 
pH7 pH7 50%TFE 50%TFE 
Figure 2.37. Deconvolutions of CD spectra into % secondary structure expressed 




2.5.5. Fluorine NMR. 
The basis of this work on ubiquitin fluorinated analogues was to incorporate fluorine 
within the primary sequence and assess the effect of this substitution on the tertiary 
structure. The difficulties encountered in folding these analogues has allowed us to 
map out the folding with both 'H NMR and 191 NIvIR studies starting from a non-
native tertiary fold to a native fold. 
Table 2.2. Summary of 19F NMR data for ubiquitin fluorinated analogues with 
tertiary fold as indicated by 1D 'H NMR also shown: data recorded at 600MHz, 









FLeu amino acid* NA -2237 
[FLeu56,FLeu67]ub I non-native -2215 -2218 -2232 
[FLeu50,FLeu67 ]Ub I non-native -2213 
[FLeu50,FLeu67]ub IV native-like -2174 -221-3 -2221 
[FLeu50,FLeu67 ]IJb V native -2171 -2211) 
[FLeu43 ,FLeu67]IJb I non-native -2214 
ft'Leu43,FLeu67]ub IV native-like -2217 -2221 -2268 
-2264 
[FLeu43,FLeu67]Ub V native -22210 -2263 
[FLeu67]ub non-native -2215 -221-9 
The 'F NMR results clearly illustrate the large variation in chemical shifts of ca 
1 Oppm between both the different analogues and different folded states of the 
analogues, and correlates well with the expected dispersion of 5-15ppm for a typical 
fluorinated amino acid incorporated into a protein. 113  This is expected since a FLeu 
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residue which is experiencing a different environment as a result of folding will 
resonate at a different chemical shift. 
In the non-native structures a degenerate signal is present at -2213 to -221 7ppm 
which can be assigned to FLeu residue in an unfolded environment. The results of 
[FLeu56 ,FLeu67]Ub, [FLeu43,FLeu67JUb, and [FLeu67]Ub would indicate that FLeu67 
moves to the lower frequency of ca -2220ppm in a folded environment although this 
is not seen in [FLeu 50,FLeu67]Ub whereby it moves to the higher frequency of - 
2210ppm. Therefore, it appears that the folded chemical shift frequency of FLeu67 is 
similar to the frequency of the FLeu residues in a non-native fold. 
4M / v# 
-216 	-218 	-220 	-222 	424 	-226 	ppm 
Figure 2.38. 19F NMR spectra of [FLeu 56,FLeu671Ub I. 
The three signals from the non-native [FLeu 56,FLeu67]Ub I (figure 2.38.) suggest 
limited folding in a proportion of protein molecules resulting in the extra signals at the 
lower frequencies of -2218ppm assigned to FLeu67 in a folded environment and at - 








-216 	-218 	-220 	 -226 	ppm 
Figure 2.39. 19F NMR spectra of (a) IFLeu 50,FLeu67IUb I, (b) [FLeu5°,FLeu67lUb 
IV and (c) [FLeu 50,FLeu67JUb V. 
From the results of [FLeu 50,FLeu67]Ub I (figure 2.39a.) only one signal is obtained at 
-221•3ppm from the non-native state signifying the same environment for both FLeu 
residues. However, in the native-like [FLeu 50,FLeu67]Ub IV (figure 2.39b.) which 
was assigned as the MetS-oxidel, two main signals at -2174 & -221-3ppm and a 
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smaller signal at -222•lppm are observed and reflects the less compact state present. 
Formation of the native fold by reduction of the methionine to give 
[FLeu 50,FLeu67]Ulj V (figure 2.39c.) results in the expected two signals at -221 Oppm 






-216 	418 	-220 	-22 	-224 	-226 	ppm 
Figure 2.40. 19F NMR spectra of (a) [FLeu,FLeu 67]Ub I, (b) [FLeu,FLeu 67]Ub IV and (c) [FLeu,FLeu 67JUb V. 
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The non-native fold of [FLeu43,FLeu67]Ub I (figure 2.40a.) gives only one signal at - 
221 4ppm. In the native-like [FLeu 43,FLeu67]Ub IV (figure 2.40b.) assigned as the 
MetS-oxidel, one main signal at -2221ppm and three smaller signals at -2217, - 
2264 and -2268ppm are present. Following reduction of the methionine to give 
[FLeu43,FLeu67]Ub V (figure 2.40c.) we obtain the expected two signals, at -2220 
assigned to FLeu67 and at the lower frequency of -2263 ppm assigned to FLeu43. 
 14 
. 	 ' 
-216 	-218 	-220 	-222 	424 	-226 	ppm 
Figure 2.41. 19F NMR spectra of IFLeu 67IUb. 
The results of the mono-substituted [FLeu 67]Ub (figure 2.41.) allow assessment of the 
stabilising or otherwise influence of two fluorines compared to one fluorine in the 
hydrophobic core, and also identification of the chemical shift due to the FLeu67 
residue. Two signals are seen at -2215ppm and -2219ppm indicating the presence of 
more than one conformation in which the environment of the FLeu residue is only 
marginally different. 
It is interesting to note the shape of the 19F NMR peaks, all of which are broad with 
no detectable splitting pattern except for the native-like & native folds of 
[FLeu 50,FLeu67]ub IV & V. The splitting pattern in the latter shows the expected 
triplet of doublets observed in the free amino acid with coupling constants of 140 and 
476 Hz compared to 208 and 476 Hz in the amino acid. 
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It is important to identify the environment experienced by each FLeu residue and 
hence explain the distribution of chemical shifts and further NUR analysis is 
continuing on the structure determination of these ubiquitin fluorinated analogues. 
The actual origins of these tertiary structure induced fluorine chemical shifts remain to 
be investigated further but are known to include the anisotropic shielding from the 




Section 2.6. [3-Norleucine,43-norvalinè]ubiquitin. 
A nonhierarchical model of protein folding has been proposed by Dill in which the 
driving force for protein folding is the hydrophobicity of the amino acid sequence.' 
The resultant hydrophobic collapse gives compact conformations which direct the 
subsequent formation of secondary and tertiary structure. This is in contrast to the 
framework or hierarchical model of folding in which the early formation of secondary 
structure guides the progressive formation of further secondary and tertiary 
structure. 114 
The importance of hydrophobicity as the main driving force for protein folding was 
noted by Kauzmann in 19591  although there is some confusion over the actual 
meaning of the term hydrophobicity. 115 At least three different meanings have been 
used: 
• transfer of nonpolar solutes into an aqueous solution 
• transfer of nonpolar solutes into an aqueous solution with 
a particular temperature dependence 
• ordering of water molecules around nonpolar solutes 
(molecular model) 
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Figure 2.42. Structures A and B nucleate to form the 3x3 matrix C. 
This somewhat simplified diagram of the hydrophobic core illustrates that there are 
many ways, of which two are shown in forming a 30 matrix and similarly the same 
argument applies to the core of a protein. 
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We were interested in maintaining the overall volume of the hydrophobic core while 
at the same time modifying the distribution of alkyl groups around the core. The 
analogue chosen for synthesis was [Nle 3,Nva43]Ub in which the linear norleucine and 
norvaline replace isoleucine and leucine respectively (figures 2.43. & 2.44.). The 
effective result is the transfer of one methyl group across the hydrophobic core and 
due to the commercial availability of amino acids we chose to remove the side-chain 
methyl on the 0—carbon of residue 3. However, removal of this methyl group is a 
surface change and would be expected to be less destabilising than a core deletion. 
Figure 2.43. Ribbon diagram of ubiquitin with 11e3 & Leu43 shown: produced 
using Insight II program. 
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Residues 3 & 43 are not in contact with each other with the distances between the ö 1 















j va 43 
Figure 2.44. Representation of substitutions within the core of ubiquitin. 
This means that the modification results in the redistribution of the internal space 
across the core. Surprisingly, although ubiquitin is a highly compact molecule there 
are several gaps within the core and these could be modified in future ubiquitin model 
studies (figure 2.45.).h16 
Ile-3 	 changed to 
Cy2 
He-23 	 changed to 
-Ca-C -CrC5-Cc-Cc 
,Cöj -C 
Leu-50 & Leu-67 	changed to -ca-CO-Cy 
*̀ ~C82 
Ile-61 	 changed to 
cY2-c 2 
Figure 2.45. Possible modifications within the hydrophobic core of ubiquitin as 
suggested by Alexeev." 6 
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The suggestions noted by Aleexev involve a-amino acids that are not commercially 
available and therefore a synthetic protocol would need to be developed to allow easy 
access of these novel a—amino acids. Recently, the synthesis of the suggested Ile3 
modification to (2S,3 S)-2-amino-3-methylhexanoic acid has been achieved by 
Professor Young & co-workers at the University of Sussex. 117 
Hydrophobic core modifications such as the one described above are introducing the 
possibility of separating the parameters of thermodynamics and kinetics. For example, 
maintenance of the folded hydrophobic core but with a redistribution of the alkyl side-
chains around the core would result in the same overall thermodynamics of the folded 
protein but the kinetics in obtaining the native fold from the unfolded state may be 
altered. 
The synthesis of [N1e3,Nva43]Ub gave excellent yields of 67% for the N-terminal 
methionine on the resin (figure 2.46.). 
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Progress of Synthesis 
Figure 2.46. Progress of [NJe 3,Nva"3]Ub synthesis as monitored by UV at 302nm 
of the deprotection solution containing the piperidine-fulvene adduct. 
Purification was straightforward using the standard Tbfmoc/PGC protocol, desalting 
by gel filtration and semi-preparative RP I-IPLC gave [Me 3 ,Nva43 ]Ub II in good 
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yields. The purity of the product was confirmed by AAA and MALDT MS and 
furthermore it was noted that the analytical RP I{PLC was relatively sharp (figure 
2.47.). Before starting structural analysis [N1e 3,Nva43 ]Ub II was dissolved in 8M urea 
and dialysed against decreasing concentrations of urea to allow refolding from the 
denatured state. 
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Figure 2.47. Analytical RP HPLC of [N1e 3,Nva43]Ub H. 
The results of the far UV circular dichroism analysis are shown in figure 2.48. 
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Figure 2.48. Deconvolutions of CD spectra into % secondary structure expressed 




Excellent correlation are seen for the results at pH 7 and 50% TFE. At pH 7, the a-
helicity is marginally reduced to 14% in [N1e3,Nva43]Ub II compared to 19% in 
Ub(bovine). Addition of 50% TFE increases the a—helicity to the same extent in both 
but with increased maintenance of 13-sheet structure in [N1e3,Nva43]Ub II compared 
to Ub(bovine). These results strongly suggest that the overall tertiary structure in 
[N1e3,Nva43]Ub II is similar to that in Ub(bovine). 
With these encouraging results the fluorescence of the single Tyr59 was investigated 
using fluorescence studies. However, no unfolding curve was observed with only a 
general increase in fluorescence noted (figure 2.49.). 
Fluorescence - monitored denaturation of 
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Figure 2.49. Plot of relative fluorescence of [N1e 3,Nva43]Ub H versus IGdmClI. 
Since the Tyr residue is located on the surface loop (5 1-59) it could flip out slightly 
resulting in no unfolding curve but still maintaining the overall native fold. For 
example, studies by Ecker el at on the mutant [Phe 45 ]Ub in which the Tyr is 
substituted with Phe gave a similar 2D NOESY spectrum to that of WT ubiquitin and 
was 70-100% biologically active as determined by in vitro protein degradation 
assays." 8 This NIVIR similarity in the presence of biological activity suggests that the 
hydrogen bond between the side-chain of Tyr59 and the backbone amide of G1u5 I is 
not crucial for attainment of the native fold. However, in contradiction to a similar 
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native fold for the mutant [Phe 45 ]Ub Ecker el a/ did note that it was only sparingly 
soluble at less than I mg/mi which is characteristic for a misfolded protein. 
Initial 1D 'H NPvIR studies on [N1e3,Nva43]IJb II indicated a reasonable dispersion of 
chemical shifts up to ca 9ppm but with slightly reduced definition. However, a much 
improved NMR spectrum was obtained after the sample was lyophilised and 
redissolved in the NMIR buffer at pH 48. Part of the 2D NOESY spectrum is shown 
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Figure 2.50. Region from the 2D NOESY spectrum of [N1e3,Nva43JUb II at 600 





Section 2.7. [68-DHistidine]ubiquitin. 
The synthesis of [DHis61]lJb was performed in order to investigate the importance of 
the chirality of the single histidine at position 68. This involves a surface change on 
the central strand of 13-sheet in whicli Ole nin.-ni,tnnl D-histidine was substituted for 
L-histidine (figure 2.5 1 .). 
Figure 2.51. Ribbon diagram of 13-sheet structure of ubiquitin with L-histidine 
shown in yellow and D-histidine shown in pink: produced using Sybil molecular 
modelling program. 
No problems were encountered in the synthesis with a final yield of 58% for the N-
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Figure 2.52. Progress of IDHis 68IUb synthesis as monitored by UV at 302nm of 
the deprotection solution containing the piperidine-fulvene adduct. 
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A timed cleavage on a small quantity of resin bound product was performed in order 
to optimise the hydrolysis time. The results (figure 2.53.) clearly indicated that 4 
hours is sufficient for the hydrolysis of the peptide resin-linkage and removal of side- 
chain protection. 
Figure 2.53. Analytical RP HPLC's for the timed hydrolysis of resin bound 
[DHis68]Ub at (A) 2 hrs, (B) 3 hrs and (C) 4 hrs. 
Two step purification using Tbfinoc/PGC and desalting by gel filtration gave 
[DHi568]IJlo I in good yields. The purity of the product was confirmed by AAA and 
MALDI MS (figure 2.54.) and it was noted that the analytical RP HPLC of 
[DHis68]ub I was relatively sharp. Prior to structural analysis [DHis 68]Ub I was 
dissolved in 8M urea and dialysed against decreasing concentrations of urea to. permit 
refolding from the denatured state. 
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Figure 2.54. MALDI MS of IDHisIUb I, M+1 requires 85656 Da. 
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The results for the far UV circular dichroism analysis are shown in figure 2.55. 
CD Analysis [DHis68JUb I 
60 





8 10 a) 
ci, 	0 
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Figure 2.55. Deconvolutions of CD spectra into % secondary structure expressed 
as each of the following structures : heavily shaded bars, a-helix and clear bars, 
13-sheet. 
The circular dichroism results at pH 7 indicate the a-helicity is much reduced to 10% 
in [DHis68]Ub I compared to 19% in Ub(bovine). However, good correlation is 
observed for the 13-sheet content at 50 and 52% for [DHis68]Ub I and Ub(bovine) 
respectively. Addition of 50% TFE results in promotion of a-helicity to ca 50% in 
both cases with an increased reduction in 13-sheet  for [DHis68]Ub I. 
Fluorescence studies on Tyr59 indicated that it is already exposed to the solvent even 
in non-denaturing conditions with only a slight increase in fluorescence observed with 
increasing concentrations of guanidinium chloride (figure 2.56.). 
Fluorescence - monitored denaturation of 
[DHis68]Ub 
1.2 
U 	I 	 6 
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Figure 2.56. Plot of relative fluorescence of [DHis]Ub I versus IGdmCll. 
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The 1D 1H NMR spectrum of [DHis 68]Ub I shows both limited chemical shift 
dispersion and a much reduced definition of signal, which is indicative of a non-native 
fold. As seen in the 2D NOESY spectrum (figure 2.57.), there is a much reduced 
dispersion of chemical shifts which is characteristic of a random coil structure. 
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Figure 2.57. Region from the 2D NOSEY spectra of [DHis]Ub I shown in red 
and of Ub(bovine) shown in black, both recorded at 600 MHz, pH 48 and 25°C. 
Although this analogue has been purified by the Tbfmoc/PGC protocol which is 
known to induce non-native folding in native ubiquitin, this is clearly not always the 
case as seen for [N1e3 ,Nva43]Ub in which a native-like fold is formed. Therefore, it 
seems probable that this is a true denatured state rather than a Tbfmoc induced non-
native fold. It could be postulated that the replacement with D-histidine would result 
in the twisting of final strand of 13—sheet disrupting the formation of the hydrophobic 










2.8. Biological Activity. 
The biological activity of synthetic ubiquitin and analogues is presently being 
determined by Professor R.J. Mayor and Maureen Mee at the University of 
Nottingham. The assay involves measuring the conjugation of ubiquitin radiolabelled 
with 121  iodine to rabbit reticulocytes (fraction II) in the presence and absence of 
ATP. 120 
The results from the assay will allow assessment of the tertiary structure requirements 
for the biological activity. In particular, the different folds of synthetic ubiquitin will 
permit a direct comparison between biological activity and protein fold. For example, 
in the study of disulphide engineered ubiquitin mutants it was found that the activity 
of the conforniationally restricted mutant [Cys 4,Cys66]Ub was much reduced 
compared to the filly active [Cys 4,Cys 14]Ub mutant, indicating that conformational 
mobility is important for the activity of ubiquitin. 121 
2.9. Summary. 
Solid phase peptide synthesis allows for the facile incorporation of unnatural and 
novel synthetic a-amino acids into the primary sequence of proteins, as demonstrated 
for the ubiquitin analogues discussed. Continued advances in SPPS methodology, in 
particular more effective coupling procedures result in improved chain assembly 
which provides the opportunity for the synthesis of larger proteins. Alternatively, 
access to multi-domain proteins can be gained by using the chemical ligation of 
unprotected peptide fragments. 
A major challenge for protein chemists is the purification of the correct sequence from 
the unwanted truncates which have accumulated during peptide synthesis. This task is 
simplified by utilising the hydrophobic properties of the Tbfmoc group for purification 
of the required peptide from the deletions. However, our results for synthetic 
ubiquitin demonstrate that this approach may in some instances result in non-native 
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folding and that optimisation of subsequent folding procedures are required to gain 
access to the native state. 
Synthesis of the ubiquitin analogues incorporating (2S,4S)-5-fluoroleucine have 
opened up the possibility of using fluorine NIvIIR as a specific 'tag' for characterising 
folding intermediates without the complexity of proton NMR which often gives poor 
dispersion of chemical shifts for these largely unstructured intermediates. 
The hydrophobic core modification analogue of [N1e 3,Nva43]Ub has shown the 
capacity for folding to the native-like fold following the redistribution of methyl 
groups within the core notwithstanding the deletion of one methyl group on the 
surface of the protein. Development of a synthetic protocol to enable access to a 
wide variety of hydrophobic cc—amino acids would allow the synthesis of various 
hydrophobic substitutions to probe the importance of hydrophobicity as the main 
driving force for protein folding. 
Thus, an endless array of modifications are available for use in SPPS to investigate 
folding or biological studies in proteins. The design of these substitutions in model 
proteins is ultimately limited by the boundaries of our imagination. 
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Chapter 3. Experimental 
Section 3.1. Notes. 
9-Fluorenylmethoxycarbonyl (Fmoc) protected amino acids were purchased from 
either Bachem or Novabiochem. ' 5N-Glycine was obtained from Sigma and Fmoc 
protected using the method of Shute and Rich. 122 (2S,4S)-5-Fluoroleucine (FLeu) 
was synthesised by B.A. Starkmann, University of Sussex, UK 123  All amino acids 
used were of the L-configuration unless otherwise stated. Bachem supplied the 4-
alkoxybenzylalcohol fuinctionalised polystyrene resin (Wang). Peptide synthesis grade 
dimethylformamide (DMF), 1 -4-dioxan and piperidine were supplied by Rathburn 
Chemicals. The N-N-diisopropylethylamine (DIEA) and trifluoroacetic acid (TFA) 
used were peptide synthesis grade and purchased from Applied Biosystems (ABI). 1-
Hydroxybenzotriazole (HOBt) was obtained from Aldrich and ethyl- 1-hydroxy-1H-
l,2,3-triazole-4-carboxylate (HOCt) was synthesised within the research group. (17-
Tetrabenzo[a, c,g, i]fluorenyt)methylchloroformate (TbfhocCl) used was also 
synthesised within the research group. Porous graphitised carbon (PGC) was 
supplied by Shandon Scientific. All other reagents used were AR grade or better and 
were purchased from either Aldrich, Fluka or Sigma. High performance liquid 
chromatography (HPLC) was carried out using either an ABI system comprising 2 x 
1406A solvent delivery systems, a 1480A injection/mixer and a 783A 
detector/controller, or a Gilson system comprising 2 x 306 solvent delivery systems, a 
81 1C dynamic mixer, a 805 manometric module, and a 119 UV/VIS detector. HPLC 
grade acetonitrile (CH 3 CN) was supplied by Rathburn Chemicals and HPLC grade 
TFA was obtained from Fisons. Fast protein liquid chromatography (FPLC) was 
carried out on a Pharmacia FPLC system with Liquid Chromatography Controller 
LCC-501 Plus using a Superdexrm 75 HR 10/30 column and the conditions stated in 
the text. Gel filtration and cation exchange chromatography were carried out using 
PharmacialLKB apparatus comprising 2 x LKB 2138 UVICORDS, a Pharmacia 2132 
Microperpex peristaltic pump, an LKB 2112 redirac fraction collector and where 
appropriate a Pharmacia Gm gradient mixer. Sonication of samples used a Decon 
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FS300b sonic bath. High and low resolution fast atom bombarbment mass spectra 
(FAB MS) were measured on a Kratos MS50TC using a combination of 3-
nitrobenzy1alcohol and thioglycerol as matrix. Matrix assisted laser desorption 
ionisation mass spectra (MALDI MS) were measured on a Perspective Biosystems 
VoyagerTM BiospectrometryTM Workstation using either a-cyano-4-hydroxycinnamic 
acid or 3,5-dimethoxy-4-hydroxycinnamjc acid as matrix. Calculated masses were 
based on average isotope composition and were derived using the program 
ADDMASS. Amino acid analysis (AAA) were performed on an LKB 4151 amino 
acid analyser equipped with an LKB 2220 Recording Integrator following hydrolysis 
of the peptide (02 to 05mg) in 6M HC1 (containing 5mgml' Na2S03) at 110°C in 
sealed Carius tubes at the times indicated in the text. Proton NMR spectra were 
recorded on either a Bruker WP200 (200 MHz) or a Varian VXR 5000 (600 MHz) 
instrument in the solvent indicated and the chemical shifts were measured relative to 
tetramethylsilane (TMS) assigned to zero. Fluorine NMR spectra were recorded on a 
Varian VXR 5000 (600 MHz) instrument in the solvent indicated and the chemical 
shifts were measured relative to CFCI 3  assigned to zero. Circular dichroism (CD) 
spectra were recorded at 20°C on a JASCO J600 spectropolarimeter in the solvents 
indicated. Fluorescence spectra were recorded on a Perkin Elmer LS50 luminescence 
spectrometer fitted with a Grant LTD-6 thermostatic control. Melting points were 
determined using a Koffler hot stage melting point apparatus and are uncorrected. 
Analytical thin layer chromatography (TLC) used aluminuim sheets precoated with 
silica gel 60 F254  (Merck) in the solvent systems indicated in the text. Visualisation of 
the compounds was achieved either by ultraviolet (UV) absorption at 254nm or with 
ninhydrin for compounds with free amino groups. FTIR spectra were recorded on a 
BIO-RAD FTS-7/SPC 3200 spectrophotometer using polystyrene (1603cm') as the 
standard. Elemental analyses were performed on a Perkin-Elmer 2400 CHN 
elemental analyser. UV spectra were recorded on a Varian Cary 210 
spectrophotometer in the solvents indicated. Optical rotations were measured on an 
AA1000 polarimeter (Optical Activity Ltd) using a 10cm cell in the solvents indicated. 
Refractive indices were measured on an Abbe 60 refractometer. A Corning ion 
analyser 150 was used for all pH measurements. Dichioromethane (DCM) was dried 
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using calcium hydride when required. Ubiquitin(bovine) was purchased from Sigma. 
Throughout the text ether refers to diethyl ether. 
Section 3.2. Solid Phase Peptide Synthesis. 
All peptides were synthesised on an ABI 430A automated peptide synthesiser. The 
efficiency of chain assembly was monitored from measuring the UV absorbance at 
302nm of the deprotection solution containing the piperidine-fulvene adduct. 124  An 
orthogonal synthetic strategy was employed utilising the base labile Fmoc group for 
Naamino protection and complementary acid labile side-chain protection and acid 
labile peptide-resin linkage. The following side-chain protecting groups were used: 
2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc) for the guanidino group of arginine; 
4,4'-dimethoxybenzhydryl (Mbh) for asparagine and glutamine; 'r-triphenylmethyl 
(Trt) for histidine; tertiary-butyl (But)  ethers for serine, threonine and tyrosine; B ut 
esters for aspartic and glutamic acid and tertiary-butyloxycarbonyl (Boc) for lysine. 
The first (C-terminal) amino acid was attached to the 4-alkoxybenzylalcohol 
functionalised polystyrene resin manually and then transferred to the reaction vessel 
for automated peptide synthesis. The resin was first swollen in either DMF or 
DMF/1,4-dioxan (1:1) prior to assembly of the peptide in a stepwise fashion through 
recurrent capping, deprotection and coupling steps, using one of the two programmed 
methods summarised below. 
Programmed Method 1 
Capping. The unreacted functional sites are capped using acetic anhydride 
(05M), DIEA (0125M) and HOBt (02% w/v) in DMF (lOmi) with vortexing for 10 
minutes. The reaction vessel is then drained and washed with six portions of 
DMF/1,4-dioxan (1:1). 
Deprotection. The Nu  Fmoc protecting group is cleaved using 20% v/v piperidine 
in DMF (lOmi) with vortexing for 3 minutes. Deprotection is then repeated for a 
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second time with vortexing for 15 minutes. Finally the resin is washed with six 
portions of DMF/1,4-dioxan (1:1) 
3. Coupling of the next amino acid. Amino acids are coupled either as the 
symmetrical anhydride or the active ester of HOBt or HOCt. The symmetrical 
anhydrides are formed from reacting the Fmoc amino acid (2 equivalents) with N-N'-
diisopropylcarbodiimide (DIC) (1 equivalent) in DMIF/1,4-dioxan (1:1) (8m1). The 
active esters are formed from reaction of the Fmoc amino acid (1 equivalent) with 
either HOBt or HOCt (1 equivalent) and DIC (1 equivalent) in DMF/1,4-dioxan (1:1) 
(8m1). After vortexing for 30 minutes (standard cycle), the reaction vessel is drained 
and washed with six portions of DMF/1,4-dioxan (1:1). 
Programmed Method 2 
Capping. The unreacted functional sites are capped using acetic anhydride 
(0- 5M), DIEA (0- 125M) and HOBt (0.2% w/v) in DMF/1,4-dioxan (1:1) (lOmi) with 
vortexing for 10 minutes. The reaction vessel is then drained and washed with six 
portions of DMF/1,4-dioxan (1:1). 
Deprotection. The NaFmoc protecting group is cleaved using 20% v/v piperidine 
in DMF/1,4-dioxan (1:1) (lOmi) with vortexing for 6 minutes. Two further 
deprotections are repeated to ensure complete removal of the Fmoc group with 
vortexing for 15 minutes each. Finally the resin is washed with six portions of 
DMF/1,4-dioxan (1:1). 
Coupling of the next amino acid. All amino acids except His are coupled as the 
HOCt ester formed from reaction of the Fmoc amino acid (1 equivalent) with HOCt 
(1 equivalent) and DIC (1 equivalent) in DMF/1,4-dioxan (1:1) (8m1). His is coupled 
in a similar manner but as the HOBt ester. After vortexing for 30 minutes (standard 




Method 1 uses only DMF for the capping and deprotection stages while the coupling 
of amino acids uses a 1:1 mixture of DMF/1,4-dioxan. This change in solvents is 
known to effect resin swelling, therefore in method 2 a 1:1 mixture of DMF/1,4-
dioxan is used throughout all three stages. However, the Fmoc deprotection is much 
slower in DMIF/1,4-dioxan (1:1) compared to DMF alone and therefore an extra 
deprotection step is required. 125 
Section 3.3. Analtyical and Protein Structural Analysis. 
High Performance Liquid Chromatography (HPLC). Separations were achieved 
using linear gradients of Buffer B in A (A=0 1% TFA in MQ-grade water, B=009% 
TFA in CH3CN). Sample absorbance was recorded at either 214nm (amide bonds) or 
at 364nm (Tbfiuioc group) unless otherwise stated. The columns and conditions used 
are shown below. 
Analytical RP HPLC. 
Columns : one of the following columns was used: 
Column A 	ABI aquapore RP300 RP silica 74m spherical silica, 220 x 46nmi C8 
Column B 	Vydac RP silica 5p.m spherical silica, 250 x 46mm C8 
Column C 	Vydac RP phase silica 5pm spherical silica, 250 x 46mm C18 
Column D 	HICHROM RP base deactivated spherical silica, 250 x 46mm C8/C18 
Gradients and conditions : all analytical HPLC's used the following gradient in 
combination with a 2m] loop and a flow rate of lmllminute: 
Gradient I 	(t,%B)(0, 1 0)(2, 1 0)(3 2,90)(34, 10): 1 mI/minute 
Semi-Preparative RP HPLC. 
Columns : one of the following columns was used: 
Column E 	ABI aquapore RP300 RP silica 74m spherical silica, 250 x 92mm C8 
Column F 	Vydac RP silica 10pm spherical silica, 250 x 22mm C18 
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Gradients and conditions : one of the following gradients was used in combination 
with a 5ml loop and a flow rate as described: 
Gradient II (t,%B)(0, 10)(2,20)(22- 5, 50)(24-5,90)(26-5,10) :  5mllminute 
Gradient III (t,%B)(0, 1 0)(2, 1 0)(32,90)(34, 10): 1 Omllminute 
Gradient IV (t,%B)(0,10)(25,70)(27,90)(29,10) : 10mllminute 
Gradient V (t,%B)(0,10)(5,10)(25,60)(27,10) : 9mllminute 
Gradient VI (t,%B)(0, 10)(5,10)(3  5,60)(3 7,10): 1 Omllminute 
Gradient VII (t,%B)(0,10)(2,10)(32,90)(34,10): 5mllminute 
Gradient VIII (t,%B)(0, 1 0)(5, 10)(3  5,90)(3 7,10): 5mllminute 
Circular Dichroism Spectra and Analysis. All samples were prepared from the 
lyophilised peptide unless otherwise described in the text. Stock protein solutions 
were usually at concentrations of 05mgmY 1 and prepared in 50mM Na borate buffer 
pH 7 or MQ-grade water as described in the text. Protein concentrations were 
determined either by weight (ubiquitin peptides) or from duplicate HPLC integrations 
using a known concentration (typically 2mgmf 1) of purified ubiquitin(bovine) supplied 
by Sigma as the standard. Additional samples were prepared using aliquots of the 
stock solution with either 2,2,2-trifluroethanol (TFE) or methanol as described in the 
text. Samples were either filtered (Sartorius Minisart RC4, 45tm) or centrifuged 
(13 000 rpm x 5 minutes) prior to analysis. CD spectra were measured between 190-
240nm at 20°C and the secondary structure estimated using the CONTIN 
procedure. 126 
Fluorescence Studies and Analysis. All samples were prepared from the lyophilised 
peptide unless otherwise described in the text. Stock protein solutions were usually at 
concentrations of 100.M and prepared in 50mM 4-morpholinepropanesuiphonic acid 
(MOPS) pH 7 using MQ-grade water. The guanidinium chloride (GdmCl) ( ~:99%, 
Life Technologies, Inc) used was typically 78M as determined by refractive index 
measurements and the following equation: 127 
Molarity = { 57i 47x(iN) } + (
38-68X(AN)2
)  - ( 
91 60x(AN) 3 ) 
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where AN is the difference in refractive index between the GdmCl and MOPS 
solutions at the sodium D line. 
In general 15-20 data points were measured over the range 0 to 6M GdmCl. For each 
data point I OOpJ of stock protein solution was added to the appropriate volume of 
GdmCl stock solution and made up to 1000 jtl with MOPS buffer pH 7. The solutions 
were centrifuged (13000 rpm x 5 minutes) and incubated at 25 °C for at least 3 hours 
prior to fluorescence measurements. Fluorescence emission was monitored at 303nm 
with excitation at 280nm (emmision/excitation slit width=5nm) in a thermostatted cell 
at 25°C. The data are presented as relative fluorescence versus concentration of 
GdmCl. 
NMR Spectra and Analysis. Protein solutions were prepared in either MQ-grade 
water at pH 31, 48, 49 or 51 or in 25mM C 2D302Na buffer pH 48 with 
concentrations in the range 2 to 6mgml 1 . The pH was adjusted when required using 
2M NaOH or 2M HC1. All samples were centrifuged (13000 rpm x 5 minutes) prior 
to analysis with the NIVIR spectra collected at either 15 or 25 °C as stated in the text. 
Tryptic Mapping. 128  Protein (2mg) was dissolved in I  of buffer containing 50mM 
Tris/HC1 pH 82, 6-5M urea and 10mM CaC1 2. Trypsin (5% w/w with protein) was 
added and the solution was incubated at 37 °C for 4 hours. Additional trypsin (5% 
w/w with protein) was added and the digestion allowed to proceed for a further 4 
hours. The solution was then acidified to pH 2 with 6M HC1 and stored at -20°C until 
required. The peptide fragments obtained were separated by analytical RP HPLC 
(Column C or D) and gradient (t,%B)(0, 10)(2,1 0)(50,70)(52 - 5, 100)(57-5,100)(65,  10) 
at lmllminute, monitoring at 205nm and using the following buffers: 
Buffer A 01% TFA ,01% TEA in MQ-grade water 
Buffer B 01% TFA ,01% TEA in 40% aqueous CH 3CN 




Section 3.4. Experimental (general). 
Coupling of the C-Terminal Amino Acid onto the 4-Alkoxybenzylalcohol 
Functionalised Polystyrene Resin. Two methods of activation were used to couple 
the first amino acid onto the resin. 
Symmetrical Anhydride. Fmoc-Gly-OH (057g, 192mmol) was dissolved in 
DMF (lOmi) and DIC (150tl, 096mmo1) added. The solution was sonicated at RT 
for 15 minutes before being added to 4-alkoxybenzylalcohol functionalised 
polystyrene resin (100g, 096mmol) previously swollen in DMF (lOml). A catalytic 
amount of 4-dimethylaminopyridine (10mg, 008mmol) was added and the resin was 
sonicated at RT for 60 minutes. The flintionalised resin was then separated by 
filtration, washed with DMF and ether and dried overnight in a desicator. The resin 
substitution was then determined. This procedure generally gave resin loadings with a 
functionality of ca 020mmolg 1 . 
Acid Chloride. Fmoc-Gly-OH (0939g, 3. l6mmol) was suspended in dry DCM 
(50m1) and freshly distilled thionyl chloride (220m1, 30 l6mmol) added dropwise 
under nitrogen. The mixture was heated under reflux at 50°C for 2 hours after which 
the DCM and thionyl chloride were removed in vacuo. The solid obtained was 
redissolved in dry DCM and concentrated in vacuo. This was repeated to give Fmoc-
GIy-Cl FTIR v(DCM) 1810 (acid chloride) and 1698cm' (urethane). The Fmoc-
Gly-Cl obtained was dissolved in dry DCM (lOml) and added to 4-
alkoxybenzylalcohol functionalised polystyrene resin (200g, 1 60mmol) previously 
swollen in dry DCM (25ml) and pyridine (3m1). The mixture was sonicated at RT for 
90 minutes before the functionalised resin was separated by filtration, washed with 
DCM and ether and dried in a desicator overnight. The resin substitution was then 




Determination of Resin Loading. The loading efficiency was determined by 
sonicating duplicate samples of the dried resin (3 to 5mg) in 20% v/v piperidine in 
DMF (lOmi) for 10 minutes. The UV absorbance between 350 to 290nm of the 
solutions were then measured and the resin loading calculated by a computer program 
which utilises the absorbance at 302nm of the piperidine-fulvene adduct (F, adduct 3021m = 
15400 dm3  mof' cm'). The values for the resin loading obtained are listed in the text. 
Glycyiglycine Content in the Loaded Resin. Fmoc-Gly-resin (20mg) was sonicated 
in 20% v/v piperidine in DIvIF (lOml) for 10 minutes. The resin was then separated 
by filtration and washed with DMF, DCM and ether. Following cleavage with 95% 
aqueous TFA (lOml) for 1 hour, the solution was filtered, concentrated in vacuo and 
the residue triturated with ether (50m1). The supernatant was decanted off and the 
solid product dissolved in citric acid buffer pH 22 (2ml) for amino acid analysis. The 
retention time (Ri) of the amino acid in the sample was then compared with glycine 
(R=586 minutes) and glycylglycine (R=1046 minutes) standards. No glycylglycine 
was detected in any Fmoc-Gly-resin prepared. 
Determination of the Fmoc Content in the Completed Peptide-Resin. Following 
completion of peptide assembly the Fmoc protecting group was left on the final (N-
terminal) amino acid to allow for quantitative Fmoc deprotection. Duplicate samples 
of the dried Fmoc-peptide-resin (5-10mg) were sonicated in 20% v/v piperidine in 
DMF (lOmi) for 10 minutes. The UV absorbance between 350 to 290nm of the 
solutions were then measured and the Fmoc loading calculated by a computer 
program which utilises the absorbance at 302nm of the piperidine-fulvene adduct (c 
adduct 302 = 15400 dm3 mot' cm'). The values for the quantitative Fmoc deprotection 
obtained are listed in the text. 
Determination of Tbfmoc Loading in the Resin Bound Peptide. Two methods 




Absorbance at 364nm. Duplicate samples of the dried Tbfhioc-peptide-resin (3-
5mg) were sonicated in 20% v/v piperidine in 1,4-dioxan (IlOmi) for 10 minutes. The 
UV absorbance between 400 to 350nm of the solutions were then measured and the 
loading estimated using the equation: 129 
Tbfmoc functionality (mmolg') = 0613 x Absorbance at 364nm 
mass of Tbflnoc-peptide-resin (mg) 
Trial Cleavage of Tbfmoc-peptide-resin. Tbfmoc-peptide-resin (10-15 mg) was 
cleaved using the conditions stated for each peptide in the text and analytical RP 
HPLC of the lyophilised peptide provided both a qualitative Tbfmoc loading test and 
a trial cleavage test. 
Fmoc-(2S,4S)-5-Fluoroleucine. 	(2 S,4S)-5-Fluoroleucine hydrochloride (1-00g, 
53 9mmol) and sodium carbonate (1-14g, 1 075mmo1) were dissolved in water (21 ml) 
and acetone (9m1). Following addition of Fmoc-N-hydroxysuccinimide (182g, 
539mmo1), the solution was stirred overnight. Ethyl acetate (200m1) was added and 
the solution acidified to pH 2 with 6M HC1. The ethyl acetate layer was separated, 
washed with water (2x80m1), dried (MgSO 4) and the solution concentrated in vacuo 
to give a yellow oil. Trituration of this oil with hexane gave the title compound as a 
white solid (182g, 490mmol, 91%). 
mp 145-153°C; CHN : Found C 6789, H 570, N 386, C21H22N04F requires C 
67•91, H 597, N 377%; TLC : Rf (CHCI3 :MeOH:AcOH, 85:10:5) 074, Rf 
(isopropanol:pyridine:AcOH:H 20, 15:10:3:12) 084; FTJR : v (CHBr 3 mull) 3340 
(NH), 3022 (CH aromatic), 2960 (CH aliphatic), 1719 (carboxyl), 1680cm' 
(urethane); Ainax (DMF) 302nm (=67200 dm3 mol 1 cm'); FAB MS : 372-16111 
C21H22N04F requires 372-15920; 'H NTvIIR (200MHz, d 6-DMSO) : 728-788 (m, 8H, 
aromatic), 425-447 (m, 6H, aCH, 6CH 2F, Fm0cCHCH2), 153-197 (m, 3H, 13CH 2 , 
yCH), 089-091ppm (d, J=6-6OHz, 3H, 6CH3 ); 19f NMR (600MHz, d 6-DMSO, 'H 




Section 3.5. Ubiquitin(synthetic). 
The synthesis was performed on a 0 immol scale using the flinctionalised resin Fmoc-
Gly-(OCH2C61-LOR) (0444g, 0225mmo1g 1) and method 2 of the programmed cycles 
with online monitoring of the deprotection solution at 302nm. All amino acids were 
single coupled using the HOCt ester (immol) except His which was double coupled 
as the HOBt ester (immol each). The side-chains of amino acids were protected as 
previously described. Following completion of assembly the N-terminal Fmoc was 
left on and the resin bound product was capped by sonication for 1 hour in acetic 
anhydride (05M), DIEA (0125M), and HOBt (02% w/v) in DCM (20m1). The 
peptide-resin was separated by filtration, washed with DMF and 1,4-dioxan and 
divided into two equal portions which were stored in 1,4-dioxan at 4 °C until required. 
Quantitative Fmoc deprotection gave 0038mmo1g 1 , 66% of the theoretical 
maximum. One portion was purified starting with the TbfmocfPGC protocol while 
the second portion was purified using a non-TbfmocfPGC protocol. 
3.5.1. TbfmocLPGC Protocol. Approximately one half of the peptide-resin was 
sonicated in 20% v/v piperidine/DIMF at RT for 20 minutes and subsequently washed 
with DMF, DCM and ether and dried under water suction for 30 minutes. The dry 
resin (950mg, 0036mmols) was then added to a suspension of TbfInocCl (497mg, 
0.108mmol) and DIEA (189.tl, 0i08mmol) in dry DCM (lOmi) and sonicated at RT 
for 3 hours in the dark. The Tbfhioc-peptide-resin was separated by filtration and 
washed thoroughly with DCM and additionally with ether. The Tbflnoc-peptide-resin 
was then swollen in phenol (075g), 1,2-ethanedithiol (EDT) (2m1) and thioanisole 
(05m1) and triisopropylsilane (TIS) (200p.l) for 30 minutes under nitrogen whilst 
protected from the light. Water (05ml) and TFA (lOml) were then added and the 
cleavage mixture stirred for a further 4 hours. The resin was separated by filtration, 
washed with TFA (5m1) and the combined filtrate and washings concentrated in vacuo 
to give an oil, which yielded the crude Thfhioc-peptide on trituration with 2% v/v 13-
mercaptoethanol in ether (lOOml). The ether was decanted off and the crude Tbfmoc-




3.5.1.1. Tbfinoc/PGC and Gel Filtration G50 Sephadex. The crude Tbfmoc-
protein was dissolved in 6M GdmCl (20ml) and diluted with isopropanol (20m1), and 
centrifuged to remove a small amount of insoluble material. PGC (HPLC grade, 7pm, 
1280mg) was added and the solution was vortexed and then centrifuged. Adsorption 
of the Tbfinoc-protein was monitored by analytical RP HPLC of the supernatant at 
364nm. The PGC was then subjected to the following wash protocol with alternate 
vortexing and centrifugation: 
6M GdmCllisopropanol (1:1) (80ml) 
6M GdmCllisopropanol (1:1) (80m1) 
6M GdmCllisopropanol (1:1) (80m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (40m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (32m1) 
The supernatant from washes 4 & 5 were combined, neutralised to pH 45 with acetic 
acid (HOAc) and the isopropanol removed in vacuo prior to being loaded onto a 
Sephadex G50 (fine) column (660 x 30mm) pre-equilibriated with 30% aqueous 
HOAc. The column was then eluted at 39 mlh' with monitoring at 254 and 277nrn 
and collecting 20 minute fractions. Protein fractions 10-17 inclusive were combined, 
diluted with water and lyophilised twice to give Ub(syn) I (75 mg). 
• Ub(syn)I 
HPLC (Column A, Gradient I): R 17- 6  minutes; 
MALDI MS: 85887 (Na adduct), C 378H630N1050 11 8S1 requires 85659 Da; 
AAA (40hrs) : Asp 7 723, Thr7 651, Ser3 234, Glu12 1241, Pr03 368, Gly6 555, 
Ala2 235, Va14 390, Met, 085, Ile 7 573, Leu9 738, Tyri 059, Phe2 198, His 1 063, 
Lys7 710, Arg4 340; 
AAA (60hrs) : Asp7 838, Thr7 656, Ser3 282, Glu 12 1203, Pr03 371, Gly6 592, 
Ala2 223, Va14 367, Met 1 071, Ile7 6-82, Leu9 697, Tyr i 066, Phe2 204, His 1 064, 
Lys7 6-85, Ar94 258. 
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CD results: 	 cc-helix (%) n-sheet (%) remainder (%) 
50mM Na borate pH 7 	14 +/- 0-94 47 +/- 0-98 39 +/- 1-70 
+50% TFE 	 44 +/- 0-52 	28 +/- 0-75 	28 +/- 0-91 
3.5.1.2. Refolding from 6M GdmCl, 50mM NH4OAc, 5mM DTT at p11 45. 
Ub(syn) I (50mg) was dissolved in 6M GdmCl, 50mM NH4OAc, 5mM DTT at pH 
45 (40ml) and sequentially dialysed (MWCO2000, Cellu Sep Hi) against nitrogen 
saturated solutions of 50mM NH4OAc, 5mM DTT at pH 45 (2000m1), 50mM 
NH4OAc, 2mM DTT at pH 45 (3000m1), 50mM NH4OAc at pH 45 (3000m1) for 24 
hours at each step. One half of the protein solution was lyophilised twice to give 
Ub(syn) II (248mg). Following removal of 10mg for 1H NMR, the remainder of 
Ub(syn) II was purified by FPLC (section 3.5.1.4.). The second half of the refolded 
protein solution was further purified by cation exchange chromatography (section 
3.5.1.3.). 
• Ub(syn) II 
HPLC (Column A, Gradient I): R 17-6 minutes; 
MALDI MS: 85887 (Na adduct), C 37814 30N10 50118S1 requires 85659 Da. 
3.5.1.3. Cation Exchange/CM-Sepharose CL6B. The second half of refolded 
Ub(syn) II was concentrated by ultrafiltration (Amicon, MWCO=3 000) from 40m1 to 
15m1 and loaded onto a CM-Sepharose CL613 column (280 x 16mm) pre-equilibriated 
with 50mM NH4OAc pH 45. A pH gradient of 50mM NH4OAc pH 45 to 50mM 
NH4OAc pH 55 (500m1) was run at 30mlW 1 overnight with monitoring at 277 and 
226nm. The column was then run isocratically at 50mM NH 4OAc pH 55 (60ml) for 
2 hours after which a salt gradient of 50mM NH 4OAc pH 55 to 03M NH4OAc at pH 
55 (300m1) for 10 hours was applied to elute the protein from the column. Protein 
fractions (510-555m1), (555-600m1), (600-645m1), (645-675m1) and (675-705m1) 
were combined and repeatedly lyophilised to give Ub(syn) LII Fl (04mg), F2 
(03mg), F3 (06mg), F4 (20mg) and F5 (07mg). 
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• Ub(syn) m F! 
HPLC (Column A, Gradient I): R 184 minutes; 
• Ub(syn) III F2 
HPLC (Column A, Gradient I): R 17-6 minutes; 
• Ub(syn) m F3 
HPLC (Column A, Gradient I): R 176 minutes; 
• Ub(syn) ifi F4 (used in 'H NMR studies) 
HPLC (Column A, Gradient I): R 17-6 minutes; 
MALDI MS 85887 (Na adduct), C 373H630N 1050, 18 S 1 requires 85659 Da; 
AAA (40hrs) : Asp 7 718, Thr7 572, Ser3 236, Glu 12  1396, Pr03 279, Gly6 581, 
Ala2 225, Va14 381, Met, 107, lie7 705, Leu9 814, Tyr, 098, Phe2 208, His, 076, 
Lys7 693, Ar94 431. 
• Ub(syn) HI F5 
HPLC (Column A, Gradient I): R 184 minutes; 
3.5.1.4. FPLC/SuperdexTM 75. Ub(syn) 11(14mg) was dissolved in 50mM HOAc, 
10M NaCl pH 45 (800p.l) and purified by FPLC using a SuperdexTm 75 HR 10/30 
column eluting with 50mM HOAc, 1 0M NaCl pH 4 - 5, 200 jtl loop and monitoring at 
280nm. Protein fractions (1251-1400m1) and (1401-1500mi) were combined and 
each dialysed (MWCO=2000, CelluSep Hi) against nitrogen saturated solutions of 
50mM NH4OAc at pH 45 (500m1) x 2 for 24 hours at each step. Repeated 
lyophilisation gave Ub(syn) IV Fl (24mg) and Ub(syn) IV F2 (26mg). Ub(bovine) 
eluted in fractions (1401-1500m1) using the same column and conditions described 
above. 
• Ub(syn) IV F! 
HPLC (Column A, Gradient I): R 17.4 minutes; 
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• Ub(syn) IV F2 (used in 'H NMR studies) 
HPLC (Column A, Gradient I): R 17-6 minutes; 
MALDI MS : 85681, C3 78H430N,050 113 S 1 requires 85659 Da; 
AAA (40hrs) : Asp 7 771, Thr7 698, Ser3 267, Glu12  1428, Pr03 300, G1y6 591, 
Ala2 234, Va14 424, Met, 060, Ile7 686, Leu9 796, Tyr1 065, Phe2 220, His, 057, 
Lys7 675, Arg4 400. 
3.5.2. Non-TbfmociPGC Protocol The second half of peptide-resin was sonicated 
in 20% v/v piperidinefDMF at RT for 20 minutes and subsequently washed with 
DMF, DCM and ether and dried under water suction for 30 minutes. The dry resin 
(950mg, 0036mmols) was then swollen in phenol (075g), EDT (2ml), thioanisole 
(05m1) and TIS (20041) for 30 minutes under nitrogen. Water (05m1) and TFA 
(lOmi) were then added and the cleavage mixture stirred for a further 4 hours. The 
resin was separated by filtration, washed with TFA (5m1) and the combined filtrate 
and washings concentrated in vacuo to give an oil, which yielded the crude protein on 
trituration with 2% v/v 3-mercaptoethanoI in ether (lOOml). The ether was decanted 
off and the crude protein dissolved in 20% aqueous CH 3CN (50m1), diluted with 
water and lyophilised. 
3.5.2.1. Gel Filtration G50 Sephadex and Refolding from 6M GdmCl, 50mM 
NH40Ac, 5mM DTT at pH 45. The lyophilised protein (from 3.5.2.) was dissolved 
in 6M GdmCl, 50mM NH4OAc, 5mM DTT pH 45 (20m1) and left stirring at RT 
overnight. The protein solution was then divided equally and taken through in two 
batches. Protein solution (lOml) was loaded onto a Sephadex G50 (fine) column (660 
x 30mm) pre-equilibriated with 6M GdmCl, 50mM NIH4OAc, 5mM DTT pH 45. 
The column was then eluted at 36m1h 1 with monitoring at 277nm and collecting 20 
minute fractions. Protein fractions 12-15 inclusive were combined and dialysed 
(MWC0=2000, CelluSep Hl) against nitrogen saturated solutions of 50mM 
NH4OAc, 5mM DTT at pH 45 (2000m1), 50mM NH4OAc, 2mM DTT at pH 45 
(3000m1) and 50mM NIH4OAc at pH 45 (3000m1) for 24 hours at each step. The 
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procedure was then repeated for the second batch. One portion of the refolded 
protein solution was further purified by cation exchange chromatography (3.5.2.2.) 
while the second portion was purified by FPLC (3.5.2.3.). 
3.5.2.2. Cation Exchange/CM-Sepharose CUB and Semi-Preparative RP 
HPLC. One portion of the refolded protein solution was concentrated by 
ultrafiltration (Amicon, MWCO=3000) from 105m] to 1 5m1 and loaded onto a CM-
Sepharose CL613 column (280 x 16mm) pre-equilibriated with 50mM NH 4OAc pH 
45. A pH gradient of 50mM NH4OAc at pH 45 to 50mM NthOAc pH 55 (500m1) 
was run at 30mlW' overnight with monitoring at 277 and 226nm. The column was 
then run isocratically at 50mM NH4OAc pH 55 (60m1) for 2 hours after which a salt 
gradient of 50mM NH4OAc pH 55 to 03M NthOAc at pH 55 (300m1) for 10 hours 
was applied to elute the protein from the column. Protein fractions (661-675m1) were 
combined and repeatedly lyophilised. Further purification of the synthetic material 
obtained by semi-preparative RP HPLC (Column E, Gradient II) and subsequent 
lyophilisation gave Ub(syn) V (4.0mg). 
• Ub(syn) V 
HPLC (Column A, Gradient I): Rt 176 minutes; 
MALDI MS 85887 (Na adduct), C 378H530N1050118 S 1 requires 85659 Da; 
AAA (40hrs) : Asp 7 678, Thr7 602, Ser3 252, G1u 12 1171, Pr03 327, Gly6 6-07, 
Ala2 215, VaL1 406, Met 1 098, Be7 6-70, Leu9 790, Tyr i 100, Phe2 215, His1 077, 
Lys7 6-78, Arg4 272. 
3.5.2.3. FPLC/SuperdexTM 75. The second portion of refolded protein solution was 
lyophilised and then dissolved in 50mM HoAc, 10 M NaCl pH45 (1500tl) and 
purified by FPLC using a SuperdexTM 75 HR10/30 column eluting with 50mM HOAc, 
10M NaCl pH 45, 200i1 loop and monitoring at 280nm. Protein fractions (1401-
1500m1) were combined and subsequently dialysed (MWCO2000,CelluSep Hi) 
against nitrogen saturated solutions of 50mM N}LOAc at pH 45 (1000ml) and 
50mM NH4OAc at pH 45 (2000ml) for 24 hours at each step and lyophilised to give 
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Ub(syn) VI (91mg). Ub(bovine) eluted in fractions (1401-1500m1) using the same 
column and conditions described above. 
• Ub(syn) VI 
HPLC (Column A, Gradient I): R 17-6 minutes; 
MALDI MS : 85887 (Na adduct), C 378H630N1050118S 1 requires 85659 Da; 
AAA (40hrs) : Asp 7 725, Thr7 659, Ser3 249, G1u 12 1254, Pr03 221, Gly6 562, 
Ala2 225, Va14 379, Met 1 084, Ile 696, Leu9 821, Tyr i 080, Phe2 205, His 1 100, 
Lys7 713, Arg4 377. 
Section 3.6. Ubiquitin-(1 -35)-Peptide. 
H-Met-Gln-Ile-Phe-Val-Lys-Thr-Leu-Thr-Gly-Lys-Thr-Ile-Thr-Leu-Glu-Val-Glu-
Pro-Ser-Asp-Thr-Ile-Glu-Asn-Val-Lys-Ala-Lys-Ile-Gln-Asp-Lys-GIu-Gly-OH 
The synthesis was performed on a 0125mmo1 scale using the functionalised resin 
Fmoc-GIy-(OCH2C6H40R) (0306g, 0406mmo1g) and method 1 of the programmed 
cycles with online monitoring of the deprotection solution at 302nm. The side-chains 
of amino acids were protected as previously described with the exception of Gln/Asn 
which were incorporated unprotected. Most amino acids were double coupled using 
the symmetrical anhydride (05mmol) and the HOBt ester (05mmol). The exceptions 
to this were Gly which was single coupled using the symmetrical anhydride (immol), 
and AsnIGln which were double coupled using the HOBt ester (05mmol each). 
Following completion of assembly the N-terminal Fmoc was left on and the resin 
stored in 1,4-dioxan at 4°C until required. Quantitative Fmoc deprotection gave 
0069mmolg', 70% of the theoretical maximum. 
3.6.1. Semi-Preparative RP HPLC. Approximately one half of the peptide-resin 
(400mg) was sonicated in 20% v/v piperidine/DMF at RT for 20 minutes and 
subsequently washed with DMF, DCM and ether and dried under water suction for 30 
minutes. The dried peptide-resin was then cleaved using EDT (imi), thioanisole 
(05m1), water (05ml) and TFA (12m1) with stirring under nitrogen for 4 hours. The 
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resin was separated by filtration, washed with TFA (5m1) and the combined filtrate 
and washings concentrated in vacuo to give an oil, which yielded crude peptide on 
trituration with 2% v/v 3-mercaptoethanoI in ether (lOOml). The ether was decanted 
off and the crude peptide dissolved in 20% aqueous HOAc (20ml), diluted with water 
and lyophilised. Purification of the crude peptide by semi-preparative RP HPLC 
(Column F, Gradient III) and lyophilisation gave 780mg. Further purification by 
semi-preparative RP HPLC (Column F, Gradient IV) and repeated lyophilisation gave 
Ub(1-35) (59.1mg). 
• Ub(1-35) 
HPLC : (Column C, Gradient I): R 1 173 minutes; 
MALDI MS: 39063: FAB MS: 3906-1417, C 172H292N43057S 1 requires 39065244Da; 
AAA (40hrs) : Asp 3 308, Thr5 443, Ser i 096, G1u6 659, Pro 1 095, G1y2 209, Ala 1 
1- 12, Val3 291, Met 1 070, Ile4 406, Leu2 223, Phe 1 100, Lys5 479. 
CD results: cc-helix (%) f3-sheet (%) remainder (%) 
H20 pH 46 1 +/- 11 43 +/- 11 56+/- 2-0 
+25% TFE 19 +/- 1-2 51 +/- 1-2 30 +/- 2-2 
+50% TFE 30 +/- 1-1 52 +/- 1-1 17 +/- 2-0 
H20 pH 2 2 +/- 0-3 37 +1- 05 60 +/- 0-6 
+30% MeOH 8 +/- 0-6 46 +/- 07 45 +/- 1-2 
+60% MeOH 25 +/- 1-5 62 +/-1-5 13 +/- 2-7 




The synthesis was performed on a 0125mmol scale using the functionalised resin 
Fmoc-Gly-(OCH2C6H40R) (0i96g, 0635mmolg 1) and using method 1 of the 
programmed cycles with online monitoring of the deprotection solution at 302nm. 
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The side-chains of amino acids were protected as previously described. Most amino 
acids were double coupled using the symmetrical anhydride (05mmol) and the HOBt 
ester (05mmol). The exceptions to this were Gly which was single coupled using the 
symmetrical anhydride (immol), His was treble coupled as the HOBt ester (immol 
each) and AsnlGln were double coupled as the HOBt ester (05nimol each). 
Extended coupling times were used for residues G1n41 to 1le36. Following 
completion of assembly the N-terminal Fmoc was left on and the resin stored in 1,4-
dioxan at 4°C until required. Quantitative Fmoc deprotection gave 0052mmolg, 
42% of the theoretical maximum. 
3.7.1. Tbfnioc/PGC, Gel Filtration Sephadex G25 and Semi-Preparative RP 
HPLC. Approximately one half of the peptide-resin (420mg, 0023mmo1) was 
sonicated in 20% v/v piperidine/DMF at RT for 20 minutes and subsequently washed 
with DMIF, DCM and ether and dried under water suction for 30 minutes. The dried 
peptide-resin was then added to a suspension of TbfmocCl (303mg, 0066mmol) and 
DIEA (121.11, 0066mmo1) in DCM (6m1) and sonicated at RT for 3 hours in the dark. 
The Tbfinoc-peptide-resin was separated by filtration and thoroughly washed with 
DCM and additionally with ether. The dried Tbfhioc-peptide-resin was cleaved for 4 
hours with stirring using phenol (075g), EDT (2m1), thioanisole (05nil), water 
(05m1) and TFA (lOml) under nitrogen whilst protected from the light. The resin 
was separated by filtration, washed with TFA (5m1) and the combined filtrate and 
washings concentrated in vacuo to give an oil, which yielded solid Tbfhioc-peptide 
on trituration with ether (lOOmi). The ether was decanted off and the Tbfmoc-
peptide dissolved in 6M GdmCl (lOmi) and diluted with isopropanol (lOmi). PGC 
(HPLC grade, 7pm, 600mg) was added and the solution was vortexed and then 
centrifuged. Adsorption of the Tbfinoc-protein was monitored by analytical RP 
HPLC of the supernatant at 364nm. The PGC was then subjected to the following 
wash protocol with alternate vortexing and centrifugation: 
6M GdmCl/isopropanol (1:1) (40m1) 
6M GdmCl/isopropanol (1:1) (40m1) 
6M GdmCl/isopropanol (1:1) (40m1) 
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10% pipendine in 6M GdmCl/isopropanol (1:1) (20nil) 
10% piperidine in 6M GdmCllisopropanol (1:1) (20m1) 
The supernatant from washes 4 & 5 were combined, neutralised to pH 45 with HOAc 
and the isopropanol removed in vacuo prior to being loaded onto a Sephadex G25 
(fine) column (800 x 15mm) pre-equilibriated with 30% aqueous HOAc. The column 
was then eluted with at 48mlh with monitoring at 226 and 277nm and collecting 20 
minute fractions. Protein fractions 9-14 were combined, diluted with water and 
lyophilised to give 60mg. Further purification by semi-preparative RP HPLC 
(Column F, Gradient V) and repeated lyophilisation gave Ub(36-76) (41.9mg). 
• Ub(36-76) 
HPLC (Column C, Gradient I): R 166 minutes; 
MALDI MS: 46794, FAB MS : 46785842, C 206H341N62062 requires 46783517 Da; 
AAA (40hrs) : Asp 4 393, Thr2 191, Ser2 183, G1u6 589, Pr02 234, G1y4 402, Ala 1 
095, Val 099, Ile3 247, Leu7 722, Tyr i 060, Phe 1 097, His 1 088, Lys2 203, Ar94 
356. 
CD results: cc-helix (%) 3-sheet (%) remainder (%) 
H20 pH46 5 +/- 0-7 39 +1 -08 56 +/- 1-3 
+25% TFE 56 +/-0- 75 44 +/- 0-76 0 +/-73x10 7 
+50% TFE 65 +/- 0-96 35 +/- 0-96 0 +1- 93x10 7 
H20 pH 2 6 +/- 0-65 47 +1- 075 46 +/- 1-2 
+30% MeOH 12+/-1-7 43 +/- 1-7 45 +/- 3-1 
+60% MeOH 55 +/- 2-1 40 +/- 2-2 5 +/- 4-0  
Section 3.8. Ubiquitin-(68-76), (66-76), (64-76)-Peptides. 
Ub (68-76) Ac-His-Leu-Val-Leu-Arg-Leu-Arg-Gly-Gly-OH 
Ub (66-76) Ac-Thr-Leu-His-Leu-Val-Leu-Arg-Leu-Arg-Gly-Gly-OH 
Ub (64-76) Ac-Glu-Ser-Thr-Leu-His-Leu-Val-Leu-Arg-Leu-Arg-Gly-Gly-OH 
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Ub(68-76), (66-76),(64-76) contd. The synthesis was started on a 025mmo1 scale 
using the functionalised resin Fmoc-Gly-(OCH 2C6R40R) (0379g, 0660mmo1g') and 
method 1 of the programmed cycles with online monitoring of the deprotection 
solution at 302m. The side-chains of amino acids were protected as previously 
described. All amino acids were treble coupled, once as the symmetrical anhydride 
(05mmol) and twice as the HOBt ester (05mmol each). The exceptions to this were 
Gly which was single coupled as the symmetrical anhydride (immol) and His which 
was treble coupled as the HOBt ester (immol each). One third of the resin was 
removed after the coupling of His 68 and the N-terminus acetylated by sonication at 
RT for 20 minutes in acetic anhydride (05M), DIEA (0125M), and HOBt (02% 
w/v) in DMF (20m1). The resin was separated by filtration, washed with DMF and 
ether and dried in a desicator overnight to give Ub(68-76)-resin (300mg). The 
synthesis was continued until Thr 66 when half of the remaining resin was removed 
and the N-terminus acetylated in an identical manner to that above giving Ub(66-76)-
resin (270mg). Following the coupling of Glu 64 the Fmoc group was removed and 
the N-terminus acetylated on the peptide synthesiser, the resin was then washed with 
DMF and ether and dried in a desicator overnight to give Ub(64-76)-resin (316mg). 
All three resins were stored at -20 °C until required. 
3.8.1. Semi-Preparative RP HPLC Purification of Ub(68-76). Ub(68-76)-resin 
(140mg) was swollen in a mixture of EDT (05m1) and thioanisole (05ml) under 
nitrogen for 30 minutes. Water (05m1) and TFA (lOmi) were added and the mixture 
was stirred for 3 hours. The resin was then separated by filtration, washed with TFA 
(5m1) and the combined filtrate and washings concentrated in vacuo to give an oil, 
which yielded the crude peptide on trituration with ether (lOOml). The ether was 
decanted off and the crude peptide dissolved in 20% aqueous HOAc (20m1), diluted 
with water and lyophilised twice to give crude peptide (52mg). Purification by semi-





HPLC : (Column A, Gradient I): Rt 155 minutes; 
FAB MS : 106265265 , C 47H84N 170 11 requires 10626536 Da; 
AAA (20hrs): G1y2 226, Val, 103, Leu3 291, His 1 089, Ar92 213. 
CD results: cc-helix (%) r3-sheet (%) remainder (%) 
H20pH46 2+/-067 62 +/ 0-69 36 +/- 1-2 
+25% TFE 6 +/- 0-87 48 +1- 10 46 +/- 1-7 
+50% TEE 17 +/- 0-4 46 +/- 0-57 37 +/- 0-7 
H20 pH 2 0 +1- 37E 7  61 +/- 0-59 39 +/-0- 59 
+30% MeOH 2 +/- 0-91 50+!- 10 48 +/- 1-7 
+60% MeOH 9 +/- 0-83 54 +/-096 37 +/- 1-6 
3.8.2. Semi-Preparative RP HPLC Purification of Ub(66-76). Ub(66-76)-resin 
(140mg) was purified in an identical manner to that described in section 3.8.1 to give 
crude peptide (46mg) and pure Ub(66-76) (28mg). 
• Ub(66-76) 
HPLC : (Column A, Gradient I): Rt 172 minutes; 
FAB MS : 1276-79541, C 57H102N19014 requires 12775585 Da; 
AAA (20hrs) : Thr 1 104, G1y2 223, Val 1 1- 14, Leu4 377, His 1 0- 88, Ar92 1.99. 
CD results: a-helix (%) 13-sheet (%) remainder(%) 
H20 pH 46 0 +!- 34E 7  58+/ 0 - 55 42+/-0-55 
+25% TEE 37+/-0-64 63+/-0-64 0 +1- 62E 7 
+50% TFE 36+/-1-0 64+/-1-0 0 +!- 99E 7 
H20 pH 2 0 +1- 30E 7  60+/-0-48 40+/-0-48 
+30% MeOH 0+/-1.0  36+!- 11 64+/-1-9 
+60% MeOH 14+/-0-91 48 +/- 1-0 37 +/- 1-7 
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3.8.3. Semi-Preparative RP HPLC Purification of Ub(64-76). Ub(64-76)-resin 
(140mg) was purified in an identical manner to that described in section 3.8.1 to give 
crude peptide (25mg) and pure Ub(64-76) (11 mg). 
• Ub(64-76) 
HPLC : (Column A, Gradient I): R 172 minutes; 
FAB MS : 149284850, C 65H114N210 19 requires 14937521 Da; 
AAA (20hrs) : Thr 1 098, Ser i 095, G1u 1 116, Gly2 217, Va1 1 101, Leu4 373, His 1 
089, Ar92 200. 
CD results: a-helix (%) n-sheet (%) remainder (%) 
H20 pH 46 0 +1- 37E 7  61 +/0- 52 39 +/-0- 52 
+25% TFE 33 +/- 1-6 52+/-1-6 39 +/- 0-52 
+50% TFE 24+/-1-9 45 +/- 2-0 31 +/- 3-6 
H20 pH 2 0 +!- 35E 7  66 +/-0- 57 34 +/- 0-57 
+30% MeOH 7 +/- 0-81 52 +!- 085 41 +/- 1-5 
+60% MeOH 20 +,'- Fl 48 +!- Fl 33 +/- 1-9 
Section 3.9. [1 O,35,47&53-15N-Glycine, 56&67-(2S,4S)-5-fluoroleucine] 
ubiquitin. 
The synthesis was performed on a 0 immol scale using the functionalised resin Fmoc- 
Gly-(OCH2C6H40R) (0246g, 0406mmolg 1) and method 1 of the programmed cycles 
with online monitoring of the deprotection solution at 302nm. The side-chains of 
amino acids were protected as previously described. Most amino acids were double 
coupled using the symmetrical anhydride (05mmol) and the HOBt ester (immol). 
The exceptions to this were, Gly 75 single coupled using the symmetrical anhydride 
(immol), 15N-Gly 10,5,47 & 53 single coupled using the HOBt ester (lmmol), His 
treble coupled as the HOBt ester (05, FO, FOmmol) and Mn/Gin double coupled as 
the HOBt ester (05, FOmmol). FLeu was single coupled as the HOBt ester 
(04mmol) by sonication at RT for 24 hours. Following completion of assembly the 
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N-terminal Fmoc was left on and the resin stored in 1,4-dioxan at 4 °C until required. 
Quantitative Fmoc deprotection gave 0021mmolg 1 , 34% of the theoretical 
maximum. 
3.9.1. TbfmoclPGC and Semi-Preparative RP HPLC. Approximately one quarter 
of the peptide-resin was sonicated in 20% v/v piperidinefDMF for 20 minutes and 
subsequently washed with DMF, DCM and ether and dried under water suction for 30 
minutes. The dry resin (255mg, 54x10 3mmol) was then added to a suspension of 
TbfinocCl (75mg, 0016mmol) and DIEA (28.tl, 016mmol) in DCM (5m1) and 
sonicated at RT for 3 hours in the dark. The Tbfiiioc-peptide-resin was separated by 
filtration and washed thoroughly with DCM and additionally with ether. The dried 
Tbfmoc-peptide-resin was swollen in a mixture of EDT (025m1), ethyl methyl 
sulphide (025m1) and thioanisole (0 - 25n-fl) for 30 minutes under nitrogen whilst 
protected from the light. Water (025m1) and TFA (9m1) were then added and the 
cleavage mixture stirred for a further 4 hours. The resin was then separated by 
filtration, washed with TFA (5 ml) and the combined filtrate and washings 
concentrated in vacuo to give an oil, which yielded crude Tbfhioc protein on 
trituration with 2% v/v 3-mercaptoethanol in ether (lOOml). The ether was decanted 
off and the Tbfmoc protein dissolved in 6M GdmCl (5m1) and diluted with 
isopropanol (5 ml) and the solution centrifuged to remove a small amount of insoluble 
material. PGC (HPLC grade, 7.im, 525mg) was added and the solution was vortexed 
and then centrifuged. Adsorption of the Tbfiuioc-protein was monitored by analytical 
RP HPLC of the supernatant at 364nm. The PGC was then subjected to the following 
wash protocol with alternate vortexing and centrifugation: 
6M GdmCl/isopropanol (1:1) (40m1) 
6M GdmCllisopropanol (1:1) (40m1) 
6M GdmCllisopropanol (1:1) (40m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (lOmi) 
10% piperidine in 6M GdmCl/isopropanol (1:1) (lOmi) 
The supernatant from washes 4 and 5 were combined, neutralised to pH 45 with 
HOAc and the isopropanol removed in vacuo. The protein solution was then desalted 
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by semi-preparative RP HPLC (Column E, Gradient VII) and lyophilised to give 
IFLeu56, FLeu67]Ub I. Purification of all four portions in a similar manner gave 
548mg overall. 
• [FLeu56, FLeu67lUb I 
HPLC (Column A, Gradient I): Rt=176 minutes; 
MALDI MS: 86067, C378H 28N1050 118 S1F2 requires 86058 Da; 
AAA (40hrs) : Asp 7 734, Thr 618, Ser3 276, Glu 12 1321, Pr03 261, Gly6 641, 
Ala2 185, Va14 409, Met 1 083, Ile7 679, Leu7 707, Tyr 1 099, Phe2 203, His 1 102, 
Lys7 674, Arg4 395. 
Tryptic digestion fragments separated by analytical RP HPLC (Column C, 2m1 loop) 
and characterised by AAA (24hrs): 
Fragment Sequence R (minutes) 
T1(30-42) IQDKEGIPPDQQR 72 
T2 (7-11) TLTGK 128 
T3 (49-54) QLEDGR 158 
T4 (55-63) TtLSDYNIQK 299 
T5 (43-48) LIFAGK 376 
T6 (1-6) MQIFVK 412 
T7 (64-72) ESTtLHLVLR 43.4 
T8 (12-27) TITLEVEPSDTIENVK 46-0 
tdenotes  FLeu residue. 
3.9.2. Refolding from 8M Urea, 50mM NH4OAc, 10mM DTT at p1145. [FLeu56 , 
FLeu67]Ub (25mg) I was dissolved in 8M urea, 50mM NH4OAc, 10mM DTT at pH 
4.5 (lOmi) and stirred at RT for 2 hours. The protein solution was then sequentially 
dialysed (MWCO=2000, Spectropor) against nitrogen saturated solutions of 6M urea, 
50mM NH4OAc, lOmMDTT at pH 45 (800m1), 4M urea, 50mM NH4OAc, 10mM 
DTT at pH 45 (800m1), 2M urea, 50mM NH 4OAc at pH 45 (800m1), 50mM 
NH4OAc at pH 45 (3000m1) and 50mM NIH 4OAc at pH 45 (3000m1) for 24 hours at 
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each step. The protein solution was then lyophilised and used in structural studies. A 
second batch (25mg) was refolded in a similar manner. 
CD results: 	 cc-helix (%) 13-sheet (%) remainder (%) 
50mM Na borate pH 	11 +1- 084 52+/-0-88 37+/-1-6 
+50% TFE 	 80 +/- 1-0 	8+/-1-5 	11 +/-1-8 
Section 3.10. [50&67-(2S,4S)-5-FI uoroleucine]ubiquitin. 
The synthesis was started on a 025mmol scale using the functionalised resin Fmoc-
Gly-(OCH2C6H40R) (1 -3 Og, 0- 193 mmolg') and method 1 of the programmed cycles 
with online monitoring of the deprotection solution at 302nm. The side-chains of 
amino acids were protected as previously described. Most amino acids were double 
coupled using the symmetrical anhydride (05mmol) and the HOBt ester (immol). 
The exceptions to this were Gly which was single coupled using the symmetrical 
anhydride (immol), His was treble coupled as the HOBt ester (05, 10, IOmmoI 
respectively) and Asn/Gln were double coupled as the HOBt ester (05, lOmmol). 
FLeu 67&50 were single coupled as the HOBt ester (1.0 and 05mmol respectively) 
by sonication at RT for 4 hours with quantitative Fmoc deprotection indicating 100% 
loading at both these residues. Following the coupling of FLeu67, the peptide-resin 
was divided equally with one half continuing on for the synthesis of 
[FLeu50,FLeu67]Ub with the remaining half stored in 1,4-dioxan at 4°C prior to being 
used in the synthesis of [FLeu43,FLeu67]Ub. Extended coupling times were used for 
residues Lys6 to Met 1. Following completion of assembly the N-terminal Fmoc was 
left on and the resin stored in 1,4-dioxan at 4°C until required. Quantitative Fmoc 
deprotection gave 0046mmolg 1 , 83% of the theoretical maximum. The resin was 
divided into four equal portions with half purified starting with the TbfmocfPG€ 
protocol and the second half purified by a non-Thfmoc/PGC protocol. 
3.10.1. TbfmocfPGC Protocol. Approximately one quarter of the peptide-resin was 
sonicated with 20% v!v piperidinefDMF (20m1) for 20 minutes and subsequently 
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washed with DMF, DCM, and ether and dried under water suction for 30 minutes. 
The dry resin (463mg, 0021mmol) was then added to a suspension of TbfmocCl 
(289mg, 0063mmo1) and DIEA (1 lt.tl,  0063mmol) in DCM (5m1) and sonicated at 
RT for 3 hours in the dark. The Tbfhoc-protein-resin was separated by filtration and 
washed thoroughly with DCM and additionally with ether. The dried Tbfmoc-
protein-resin was swollen in a mixture of phenol (075g), EDT (2m1) and thioanisole 
(05ni1) under nitrogen for 30 minutes whilst protected from the light. Water (05m1) 
and TFA (lOmi) were then added and the cleavage mixture stirred for a further 4 
hours. The resin was separated by filtration, washed with TFA (5m1) and the 
combined filtrate and washings concentrated in vacuo to give an oil, which yielded 
solid Tbfhioc-protein on trituration with 2% v/v 13-mercaptoethanol in ether (lOOmi). 
The ether was decanted off and the Tbfinoc-protein dissolved in 6M GdmCI (125m1) 
and diluted with isopropanol (125m1) and the solution centrifuged to remove a small 
amount of insoluble material. PGC (HPLC grade, 7j.im, 800mg) was added and the 
solution was vortexed and then centrifuged. Adsorption of the Tbfhioc-protein was 
monitored by analytical RP HPLC of the supernatant at 364nm. The PGC was then 
subjected to the following wash protocol with alternate vortexing and centrifugation: 
6M GdmCl/isopropanol (1:1) (40m1) 
6M GdmCl/isopropanol (1:1) (40m1) 
6M GdmCllisopropanol (1:1) (40m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (16m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (16m1) 
The supernatant from washes 4 & 5 were combined, neutralised to pH 45 with HOAc 
and concentrated in vacuo prior to being loaded onto a Sephadex G50 (fine) column 
(660 x 30mm) pre-equilibriated with 30% aqueous HOAc. The column was then 
eluted at 36m1h' with monitoring at 226 and 277nm and collecting 20 minute 
fractions. Protein fractions 14-22 inclusive were combined, diluted with water and 
lyophilised twice. Purification of a second quarter of peptide-resin in an identical 
manner gave [FLeu50,FLeu671Ub I (87. 1mg overall). 
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• [FLeu50,FLeu67]Ub I 
HPLC (Column B, Gradient I): R 18 minutes; 
MALDI MS: 86022, C373H 28N1050 118 S 1F2 requires 86018 Da; 
AAA (40hrs) : Asp 7 671, Thr7 543, Ser3 205, G1u 12 1342, Pr03 317, G1y6 6-40, 
Ala2 212, Va14 340, Met 1 101, 1ie7 653, Leu7 6-07, Tyr 1 063, Phe2 188, His1 051, 
Lys7 &50, Arg4 275; 
AAA (60hrs) : Asp 7 843, Thr7 6-63, Ser3 226, G1u 12 1170, Pr03 345, Gly 600, 
Ala2 187, Va14 368, Met 1 073, 11e7 709, Leu7 6-63, Tyr 1 067, Phe2 204, His 1 055, 
Lys7 712, Arg4 365; 
Tryptic digestion fragments separated by analytical RP HPLC (Column D, 2m1 loop) 
and characterised by AAA (24hrs): 






















t denotes FLeu residue 
3.10.1.1. Initial NMR Analysis. [FLeu50 ,FLeu67]Ub I (6-4mg) was dissolved in MQ-
grade water (700j.il) and D 20 (70jii) added giving pH51. The 1H NMR spectrum 
was recorded prior to dialysis (MWCO=2000, Spectropor) against nitrogen saturated 
solutions of 8M urea, 50mM NH4OAc, 5mM DTT at pH 45 (200m1), 50mM 
NTT4OAc, 1mM DTT at pH 45 (200m1) and finally 1mM DTT (200m1) for 24 hours 
at each step. Following dialysis the pH of the protein solution was adjusted to 51 
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and 'H NMR recorded. The protein solution was then lyophilised and subsequently 
dissolved in 25mM C2D302Na/lmM DTT/01 w/v Na azide/10% D 20 pH 48 (800 j.tl) 
and the 'H ININ4R repeated. 
3.10.1.2. FPLC/SuperdexTM 75. [FLeu50,FLeu67]Ub I (67mg) was dissolved in 6M 
GdmCl (2m1) and purified by FPLC using a SuperdexTM 75 HR 10/30 column eluting 
with 6M GdmCl, 200p.l loop and monitoring at 270 and 280nm. Protein fractions 
(1051-1150m1) and (1151-1300ml) were combined and extensively dialysed 
(MWCO=2000, Spectropor) against water and lyophilised to give 
[FLeu50,FLeu671Ub II F! (57mg) and [FLeu50,FLeu671Ub II F2 (27.3mg). 
Ub(bovine) eluted in fraction (115 1-1250m1) using the same column and conditions 
described above. 
• [FLeu50,FLeu67JUb II Fl 
HPLC (Column B, Gradient I): R 18 minutes; 
MALDI MS: 86260 (Na adduct), C 378H628N1050 118 S,F2 requires 8601-8 Da; 
AAA (40hrs) : Asp 7 598, Thr7 569, Ser3 234, G1u 12 1096, Pr03 310, Gly6 674, 
Ala2 214, Va14 374, Met 1 086, lie7 583, Leu7 568, Tyr, 059, Phe2 178, His, 069, 
Lys7 613, Arg4 310; 
AAA (ôOhrs) : Asp7 691, Thr7 568, Ser3 211, Glu12  1120, Pr03 339, G1y6 653, 
Ala2 202, VaL, 393, Met, 085, Ile 7 628, Leu7 584, Tyr 1 070, Phe2 178, His, 070, 
Lys7 646, Arg4 308. 
• IFLeu50,FLeu67IUb II F2 
HPLC (Column B, Gradient I): R 18 minutes; 
MALDI MS: 86281 (Na adduct), C 378H 28N,050118 S 1F2 requires 86018 Da; 
AAA (40hrs) Asp7 6-80, Thr7 520, Ser3 235, Glu 12 1095, Pr03 330, G1y6 644, 
Ala2 220, VaL 360, Met 1 084, Ile7 6-85, Leu7 513, Tyri 051, Phe2 190, His, 069, 
Lys7 6-36, Arg4 303; 
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AAA (60hrs) : Asp 7 721, Thr7 590, Ser3 1-98, G1u 12 11-70, Pr03 308, G1y6 622, 
Ala2 205, Va14 339, Met 1 075, lie7 6-86, Leu7 600, Tyr1 058, Phe2 210, His 1 073, 
Lys7 674, Arg4 343. 
CD results: 	 cc-helix (%) n-sheet (%) remainder (%) 






40 +/- 1-6 
+50% TFE 
	
15 +/- 1-7 
	
36 +/- 1-8 
	
50+/- 3-2 
3.10.1.3. Cation Exchange/CM-Sepharose CL6B. [FLeu 50,FLeu67]Ub II Fl /F2 
(3 3mg) were dissolved in 8M urea, 50mM NIH4OAc, 5mM DTT at pH 45 (50m1) and 
stirred at RI for 2 hours. The protein solution was then sequentially dialysed 
(MWCO=2000, Cellu Sep Hi) against nitrogen saturated solutions of 50mM 
NH4OAc, 5mM DTT at pH 45 (2000m1), 50mM NFLOAc, 2mM DTT at pH 45 
(3000m1), 50mM NH4OAc at pH 45 (3000ml) for 24 hours at each step. The protein 
solution was then loaded onto the CM-Sepharose CL6B column (280 x16 mm) pre-
equilibriated with 50mM NH4OAc pH 45. A pH gradient of 50mM NH4OAc at pH 
45 to 50mM NH4OAc pH 55 (500m1) was run at 30m11 - ' overnight with monitoring 
at 277 and 226nm. The column was then run isocratically at 50mM NthOAc pH 55 
(60m1) for 2 hours after which a salt gradient of 50mM NthOAc pH 55 to 03M 
NH4OAc at pH 55 (300m1) for 10 hours was applied to elute the protein from the 
column. Protein fractions (555-585m1), (585-660m1) and (660-705m1) and (705-
750m1) were combined and repeatedly lyophilised to give [FLeu 50,FLeu67]Ub ifi Fl 
(04mg), F2 (05mg), F3 (09mg) and F4 (04mg). No further work was done on 
these fractions. 
3.10.2. Non-TbfmocfPGC Protocol. Approximately one half of the peptide-resin 
was sonicated in 20% v/v piperidinefDMF (20ml) for 20 minutes and subsequently 
washed with DMF, DCM, and ether and dried under water suction for 30 minutes. 
The dried protein-resin (926mg, 0042mnioi) was then swollen in a mixture of phenol 
(075g), EDT (2m1), thioanisole (05m1) and TIS (200pi) under nitrogen for 30 
minutes. Water (05m1) and TFA (lOml) were then added and the cleavage mixture 
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stirred for a further 4 hours. The resin was separated by filtration, washed with TFA 
(5 ml) and the combined filtrate and washings concentrated in vacuo to give an oil, 
which yielded crude protein on trituration with 2% v/v 3-mercaptoethanol in ether 
(lOOmi). The ether was decanted off and the protein dissolved in 20% aqueous 
CH3 CN (50m1), diluted with water and lyophilised. 
3.10.2.1. Gel Filtration Sephadex G50 and Refolding from 8M Urea, 50mM 
NIL1OAc, 5mM DTT at pH 45. The lyophilised protein from above was dissolved 
in 30% HOAc (35ml) and divided equally and taken through in two batches. Protein 
solution (175m1) was loaded onto a Sephadex G50 (fine) column (660 x 30mm) pre-
equilibriated with 30% aqueous HOAc. The column was then eluted at 375n - 1W 1 
with monitoring at 226 and 277nm and collecting 20 minute fractions. Protein 
fractions 14-18 inclusive were combined, diluted with water and lyophilised twice. 
Purification of the second portion in an identical manner gave 2636mg overall. 
Protein (260mg) was dissolved in 8M urea, 50mM NthOAc, 5mM DTT at pH 45 
(SOml), stirred at RT for 2 hours and subsequently divided into two equal portions. 
Each portion was sequentially dialysed (MWCO=2000, Cellu Sep Hi) against 
nitrogen saturated solutions of 50mM NH4OAc, 5mM DTT at pH 45 (2000ml), 
50mM NthOAc, 2mM DTT at pH 45 (3000m1) and 50mM NH4OAc at pH 45 
(3000m1) for 24 hours at each step. 
3.10.2.2. Cation Exchange/CM-Sepharose CL6B. The combined protein solutions 
from both dialysis were then loaded onto the CM-Sepharose CL613 column (280 x16 
mm) pre-equilibriated with 50mM NIH 4OAc pH 45. A pH gradient of 50mM 
NH4OAc at pH 45 to 50mM NH4OAc pH 55 (500m1) was run at 30mlW 1 overnight 
with monitoring at 277 and 226nm. The column was then run isocratically at 50mM 
N144OAc pH 55 (60m1) for 2 hours after which a salt gradient of 50mM N14 4OAc pH 
55 to 03M NIH4OAc at pH 55 (300m1) for 10 hours was applied to elute the protein 
from the column. Protein fractions (660-705ml) were combined and repeatedly 
lyophilised to give IFLeu50,FLeu 671Ub IV (322mg). 
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• [FLeu 50,FLeu 67JUb IV 
HPLC (Column A, Gradient I): R 174 minutes; 
MALDI MS : 86189, C378H628N 1050118 S 1F2 requires 86018 Da; 
AAA (40hrs) : Asp 7 681, Thr7 573, Ser 232, G1u 12 1119, Pr03 292, G1y6 636, 
Ala2 198, Va14 4-11, Met, 095, 11e7 643, Leu7 683, Tyr1 087, Phe2 190, His 1 099, 
Lys7 666, Ar94 392; 
AAA (60hrs) : Asp 7 658, Thr7 533, Ser 195, G1u 12 1119, Pr03 387, G1y6 646, 
Ala2 201, Va14 354, Met 1 068, 11e7 592, Leu7 623, Tyr1 066, Phe2 168, His 1 096, 
Lys7 653, Ar94 376. 
3.10.2.3. MMA Reduction and Cation Exchange/CM-Sepharose CL6B. 
[FLeu50,FLeu67]IJb IV (32mg) was dissolved in 10% aqueous HOAc (3m1) and N-
methylmercaptoacetamide (MMA) (251tl, 285mmo1) added giving a 10% w/v 
solution, which was purged with nitrogen and incubated at 37 °C for 18 hours. 
Additional MIMA (12541, 143mmo1) was added and the solution was incubated at 
37°C for a further 30 hours. The reduction reaction was monitored by analytical RP 
HPLC at 214nm. The protein solution was then diluted to 60m1 with 50mM NH 4OAc 
at pH 45 and applied to the CM-Sepharose CL6B column and eluted with the same 
conditions as described in 3.10.2.2. This gave IFLeu50,FLeu67JUb V (16mg 
estimated). 
• [FLeu50,FLeu 67lUb V 
HPLC (Column A, Gradient I): R 17-6 minutes; 
MALDI MS: 86048, C378H628N1050 118 5 1F2 requires 86018 Da. 
CD results: 	 cc-helix (%) p3-sheet (%) remainder (%) 






50 +/- 3-1 
±50% TFE 	 82 +/-1 - 5 	0 +/-6•6ff 7 
	
18+/- 1 - 5 
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Section 3.11. [43&67-(2S,4S)-5-Fluoroleucine]ubjquitun. 
The synthesis was performed on a 0 125mmol scale starting at residue 66 with 
residues 76 to 67 already coupled to the resin. (section 3. 10.) The side-chains of 
amino acids were protected as previously described. Method 1 of the programmed 
cycles was used with most amino acids double coupled using the symmetrical 
anhydride (05mmol) and the HOBt ester (immol). The exceptions to this were Gly 
which was single coupled using the symmetrical anhydride (immol) and Asn/Gln 
which were double coupled as the HOBt ester (05, 10mmol). FLeu43 was coupled 
as the HOBt ester (05mmol) by sonication at RT for 4 hours with quantitative Fmoc 
deprotection indicating a 100% loading. Following completion of assembly the N-
terminal Fmoc was left on and the resin stored in 1,4-dioxan at 4°C until required. 
Quantitative Fmoc deprotection gave 0040mmolg 1 , 72% of the theoretical 
maximum. The resin was divided into four equal portions with half purified starting 
with the Tbfmoc/PGC protocol and the second half purified by a non-TbfmocfPGC 
protocol. 
3.11.1. Tbfmoc/PGC Protocol. Approximately one quarter of the peptide-resin was 
sonicated with 20% v/v piperidine/DMF (20m1) for 20 minutes and subsequently 
washed with DMF, DCM, and ether and dried under water suction for 30 minutes. 
The dry resin (475mg, 0019mmol) was then added to a suspension of TbfmocCl 
(26•1mg, 0057mmol) and DIEA (lOtl, 0057mmol) in DCM (5m1) and sonicated at 
RT for 3 hours in the dark. The Tbfinoc-protein-resin was separated by filtration and 
washed thoroughly with DCM and additionally with ether. The dried Tbfmoc-
protein-resin was swollen in a mixture of phenol (075g), EDT (2m1) and thioanisole 
(05m1) under nitrogen for 30 minutes whilst protected from the light. Water (05m1) 
and TFA (lOmi) were then added and the cleavage mixture stirred for a further 4 
hours. The resin was separated by filtration, washed with TFA (5m1) and the 
combined filtrate and washings concentrated in vacuo to give an oil, which yielded 
crude Tbfhioc-protein on trituration with 2% v/v f3-mercaptoethanol in ether (lOOml). 
The ether was decanted off and the Tbfhoc-protein dissolved in 6M GdmCl (125 ml) 
and diluted with isopropanol (125m1). PGC (HPLC grade, 7pm, 800mg) was added 
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and the solution was vortexed and then centrifuged. Adsorption of the Tbfmoc-
protein was monitored by analytical RP HPLC of the supernatant at 364nm. The 
PGC was then subjected to the following wash protocol with alternate vortexing and 
centrifugation: 
6M GdmCllisopropanol (1:1) (40m1) 
6M GdmCllisopropanol (1:1) (40m1) 
6M GdmCllisopropanol (1:1) (40m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (16m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (16m1) 
The supernatant from washes 4 & 5 were combined, neutralised to pH 45 with HOAc 
and the isopropanol removed in vacuo prior to being loaded onto a Sephadex G50 
(fine) column (660 x 30mm) pre-equilibriated with 30% aqueous HOAc. The column 
was then eluted at 36m1h' with monitoring at 226 and 277nm and collecting 20 
minute fractions. Protein fractions 10-14 inclusive were combined, diluted with water 
and lyophilised twice. Purification of a second quarter of peptide-resin in an identical 
manner gave [FLeu 43,FLeu671 Ub I (754mg overall). 
• [FLeu43,FLeu 67]Ub I 
HPLC : (Column B, Gradient I): R 18 minutes; 
MALDI MS: 86035, C 378H628N1050118 S 1F2 requires 86018 Da; 
AAA (40hrs) : Asp 7 659, Thr7 599, Ser3 242, G1u 12 1364, Pr03 371, Gly6 6-32, 
Ala2 210, Va14 356, Met 1 078, 11e7 663, Leu7 615, Tyr 1 080, Phe2 186, His 1 055, 
Lys7 658, Arg4 360; 
AAA (60hrs) : Asp7 713, Thr7 512, Ser3 262, Glu 12 1277, Pr03 377, G1y6 662, 
Ala2 236, Va14 352, Met 1 ND, 11e7 616, Leu7 567, Tyri 058, Phe2 191, His 1 066, 
Lysi 602, Ar94 397. 
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Tryptic digestion fragments separated by analytical PP HPLC (Column D, 2m1 loop) 
and characterised by AAA (24hrs): 
Fragment Sequence R, (minutes) 
Ti (30-33) IQDK 88 
T2 (73-76) LRGQ 104 
T3 (7-11) TLTGK 148 
T4 (49-54) QLEDGR 170 
T5 (34-42) EGIPPDQQR 246 
T6 (5 5-63) TLSDYNLQK 322 
T7 (43-48) tLffAGK 362 
T8 (1-6) MQIFVK 430 
T9 (64-72) ESTtLHLVLR 44.4 
TiO (12-27) TITLEVEPSDTIENVK 460 
denotes FLeu residue. 
3.11.1.1. Initial NMR Analysis. [FLeu43,FLeu67]Ub I (6-8mg) was dissolved in MQ-
grade water (700tl) and D 20 (70p.l)  added giving pH5 1. The 'H NMR spectrum 
was recorded prior to dialysis (MWCO=2000, Spectropor) against nitrogen saturated 
solutions of 8M urea, 50mM NH4OAc, 5mM DTT at pH 45 (200m1), 50mM 
NH4OAc, 1mM DTT at pH 45 (200m1) and finally 1mM DTT (200m1) for 24 hours 
at each step. Following dialysis the pH of the protein solution was adjusted to 51 
and 'H NUR recorded. The protein solution was then lyophilised and subsequently 
dissolved in 25mM C2D302NaJimM DTT/0 1 w/v Na azide/10% D 20 pH 48 (800 j.il) 
and the 'H NtvlIR repeated. 
3.11.1.2. FPLC/SuperdexTM 75. [FLeu43,FLeu67]Ub I (60mg) was dissolved in 6M 
GdmCl (2m1) and purified by FPLC using a SuperdexTm 75 HR 10/30 column eluting 
with 6M GdmCl, 200p.l loop and monitoring at 270 and 280nm. Protein fractions 
(1001-1150ml) and (1151-1350ml) were combined and extensively dialysed 
(MWCO2000, Spectropor) against water and lyophilised to give 
[FLeu43,FLeu67]Ub H Fl (6 1mg) and [FLeu43,FLeu67JUb H F2 (435mg). 
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Ub(bovine) eluted in fractions (1 1-51-12-50n -J) using the same column and conditions 
described above. 
• [FLeu43,FLeu67JUb H F! 
HPLC (Column B, Gradient I): R 18minutes; 
MALDI MS: 86338 (K adduct), C378H628N1050 118 S 1F2 requires 86018 Da; 
AAA (40hrs) : Asp 7 686, Thr7 599, Ser3 238, G1u 12 1201, Pr03 384, G1y6 652, 
Ala2 209, Va14 332, Met 1 032, 11e7 672,Leu7 603, Tyr i 062, Phe2 187, His 1 060, 
Lys7 639, Arg4 353; 
AAA (60hrs) : Asp 7 796, Thr7 6-54, Ser3 255, G1u 12 1342, Pr03 418, G1y6 600, 
Ala2 183, VaL1 393, Met 1 068, lie7 729, Leu7 669, Tyr1 067, Phe2 209, His 1 067, 
Lys7 719, Arg4 416. 
• [FLeu 43,FLeu67]Ub H F2 
HPLC (Column B, Gradient I): R 18 minutes; 
MALDI MS: 86423 (K adduct), C378H628N1050 118 S 1F2 requires 86018 Da; 
AAA (40hrs) : Asp 7 713, Thr7 594, Ser 231, Giu 12 1171, Pr03 402, Gly6 618, 
Ala2 216, Va14 343, Met 1 ND, lie7 682, Leu7 563, Tyr1 054, Phe2 184, His 1 053, 
Lys7 6-66, Arg4 295; 
AAA (60hrs) : Asp 7 7•95 Thr7 634, Ser3 223, Giu 12 1237, Pr03 354, G1y6 569, 
Ala2 196, VaL 379, Met 1 062, lie7 715, Leu7 6-03, Tyr i ND, Phe2 206, His 1 061, 
Lys7 735, Arg 378. 
CD results: cc-helix (%) 13-sheet (%) remainder (%) 
50mM Na borate pH 7 6 +/- 0-63 48 +1- 073 47 +/- 1-2 
+50% TFE 22 +/-1 - 5 35 +/- 1-6 44 +/- 2-8 
3.11.1.3. Cation Exchange/CM-Sepharose CL6B. [FLeu43 ,FLeu67]Ub II F1/F2 
(47•4mg) were dissolved in 8M urea, 50mM NH 4OAc, 5 mM DTT at pH 45 (50m1) 
and stirred at RT for 2 hours. The protein solution was then sequentially dialysed 
(MWC0=2000, Cellu Sep Hi) against nitrogen saturated solutions of 50mM 
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NH4OAc, 5mM DTT at pH 45 (2000m1), 50mM NthOAc, 2mM DTT at pH 45 
(3000ml), 50mM N}LOAc at pH 45 (3000ml) for 24 hours at each step. The protein 
solution was then loaded onto the CM-Sepharose column CL613 (280 x 16mm) pre-
equilibriated with 50mM NILOAc pH 45. A pH gradient of 50mM NH4OAc at pH 
45 to 50mM NH4OAc pH 55 (500m1) was run at 30 mlh' overnight with monitoring 
at 277 and 226nm. The column was then run isocratically at 50mM NthOAc pH 55 
(60m1) for 2 hours after which a salt gradient of 50mM N}LOAc pH 55 to 03M 
NH4OAc at pH 55 (300m1) for 10 hours was applied to elute the protein from the 
column. Protein fractions (570-630ml), (630-675m1) and (675-720m1) were 
combined and repeatedly lyophilised to give [FLeu43,FLeu67JUb ifi F! (40mg), F2 
(1 5mg) and F3 (3.6mg). 
• [FLeu43,FLeu671Ub ifi F3 (used in 111  NMR studies). 
HPLC (Column A, Gradient I): R 174 & 176 minutes; 
MALDI MS : 86076 (Na adduct) and 88324 (matrix adduct) C 378H628N 1050118 S 1F2 
requires 86018 Da; 
3.11.2. Non-Tbfmoc[PGC Protocol. Approximately one half of the peptide-resin 
was sonicated in 20% v/v piperidinefDMiF (20m1) for 20 minutes and subsequently 
washed with DMF, DCM, and ether and dried under water suction for 30 minutes. 
The dried protein-resin (714mg, 0029nimol) was then swollen in a mixture of phenol 
(075g), EDT (2m1), thioanisole (05m1) and TIS (200.d) under nitrogen for 30 
minutes. Water (05m1) and TFA (lOmi) were then added and the cleavage mixture 
stirred for a further 4 hours. The resin was separated by filtration, washed with TFA 
(5 ml) and the combined filtrate and washings concentrated in vacuo to give an oil, 
which yielded crude protein on trituration with 2% v/v 3-mercaptoethanol in ether 
(lOOmI). The ether was decanted off and the crude protein dissolved in 20% aqueous 
CH3 CN (50m1), diluted with water and lyophilised. 
3.11.2.1 Gel Filtration Sephadex G50 and Refolding from 8M Urea, 50mM 
NH40Ac, 5mM DTT at pH 45. The lyophilised protein from above was dissolved 
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in 30% aqueous HOAc (35m1) and divided equally and taken through in two batches. 
Protein solution (175ml) was loaded onto a Sephadex G50 (fine) column (660 x 
30mm) pre-equilibriated with 30% aqueous HOAc. The column was then eliited at 
375m1h' with monitoring at 226 and 277nm and collecting 20 minute fractions. 
Protein fractions 13-17 inclusive were combined, diluted with water and lyophilised 
twice. Purification of the second portion in an identical manner gave 1756mg 
overall. Protein (175mg) was dissolved in 8M urea, 50mM NH4OAc, 5mM DTT at 
pH 45 (50m1), stirred at RT for 2 hours and subsequently divided into two equal 
portions. Each portion was sequentially dialysed (MWC0=2000, Cellu Sep Hi) 
against nitrogen saturated solutions of 50mM NthOAc, 5mM DTT at pH 45 
(2000m1), 50n-1M N}T4OAc, 2mM DTT at pH 45 (3000m1), 50mM NH4OAc at pH 
45 (3000m1) for 24 hours at each step. 
3.11.2.2 Cation Exchange/CM-Sepharose CL6B. The combined protein solutions 
from both dialysis were then loaded onto the CM-Sepharose column CL6B column 
(280 x 16mm) pre-equilibriated with 50mM NH 4OAc pH 45. A pH gradient of 
50mM NH4OAc at pH 45 to 50mM NH4OAc pH 55 (SOOmi) was run at 30n- 1h' 
overnight with monitoring at 277 and 226m. The column was then run isocratically 
at 50mM N}LOAc pH 5•5 (60m1) for 2 hours after which a salt gradient of 50mM 
NH4OAc pH 55 to 03M NIH4OAc at pH 55 (300m1) for 10 hours was applied to 
elute the protein from the column. Protein fractions (645-690ml), these were 
combined and repeatedly lyophilised to give [FLeu43,FLeu671Ub IV (lF3mg). 
• IFLeu43,FLeu67lUb IV 
HPLC (Column A, Gradient I): R 174 minutes; 
MALDI MS: 86189, C378H 28N1050118 S 1F2 requires 86018 Da; 
AAA (40hrs) Asp7 6-52, Thr7 6-01, Ser 243, G1u 12 1107, Pr03 255, G1y6 6-61, 
Ala2 196, Val4 334, Met 1 059, Tie7 643, Leu7 6-67, Tyri 091, Phe2 173, His 1 101, 
Lys7 6-43, Arg4 363; 
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AAA (60hrs) : Asp 7 704, Thr7 576, Ser3 236, G1u 12 1071, Pr03 225, G1y6 660, 
Ala2 188, Va14 333, Met 1 057, lie7 702, Leu7 688, Tyr1 064, Phe2 227, His1 104, 
Lys7 652, Ar94 504. 
3.11.2.3. MMA Reduction and Cation Exchange/CM-Sepharose CL6B. 
[FLeu43,FLeu67]LJb IV (11mg) was dissolved in 10% aqueous HOAc (3ml) and 
(MIfvIA) (251ti, 285mmo1) added giving a 10% w/v solution, which was purged with 
nitrogen and incubated at 37°C for 18 hours. Additional M1*vIA  (12541, 143mmol) 
was added and the solution incubated at 37°C for a further 30 hours. The reduction 
reaction was monitored by analytical RP HPLC at 214nm. The protein solution was 
then diluted to 60m1 with 50mM NI{ 4OAc at pH 45 and applied to the CM-sepharose 
CL613 column and eluted with the same conditions as described in 3.11.2.2. This 
gave [FLeu 43,FLeu67]Ub V (5mg estimated). 
• [FLeu43,FLeu67]Ub V 
HPLC (Column A, Gradient I): R 1 176 minutes; 
MALDI MS: 86222 (Na adduct), C378H 628N1050118 S 1 F2 requires 86018 Da. 
CD results: 	 a-helix (%) 	3-sheet (%) remainder (%) 
50mM Na borate pH 7 	29 +/- 0-79 32 +1- 11 	39 +/- 1-4 
+50% TFE 	 100 +/-7•7E 2 0 +1- 16E 7 0 +1- 56E 7 
Section 3.12. [3-Norleucine,43-norvaline]ubiquitin. 
The synthesis was performed on a 0125mmo1 scale using the functionalised resin 
Fmoc-Gly-(OCH2C6110R) (0308g, 0406mmo1g') and method 2 of the programmed 
cycles with online monitoring of the deprotection solution at 302nm. The side-chains 
of amino acids were protected as previously described. Most amino acids were 
double coupled using the HOCt ester (10 and 05mmol). The exceptions to this were 
Gly which was single coupled using the symmetrical anhydride (immol) and His 
which was treble coupled as the HOBt ester (05, 10, lommol). Following 
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completion of assembly the N-terminal Fmoc was left on and the resin stored in 1,4-
dioxan at 4°C until required. Quantitative Fmoc deprotection gave 0042mmolg 1 , 
67% of the theoretical maximum. 
3.12.1. TbfmocfPGC and Gel Filtration Sephadex G50. Approximately 40% of 
the peptide-resin was sonicated with 20% v/v piperidinefDMF for 20 minutes and 
subsequently washed with DMF, DCM, and ether and dried under water suction for 
30 minutes. The dry resin (500mg, 0.02 immol) was then added to a suspension of 
TbfmocCl (289mg, 0063mmo1) and DI.EA (1 ljil, 0063mmo1) in DCM (5m1) and 
sonicated at RT for 3 hours in the dark. The TbfInoc-peptide-resin was separated by 
filtration and washed thoroughly with DCM and additionally with ether. The dried 
Tbfiiioc-peptide-resin was swollen in a mixture of EDT (025ml), ethyl methyl 
sulphide (025m1) and thioanisole (025m1) for 30 minutes under nitrogen whilst 
protected from the light. Water (025m1) and TFA (9m1) were then added and the 
cleavage mixture stirred for a further 4 hours. The resin was separated by filtration, 
washed with TFA (5 ml) and the combined filtrate and washings concentrated in 
vacuo to give an oil, which yielded crude Tbfhoc-protein on trituration with 2% v/v 
3-mercaptoethanol in ether (lOOml). The ether was decanted off and the Tbfinoc-
protein further washed with ether (50m1). The Thfhioc-protein was dissolved in 6M 
GdmCl (15m1) and diluted with isopropanol (15m1) and the solution centrifuged to 
remove a small amount of insoluble material. PGC (HPLC grade, 7.im, 720mg) was 
added and the solution was vortexed and then centrifuged. Adsorption of the Tbfmoc 
protein was monitored by analytical RP HPLC at 364nm. The PGC was then 
subjected to the following wash protocol with alternate vortexing and centrifugation: 
6M GdmCllisopropanol (1:1) (64m1) 
6M GdmCl/isopropanol (1: 1) (64m1) 
ÔM GdmCllisopropanol (1:1) (64m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (16m1) 
10% piperidine in 6M GdmCL/isopropanol (1:1) (24m1) 
The supernatant from washes 4 & 5 were combined, neutralised to pH 45 with HOAc 
and the isopropanol removed in vacuo prior to being loaded onto a Sephadex G50 
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(fine) column (800 x 30mm) pre-equilibriated with 30% aqueous HOAc. The column 
was then eluted at 40mlW' with monitoring at 226 and 277nm and collecting 15 
minute fractions. Protein fractions 14-19 inclusive were combined, diluted with water 
and lyophilised twice to give [N1e3,Nva43]Ub I (689)mg. 
• INle3,Nva43lUb I 
HPLC (Column B, Gradient I): K  18 minutes; 
MALDI MS: 85766 (Na adduct), C377H628N1050 118 S 1 requires 8551-8260 Da; 
tAAA (40hrs) : Asp 7 696, Thr7 565, Ser3 216, Glu12 1407, Pr03 292, G1y6 17, 
Ala2 218, Va14 383, Met 1 078, Tie6 558, Leu8 794, Tyr 1 073, Phe2 202, His 1 081, 
Lys7 660, Ar94 363. 
NlefNva seen at distinctive K's but no integration performed. 
3.12.2. Semi-Preparative HPLC. Further purification by semi-preparative HPLC 
(Column E, Gradient VT) and repeated lyophilisation gave [N1e3,Nva43]Ub II 
(54.5mg). 
• [N1e3,Nva43lUb H 
HPLC (Column B, Gradient I): K 18 minutes; 
MALDT MS: 85523, C377H628N1050 118 S 1 requires 8551-8260 Da; 
AAA (40hrs) Asp7 725, Thr7 6-72, Ser3 266, Glu12 1381, Pr03 293, G1y6 6-10, 
Ala2 223, Val4 489, Met 1 070, Tie6 606, Leu8 746, Tyri 066, Phe2 211, His 1 095, 
Lys7 6-67, Ar94 394 
Tryptic digestion fragments separated by analytical RP HPLC (Column C, 2m1 loop) 
and characterised by AAA (24hrs): 
Fragment Sequence K (minutes) 
Ti (30-33) IQDK 72 
T2 (73-76) LRGG 82 
13 (7-11) TLTGK 120 
14(49-54) QLEDGR 16-4 
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T5 (34-42) EGIPPDQQR 232 
T6 (55-63) TLSDYNTQK 342 
T7 (43-48) tNvaIFAGK 362 
T8 (1-6) MQNleF\TK 472 
T9 (64-72) ESTLHLVLR 486 
T10 (12-24) 	TITLE VEPSDTIIENVK 	49.4 
NlefNva seen at distinctive K's but no integration performed. 
3.12.3. Refolding from 8M Urea, 50 mM NH40Ac, 10 mM DTT at pH45. 
[N1e3,Nva43]Ub 11(20mg) was dissolved in 8M urea, 50mM NH4OAc, 10mM DTT 
at pH 45 (20m1) and stirred at RT for 2 hours. The protein solution was then 
sequentially dialysed (MWCO=2000, Spectropor) against nitrogen saturated solutions 
of 6M urea, 50mM NH4OAc, 10mM DTT at pH 45 (800m1), 4M urea, 50mM 
NH4OAc, 10mM DTT at pH 45 (800m1), 2M urea, 50mM NH4OAc, 10mM DTT at 
pH 45 (800m1), 50mM NH4OAc at pH 45 (3000m1) and 50mM NH4OAc at pH 45 
(3000m1) for 24 hours at each step. The protein solution was stored at 4°C until 
required. A second portion of [Nle 3,Nva43]Ub 11(20mg) was refolded in a similar 
manner. 
3.12.4. CD Analysis. [N1e3,Nva43]Ub II (2m1) of the refolded protein solution from 
above was by dialysised (MWCO=2000, Spectropor) against 50mM Na borate pH 7 
(200m1) x 2 for 24 hours at each step. 
CD results: 	 ct-helix (%) 13-sheet (%) remainder (%) 
50mM Na borate pH 7 
	




30 +/- 2-0 
+50% TFE 
	
51 +/- 1-9 
	
47 +/- 2-0 
	
2+/-36 
3.12.5. Fluorescence Studies. [N1e3,Nva43]Ub II (4m1) of the refolded protein 
solution from above was exchanged by ultrafiltration (MWCO= 1000, Filtron) into 
50mM MOPS pH 7. 
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3.12.6. NMR Studies. [Nle3,Nva43]Ub II (lOml) of the refolded protein solution 
from above was exchanged by ultrafiltration (MWCO=1000, Filtron) into 25mM 
C2D302Na, 1mM DTT at pH 48 and the 'H NMR recorded. 
Section 3.13. [68-DHistidine]ubiquitin. 
The synthesis was started on a 025mmol scale using the flinctionalised resin Fmoc-
Gly-(OCH2C6H40R) (0694g, 0360mmolg') and method 1 of the programmed cycles 
with online monitoring of the deprotection solution at 302m -n. The side-chains of 
amino acids were protected as previously described. For residues 75-69 inclusive all 
amino acids were double coupled as the HOCt ester (05mmol each) except Gly which 
was single coupled as the HOCt (immol). Following the coupling of residue 69 the 
resin was divided equally with half the resin continuing on for the synthesis of 
[DHis68]Ub. For residues 68-1 inclusive, most amino acids were double coupled 
using the symmetrical anhydride (05mmol) and HOBt ester (lOmmol). The 
exceptions to this were Gly which was single coupled using the symmetrical 
anhydride (lmmol), DHis was coupled four times as the HOBt ester (OSmmol each) 
and AsnIGln were double coupled as the HOBt ester (05 and 1 Ommol). Following 
completion of assembly the N-terminal Fmoc was left on and the resin stored in 1,4-
dioxan at 4°C until required. Quantitative Fmoc deprotection gave 0036mmo1g 1 , 
58% of the theoretical maximum. 
3.13.1. Trial Timed Cleavage of [Dllis68]Ub. Peptide-resin (40mg) was sonicated 
in 20% v/v piperidinefDlMF (20m1) for 20 minutes and subsequently washed with 
DMF, DCM, and ether and dried. The dried peptide-resin was then swollen in a 
mixture of anisole (025m1), thioanisole (025m1) and ethyl methyl sulphide (025m1) 
under nitrogen for 30 minutes. Water (025ml) and TFA (4m1) were then added. 
Aliquots (05ml) were removed after 2 & 3 hours and triturated with 2% 3-
mercaptoethanol in ether (25m1). The ether was decanted off and the protein 
dissolved in 20% aqueous HOAc, diluted with water and lyophilised. After 4 hours 
the resin was separated by filtration, washed with TFA (5 ml) and the combined filtrate 
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and washings concentrated in vacuo to give an oil, which yielded crude protein on 
trituration with 2% v/v J3-mercaptoethanol in ether (100m1). The ether was decanted 
off and the protein dissolved in 20% aqueous HOAc, diluted with water and 
lyophilised. Analytical RP HPLC's of the lyophilised products obtained after 2, 3 and 
4 hours cleavage indicated that a 4 hour cleavage was sufficient time to remove side-
chain protection and cleave the peptide-resin linkage. 
3.13.2. TbfmocfPGC and Gel Filtration Sephadex G50 Approximately 25% the 
peptide-resin was sonicated in 20% v/v piperidinefDMF at RT for 20 minutes and 
subsequently washed with DMF, DCM, and ether and dried under water suction for 
30 minutes. The dry resin (410mg, 0015nimol) was then added to a suspension of 
TbfmocCl (206mg, 0045mmol) and DIEA (78.tl, 0045mmol) in DCM (2m1) and 
sonicated at RT for 3 hours in the dark. The Tbfhioc-peptide-resin was separated by 
filtration and washed thoroughly with DCM and additionally with ether. The Tbfmoc-
peptide-resin was swollen in a mixture of anisole (05m1), thioanisole (05m1) and 
ethyl methyl sulphide (05ml) under nitrogen for 30 minutes whilst protected from the 
light. Water (0.5m1) and TFA (8m1) were then added and the cleavage mixture stirred 
for a further 4 hours. The resin was separated by filtration, washed with TFA (5m1) 
and the combined filtrate and washings concentrated in vacuo to give an oil, which 
yielded crude Tbftnoc-protein on trituration with 2% v/v 3-mercaptoethanol in ether 
(lOOml). The ether was decanted off and the Tbfinoc-protein was dissolved in 6M 
GdmCl (6m1), diluted with isopropanol (6ml) and the solution centrifuged to remove a 
small amount of insoluble material. PGC (HPLC grade, 7.tm, 500mg) was added and 
the solution was vortexed and then centrifuged. Adsorption of the Tbftnoc-protein 
was monitored by analytical RP HPLC at 364nm. The PGC was then subjected to the 
following wash protocol with alternate vortexing and centrifugation: 
6M GdmCllisopropanol (1:1) (24m1) 
6M GdmCllisopropanol (1:1) (24m1) 
6M GdmCllisopropanol (1:1) (24m1) 
10% piperidine in 6M GdmCllisopropanol (1:1) (24m1) 
10% piperidine in 6M GdmCl/isopropanol (1:1) (24m1) 
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6. 10% piperidine in 6M GdmCllisopropanol (1:1) (24m1) 
The supernatant from washes 4, 5 & 6 were combined, neutralised to pH 45 with 
HOAc and the isopropanol removed in vacuo prior to being loaded onto a Sephadex 
G50 (fine) column (800 x 30mm) pre-equilibriated with 30% aqueous HOAc. The 
column was then eluted at 40m] h' with monitoring at 226 and 277nm and collecting 
15 minute fractions. Protein fractions 15-22 inclusive were combined, diluted with 
water and lyophilised twice to give [DHis68] Ub I (3 6mg). Purification of a second 
batch of peptide-resin (270mg) in a similar manner gave an additional 3 0mg. 
• IDBis68JUb I 
HPLC (Column B, Gradient I): R 18.0 minutes; 
MALDI MS: 85678, C378H630N1050118 S 1 requires 85656 Da; 
AAA (40hrs) : Asp 7 699, Thr7 622, Ser3 228, G1u 12 1427, Pro3 325, Gly6 597, 
Ala2 209, Va14 404, Met 1 094, Tie7 6-52, Leu 9 888, Tyri 056, Phe2 210, His1 091, 
Lys7 6-94, Arg4 325. 
Tryptic digestion fragments separated by analytical RP HPLC (Column C, 2m1 loop) 
and characterised by AAA (24hrs): 
Fragment Sequence R (minutes) 
Ti (30-33) IQDK 5.4 
T2 (73-76) LRGG 6-0 
T3 (7-11) TLTGK 90 
14(49-54) QLEDGR 11-4 
T5 (34-42) EGIPPDQQR 172 
T6 (55-63) TLSDYNIQK 286 
17 (43-48) LIFAGK 342 
T8 (1-6) MQIF\TK 380 
T9 (64-72) ESTL#HLVLR 398 




3.13.3. Refolding from 8M Urea, 50mM NH40Ac, 10mM DTT at pH 45. 
[DHis68]Ub I (36mg) was dissolved in 8M urea, 50mM NH4OAc, 10mM DTT at pH 
45 (20m1) and stirred at RT for 2 hours. The protein solution was then sequentially 
dialysed (MWCO=2000, Spectropor) against nitrogen saturated solutions of 6M urea, 
50mM NH4OAc, 10mM DTT at pH 45 (800m1), 4M urea, 50mM NH 4OAc, 10mM 
DTT at pH 45 (800m1), 2M urea, 50mM NH4OAc, at pH 45 (800m1) and finally 
50mIvI NH4OAc at pH 45 (3000m1) x 3 for 24 hours at each step. Approximately 
half of the protein solution (1 On -d) was stored at 4 °C until required for NMR analysis, 
with the remaining half lyophilised and used in the other structural studies. A second 
portion (3 0mg) was refolded in a similar manner and subsequently lyophilised. 
CD results: 	 a-helix (%) 	3-sheet (%) remainder(%) 
50mM Na borate pH 7 
	
10 +1- 1.1 52+/-12 
	
38 +/- 2-1 
+50% TFE 
	
51 +1- 1•1 
	
22 +/- 1-3 
	
27+/-2-1 
3.13.4. NMR Studies. [DHis68]Ub (lOmi) of the refolded protein solution from 
above was exchanged by ultrafiltration (MWCO=2000, Amicon) into MQ-grade 
water, concentrated to ca imI, the pH adjusted to 48 and the 1 H NtvlIR recorded. 
Section 3.14. Miscellaneous Analyses on Ubiquitin(bovine). 
3.14.1. Treatment of Ubiquitin(bovine) with 10% v/v Piperidine in 6M 
GdmCllisopropanol (1:1). Ub(bovine) (95mg) was dissolved in 10% v/v piperidine 
in 6M GdmCl/isopropanol (1:1) (4m1) and stirred at RT for 40 minutes. The solution 
was then neutralised to pH 45 with HOAc and stored at 4°C overnight. Purification 
by semi-preparative RP HPLC (Column E, Gradient VIII) and subsequent 
lyophilisation gave 90mg. This was dissolved in MQ-grade water (600.tl), D 20 
(67p.l) added, the pH adjusted to 49 and the 1H NMR recorded. 
140 
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3.14.2 Oxidation of [Met']Ub(bovine) to [MetS-oxide'JUb(bovine)." 
Ub(bovine) (50mg) was dissolved in 02M aqueous HOAc (3m1) and 30% aqueous 
H202  (90p.l) added. The solution was stirred at RT for 1 hour, diluted with H 20 and 
lyophilised to give [MetS-oxide 1 ]Ub(bovine) (35mg). 
• [MetS-oxide']Ub(bovine) 
HPLC (Column A, Gradient I): R 1 174 minutes; 
MALDI MS: 85812, C378H630N1050 119 S 1 requires 85818 Da; 
AAA (40hrs) : Asp 7 680, Thr7 617, Ser3 249, G1u 12 1161, Pr03 236, G1y6 598, 
Ala2 228, Va14 418, 'Met, 082, 11e7 6-76, Leu9 829, Tyri 076, Phe2 189, His, 094, 
Lys7 674, Ar94 384. 
tThe  (Na)2 S03  present in the 6M HCl used in the hydrolysis of the protein reduces the 
methionine sulphoxide to the methionine and hence it is seen in the AAA trace. 
3.14.2. CD Analysis on IJb(bovine). 
CD results: a-helix (%) 13-sheet (%) remainder (%) 
H20pH46 19+/-14 56+/-14 25+/-25 
+25% TFE 32 +/-1 - 5 65+/- 1-6 3 +/- 2-8  
+50%TJ7E 50±/-1•9 38+/-2•0 11+/-36 
H20 pH 2 29 +/- 1-2 33 +/- 1-3 38 +/- 2-2 
+30% MeOH 24 +/- 1-7 24 +/- 2-0 53 +/- 3-3 
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